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Abstract 
 
During an acute virus infection, antigen-specific CD8 T cells undergo 
clonal expansion and differentiation into effector cells in order to control the 
infection. Efficient clonal expansion and differentiation of CD8 T cells are 
required to develop protective memory CD8 T cells. Antigen specific cells require 
3 distinct signals for their activation: TCR engagement of peptide-MHC (signal 1), 
costimulation between B7 and CD28 (signal 2), and inflammatory cytokines 
including IL-12 or type 1 IFN (signal 3). CD8 T cells that encounter antigen and 
costimulation undergo programmed cell division, but these two signals alone are 
not sufficient for full effector cell differentiation and survival into memory. CD8 T 
cells need a third signal for efficient clonal expansion, differentiation into various 
effector populations, acquisition of cytolytic effector functions, and memory 
formation. The requirements for signal 3 cytokines in CD8 T cell activation have 
only been recently described; however, the timing of exposure to these signals 
has yet to be investigated. During the course of an immune response not all T 
cells will see antigen, costimulation, and inflammatory cytokines at the same time 
or in the same order. I sought to examine how the timing of signal 3 cytokines 
affected CD8 T cell activation. I questioned how the order of these signals 
effected CD8 T cell priming and subsequent activation, expansion and 
differentiation.  
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In order to study the in vivo effects of out-of-sequence signaling on CD8 T 
cell activation, I utilized poly(I:C), a dsRNA analogue, which is known to induce a 
strong type 1 IFN response. Through the use of various congenic transgenic and 
polyclonal CD8 T cell populations, in conjunction with adoptive transfer models, 
specific T cells which had been exposed to poly(I:C) induced environments could 
be identified and tracked over time. I wanted to characterize how out-of-
sequence signaling affected T cell activation immediately after cognate antigen 
stimulation (4-5hours), and after prolonged exposure to cognate antigen (days-
weeks). 
Considering type 1 IFN can have both inhibitory and stimulatory effects on 
CD8 T cell proliferation, and when type 1 IFN provides signal 3 cytokine activity, 
it has positive effects on CD8 T cell expansion, I wanted to investigate the role of 
type 1 IFN as an out-of-sequence signal during CD8 T cell activation. We 
identified a transient defect in the phosphorylation of downstream STAT 
molecules after IFNβ signaling within poly(I:C) pretreated CD8 T cells. The 
inability of poly(I:C) pretreated CD8 T cells to respond to IFNβ signaling makes 
these cells behave in a manner more similar to T cells that only received 2 
signals, rather than ones that received all 3 signals in the appropriate order. 
Consequently, poly(I:C) pretreated, or out-of-sequence, CD8 T cells were found 
to have defects in clonal expansion, effector differentiation and function as well 
as memory generation resulting in reduced efficacy of viral clearance. 
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Out-of-sequence CD8 T cells showed suppression of CD8 T cell 
responses after prolonged exposure to cognate antigen, but naïve CD8 T cells 
pre-exposed to poly(I:C) exhibited immediate effector function within hours of 
cognate antigen stimulation, prior to cell division. Poly(I:C) pretreated naïve CD8 
T cells acquired an early activated phenotype associated with alterations of 
transcription factors and surface markers. Changes in naïve CD8 T cell 
phenotype are thought to be mediated by poly(I:C)-induced upregulation of self-
MHC and costimulatory molecules on APCs through direct type 1 IFN signaling. 
Inoculating with poly(I:C) enabled naive CD8 T cells to produce effector functions 
immediately upon stimulation with high density cognate antigen, reduced affinity 
altered peptide ligands (APLs), and in response to reduced concentrations of 
cognate antigen. Unlike conventional naïve CD8 T cells, poly(I:C) pretreated 
naïve CD8 T cells acquired the ability to specifically lyse target cells. These 
studies identified how the timing of activation signals can dramatically affect the 
acquisition of CD8 T cell effector function. 
This thesis describes how CD8 T cell exposure to activation signals in an 
unconventional order may result in altered response to antigen stimulation. 
Exposure of naïve CD8 T cells to type 1 IFN and costimulatory molecules in the 
presence of self-peptides enabled them to respond immediately upon antigen 
stimulation. Primed naïve CD8 T cells produced multiple cytokines in response to 
low-affinity, and low-density antigens, and gained ability to specifically lyse target 
cells. However, immediate effector function may come at the expense of clonal 
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expansion and effector cell differentiation in response to prolonged antigen 
exposure as out-of-sequence CD8 T cells showed reduced proliferation, effector 
function and memory formation. The findings presented here may seem 
contradictory because out-of-sequence signaling can prime T cells to produce 
immediate effector functions and yet cause defects in T cell expansion and 
effector differentiation. However, these two models ascertained T cell function at 
different points after antigen exposure; one where functions were evaluated 
within hours after seeing cognate antigen, and the other showing T cell 
responses after days of antigen stimulation. 
 Studies described in this thesis highlight the growing complexity of CD8 T 
cell activation. Not only do the presence or absence of signals 1-3 contribute to T 
cell activation, but the timing of these signals also proves to be of great 
importance. These studies may describe how both latecomer and third party 
antigen specific T cells behave when and if they encounter cognate antigen in 
the midst of an ongoing infection. Out-of-sequence exposure to IFN initially 
stimulates effector function but at the expense of efficient clonal expansion and 
subsequent memory formation. The immediate effector function that naïve T cells 
gain during out-of-sequence priming may explain how some individuals are more 
resistant to superinfections, whereas the impairment in proliferation describes a 
universal mechanism of virus-induced immune suppression, explaining how other 
individuals can be more susceptible to secondary infections. Ultimately, results 
identified here can be applied to developing better and more effective vaccines.   
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CHAPTER I: Introduction 
Type 1 IFN 
A. Type 1 IFN – an overview 
Interferons (IFNs) were the first cytokines to be discovered in 1957, and 
they were found by their ability to “interfere” with viral replication (1); however, it 
would be more than 20 years before IFNs could be purified and further 
characterized (2). IFNs are divided into 3 main categories: Type 1, Type 2 and 
Type 3 (3-11). Type 1 IFN includes 13 different IFNα genes in humans (and 14 in 
mice), 1 IFNβ gene, and several other recently identified subtypes  (3). Type 2 
IFN is comprised of a single type, IFNγ (3, 5, 7). Type 3 IFNs comprise 4 different 
IFNλ genes but will not be discussed further (3, 4, 7). Each class of IFN binds to 
its own unique receptor (3, 5, 7, 10-12). 
Type 1 IFN is induced in response to a wide range of pathogens including 
viruses, bacteria and parasites. Type 1 IFN is produced in response to pathogen 
components called pathogen associated molecular patterns (PAMPs), which are 
recognized collectively by receptors known as pattern recognition receptors 
(PRRs) (3, 4, 8, 10, 11, 13). The majority of type 1 IFN is induced by nucleic 
acids where both activation of RNA and DNA sensors leads to type 1 IFN 
production (3, 4). The production of IFN during infections is widely accepted to be 
mostly beneficial for the host, inducing a strong anti-viral response associated 
with upregulation of a number of different IFN-stimulated genes (ISG) which 
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develops an anti-viral state (3-5, 7, 10, 12, 13). However, the identification and 
mechanistic nature of many of these ISGs remain to be elucidated. Many viruses 
have evolved mechanisms to inhibit type 1 IFN induction and ISGs, including 
production of decoy receptors, inhibiting PRRs, and blocking IFN signaling 
pathways (6). 
It is established that in addition to beneficial effects, type 1 IFN can also 
have detrimental effects on the host. Type 1 IFN induction in some virus 
infections can lead to severe immunopathology (3, 11). Type 1 IFN can also be 
induced in response to bacterial infections, and similar to virus infections, the 
induction is not always beneficial. IFN has been shown to mediate pathology, to 
be detrimental to pathogen clearance, and to reduce survival of hosts in 
response to different bacterial infections (3-5, 11, 12, 14). Type 1 IFN has also 
been shown to play a role in several autoimmune disorders and cancer models 
and similar to the effects type 1 IFN has during viral and bacterial infections, it 
can also have a positive or negative role (3, 4, 11, 12). The role type 1 IFN plays 
in diseases and disorders is discussed in further detail in Section D.  
Although originally discovered for its ability to inhibit viral replication, it is 
now appreciated that IFN not only has anti-viral properties but also has a number 
of immunoregulatory roles on cells of the immune system. Through both direct 
and indirect effects mediated by other cytokines, type 1 IFN regulates many 
aspects of the immune system. IFN has a profound effect on antigen presenting 
cells (APCs) (3, 8). IFN induces maturation of immature dendritic cells (DCs) and 
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also plays an important role in natural killer (NK) cell activation (3, 8, 15). Further, 
IFN can have direct effects on CD4 T cells and B cells which can result in 
lymphocyte differentiation and enhanced antibody production (3). Notably, IFN 
can have both positive and negative effects on CD8 T cell activation and 
proliferation (3, 8). Effects type 1 IFN has on cells of the immune system will be 
discussed in more detail in Sections E, F, and G.  
B. Induction and production of type 1 IFN 
 Type 1 IFN can be produced by most cells in the body, but the PRRs that 
cells use to induce IFN are different based on pathogen and cell type. There are 
several types of PRRs: toll like receptors (TLR), retinoic acid-inducible gene I 
(RIG-I) like receptors (RLRs), and nucleotide-binding oligomerization domain 
(NOD)-like receptors (NLRs) (3, 4). All cells have the ability to detect PAMPs via 
PRRs located throughout the cell, but not all cell types express all PRRs (3, 4). 
TLR4 is expressed on the surface of cells, TLRs 3, 7, 8, and 9 are expressed 
within the endosomal compartments, and RLRs and NLRs are located in the 
cytosol (3, 4). Each of these PRRs detects different microbial products. TLR4 
recognizes lipopolysaccharide (LPS), a component expressed by bacteria (3, 4). 
The endosomal TLRs, TLR3, 7, and 8, and 9 detect dsRNA, ssRNA, and CpG 
DNA, respectively (3, 4). RLRs including RIG-I and melanoma differentiation-
associated gene 5 (MDA5) reside in the cytosol and recognize RNA products (3, 
4). NLRs recognize different viral, bacterial, and fungal components (3, 4). 
Cytosolic DNA sensors are the most recently described PRRs and include DNA-
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dependent activator of IFN-regulatory factors (DAI) and cytosolic GAMP 
synthase (cGAS) (3, 4, 16). 
An important tool in studying the production of type 1 IFN in vivo and in 
vitro is the dsRNA analogue, polyinosinic:polycytidylic acid (poly(I:C)) (17-19). 
Poly(I:C) triggers and actives TLR3 and MDA5 to a greater extent than other 
RNA sensors like RIG-I (4, 6, 20).  
 PRRs utilize different downstream signaling components but all pathways 
converge upon two transcription factors (TFs) that induce IFN expression, IFN 
regulatory factor (IRF)3 and/or IRF7 (3, 4, 21). TANK-binding kinase 1 (TBK1) 
phosphorylates IRF3/7, inducing dimerization and subsequent translocation into 
the nucleus, allowing it to act on downstream target genes, including IFNα/β (3, 
4, 22). Many PRRs, through different downstream adaptor molecules, activate 
TBK1 to induce IRF3/7 phosphorylation. The endosomal TLRs 7, 8 and 9 utilize 
the adaptor molecule myeloid differentiation primary response gene (MyD88) and 
can directly associate with IRF3/7, independent of TBK1 (3, 4). However, the 
endosomal TLR3 and the surface TLR4 utilize a different adaptor molecule, TIR 
domain containing adapter inducing IFN β (TRIF), which induces activation of the 
kinase TBK1 and subsequent phosphorylation of IRF3/7 (3, 4). The cytosolic 
sensors also activate TBK1 but do so using alternative adaptor molecules. The 
RLRs use the mitochondria-associated protein mitochondrial anti-viral signaling 
protein (MAVS) that converges on TBK1 (3, 4). The recognition of cytosolic DNA 
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utilizes the downstream adaptor stimulator of IFN genes (STING) to help mediate 
IRF3/7 activation (3, 4).  
The majority of cells constitutively express IRF3 but not IRF7 (23). When 
PRRs are engaged, type 1 IFN including IFNβ and IFNα4 are upregulated by 
activation of IRF3 (3). IRF7 is also upregulated during the first wave of IFN 
production where it can subsequently regulate other IFNα subtypes upon further 
PRR stimulation (3, 23, 24). TLR and RLR expression can also be upregulated 
by IRF3, which further promotes type 1 IFN production. The upregulation of PRR 
signaling components is important for type 1 IFN production.       
 During virus infections, type 1 IFN is produced by a variety of cell types. 
Most cells that are productively infected produce type 1 IFN and do so through 
activation of the cytosolic RLRs and DNA sensors. Upon systemic infections, 
plasmacytoid DCs (pDCs) can produce up to 95% of IFN (6, 25). Uninfected 
pDCs produce high levels of type 1 IFN through activation of endosomal TLRs 7 
and 9 (9, 23, 26, 27). Unlike other cell types, pDCs constitutively express IRF7; 
therefore pDCs have the ability to produce multiple subtypes of type 1 IFN 
without having to first induce IRF7 expression (25, 26). Once IFN is produced, it 
can act in both an autocrine and paracrine fashion. Because many components 
of the type 1 IFN production signaling pathway(s) are ISGs themselves, type 1 
IFN production induces a positive feedback loop, which allows for the production 
of large amounts of IFN in a short period of time.  
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C.  Type 1 IFN signaling 
Canonical cytokine signaling, including that of IFN, generally involves 
activation of Janus kinase (JAK) - signal transducer and activator of transcription 
(STAT) pathways (10, 12, 28-30). Cytokine receptor subunits are associated with 
1 of 4 different members of the JAK family (30). Upon ligand binding to the 
receptor, conformation changes induce auto-phosphorylation of JAK proteins 
resulting in their activation and subsequent phosphorylation of downstream STAT 
molecules (10, 30). The STAT proteins can then dimerize and translocate into 
the nucleus to act as TFs (10, 30). Over-activation of the immune system can 
result in detrimental effects including immunopathology, and therefore, cytokine 
signaling must be tightly regulated. Cytokine signaling is regulated at every step 
including cytokine receptor expression, JAK function, and STAT expression and 
activation (10, 30). JAK proteins must be functional in order to transmit the 
signals and activate downstream STATs. JAK proteins are regulated by a 
number of different proteins including the suppressor of cytokine signaling 
(SOCS) family of proteins (10, 28, 30). SOCS family members can inhibit 
cytokine signaling through three major mechanisms: 1) binding directly to the 
receptor and inhibiting STAT molecules, 2) binding to JAK proteins and inhibiting 
their function, 3) targeting cytokine receptors or JAK proteins for proteasome 
degradation (10, 28, 31). STAT molecules must also be present in order for 
cytokine signaling to occur. Therefore, without any one of these components 
(receptor, JAK and STAT), cytokine signaling can be inhibited.  
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Even though type 1 IFN comprises multiple types including α, β, ε, κ, ω 
and others, all type 1 IFN types signal through the same receptor. The type 1 IFN 
receptor (IFNAR) is comprised of two different subunits: IFNAR1, and IFNAR2 
(8-10, 32, 33) (Figure 1.1). The type 1 IFN receptor is ubiquitously expressed on 
cells throughout the body, and therefore, all cells can respond to type 1 IFN 
signals (33). However, receptor expression is not uniform across all cell types. 
For example, CD44hi CD8 T cells were found to exhibit higher expression levels 
of IFNAR1 than CD44lo CD8 T cells (34). Receptor expression can be 
upregulated or downregulated by many different mechanisms. One study found 
that IFNγ could actually induce IFNAR1 and IFNAR2 mRNA induction in a cell 
line (35). However, more is known about downregulation of the type 1 IFN 
receptor. Upon ligand binding to the receptor, the IFNAR complex is internalized, 
ubiquitinated and degraded (36).  
Each receptor component has an associated JAK protein, through which it 
transmits signals. IFNAR1 is associated with TYK2, and IFNAR2 is associated 
with JAK1 (8, 12, 30, 32, 33) (Figure 1.1). In addition, IFNAR1 is stabilized by its 
associated JAK protein TYK2 (33, 37). Therefore, without TYK2 expression, 
IFNAR1 expression levels are really low. JAK1 and TYK2 are important 
components in the canonical IFN signaling pathway. IFN binding to its receptor 
results in receptor dimerization, resulting in auto phosphorylation of JAK proteins, 
thus allowing STAT molecules to dock. The activated JAKs phosphorylate  
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Figure 1.1: Type 1 IFN Receptor signaling 
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Figure 1.1: Type 1 IFN Receptor signaling 
The type 1 IFN receptor is comprised of two subunits: IFNAR1 and IFNAR2. 
Each receptor component is associated with a specific intracellular Jak protein. 
IFNAR1 is associated with TYK2 and IFNAR2 is associated with JAK1. Type 1 
IFN receptor signaling is inhibited by SOCS1. IFN signaling can act through 
different downstream STAT proteins ultimately affecting cell fate.   
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associated STATs, inducing their dimerization and subsequent translocation into 
the nucleus and allowing for regulation of gene transcription.  
The most widely recognized pathway type 1 IFN signaling acts on is 
through activation of STAT1 and STAT2. This canonical pathway results in 
dimerization of STAT1 and STAT2 allowing for association with a third 
transcription factor IRF9, which together comprise the transcriptional regulator, 
IFN-stimulated gene factor 3 (ISGF3) (3, 4, 9, 10, 12, 30, 32, 33). ISGF3 has 
been shown to be important for the regulation of multiple ISGs by binding to IFN-
stimulated response elements (ISRE) in the ISG promoters (3, 4, 10, 12, 30, 32, 
38). Therefore, type 1 IFN signaling through the canonical JAK/STAT pathway 
induces activation of ISGF3, allowing for the regulation of hundreds of genes that 
initiate an anti-viral state. 
However, STAT1/2 are not the only STATs that have been shown to be 
activated downstream of the type 1 IFN receptor. In fact, almost all STATs can 
be activated in response to IFN stimulation and depending on their binding 
partner, each STAT can have very different effects on cells (3, 8, 32) (Figure 
1.1). Moreover, it has recently been appreciated that the JAK/STAT pathways 
are not the only signaling pathways induced by type 1 IFN. The mitogen-
activated protein kinase (MAPK) pathway, phosphoinositide 3-kinase (PI3K) and 
mammalian target of rapamycin (mTOR) pathways have all been linked to IFN 
signaling (3, 9, 32). 
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Cytokine signaling is tightly regulated to prevent over-activation of the 
immune system and needs to be induced and inhibited at the right times. Type 1 
IFN signaling is augmented by the upregulation of STAT1 and IRF9, both of 
which are ISGs themselves (12, 39). Small amounts of IFN can act on cells to 
activate ISGF3, which can upregulate components of itself thus augmenting IFN 
signaling. Therefore, type 1 IFN signaling can positively regulate type 1 IFN 
signaling. 
On the other hand, there are many mechanisms to dampen IFN signaling. 
Defects in ability to inhibit cytokine signaling can lead to over activation of cells 
and may cause immunopathology due to chronic inflammation. There are a 
number of different mechanisms that suppress type 1 IFN signaling, including 
downregulation of the receptor, by internalization and degradation, and 
upregulating proteins that negatively regulate signaling (10, 28, 36, 37). Some 
other of these negative regulators include SOCS family members, ubiquitin 
carboxy-terminal hydrolase 18 (USP18) and miRNAs (9, 10, 12). SOCS1, 
SOCS3 and USP18 all negatively regulate IFN signaling. SOCS1 inhibits type 1 
IFN signaling by binding to the receptor associated JAK protein TYK2, while 
other suppressor proteins, including USP18, displace JAK proteins (10, 12, 33, 
37). These suppressors are induced downstream of type 1 IFN signaling. Thus, 
in addition to IFN inducing positive feedback mechanism, type 1 IFN signaling 
also induces negative feedback mechanisms. Therefore a fine line exists 
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between increasing and deceasing responsiveness to IFN signals and aberrant 
signaling can have detrimental effects.  
D. Type 1 IFN function in diseases and disorders  
Type 1 IFNs were originally identified for their ability to interfere with virus 
replication. IFNs have been shown to inhibit viral replication mainly through 
induction of ISGs. ISGs inhibit all stages of viral replication, including attachment, 
fusion, transcription, translation, and release (6, 7, 10, 38). Some of the most 
well-known ISGs include IFN-stimulated protein of 15kDa (ISG15), Myxoma 
resistance GTPases (Mx), 2’5’-oligoadenylate synthetase (OAS) proteins and 
protein kinase R (PKR) (7, 9, 38). ISG15 is a protein that, like ubiquitin, attaches 
to other proteins, which may affect protein function (7, 10). This is an IFN-
regulated response and is referred to as ISGylation. ISGylation does not promote 
protein degradation like K48 linked ubiquitination does but instead can prevent 
degradation of proteins or alter their function (7, 10). Several targets of ISG15 
have been identified and include many proteins in the type 1 IFN signaling 
pathway, such as JAK1, STAT1, and RIG-I (7). Mx proteins block virus 
replication at multiple steps including transcription and translation (7, 40). The 
inhibitory mechanisms of these proteins are still being investigated and may be 
different based on the location of the Mx protein and specific virus infection (7, 
40). OAS proteins activate RNaseL, which degrades RNA. Degradation of viral 
RNA inhibits replication and can ultimately contribute to activation of PRRs 
including RIG-I and MDA5, further promoting IFN production and an anti-viral 
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state (7, 16). PKR inhibits translation of both viral and host proteins by inhibiting 
eukaryotic translation initiation factor 2a (EIF2a) via phosphorylation (7). This is 
by no means a comprehensive list of ISGs with anti-viral activity but just names a 
few of the most well-known. 
Because of the potent anti-viral effects that IFN and ISGs can have, it is 
no surprise that viruses have developed mechanisms to inhibit IFN production 
and ISG functions. Similar to the ability of ISGs to inhibit almost every part of the 
virus life cycle, viruses have developed ways to inhibit almost every part of the 
type 1 IFN pathway, from its induction and production, to the specific anti-viral 
effects of some ISGs (6, 41). Viral proteins can inhibit the PRRs and their 
associated adaptors, block TBK1 kinase activity, and inhibit IRF3/7 to prevent or 
reduce type 1 IFN production (6). Viruses can also inhibit IFN signaling by 
affecting IFN receptor expression, associated JAK/STAT proteins, and other 
transcription factors including IRF9, to inhibit IFN-induced genes (6). Even after 
ISGs are produced, viruses have developed mechanism to inhibit specific ISGs, 
including the aforementioned PKR and ISG15.  
Although known for anti-viral properties, type 1 IFN can have either 
beneficial or detrimental effects on the host depending on the infection. During 
most acute virus infections, type 1 IFN production has positive effects on both 
viral clearance and survival of the host; however, that is not always the case. 
Influenza (IAV) infections can cause a wide range of symptoms ranging from mild 
effects to fatality. Mouse strains have a wide range of susceptibility to IAV 
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infections and in one study, higher levels of type 1 IFN correlated with increased 
susceptibility of mice to IAV infections (42). pDCs were found to produce 
excessive type 1 IFN, which caused increased inflammation into the lungs during 
infection, causing damage to the lung epithelia and increased mortality (42). 
These studies suggest that although IFN primarily has anti-viral effects, that too 
much IFN can be detrimental to the host.  
In addition to IFN contributing to susceptibility of mice to an acute lethal 
IAV infection, IFN has also been linked to detrimental effects in a number of 
chronic viral infections (3, 5, 9, 12). IFN-induced increased immunosuppressive 
effects can inhibit control of the virus, or over-activation of the immune response 
may lead to excessive inflammation and immunopathology (3). Examples are 
seen in individuals infected with human immunodeficiency virus (HIV), where 
rapid progressors showed an increased IFN signature compared to non-
progressors; however, the mechanism has yet to be identified. One explanation 
for the difference could be from increased production of IFN-induced 
immunosuppressive cytokines like IL-10 (3, 9). Recent studies using the 
lymphocytic choriomeningitis virus (LCMV) clone 13 model system identified IFN 
as having detrimental effects during chronic infection. IFNAR knock out (KO) 
animals and anti-IFNAR1 antibody blocking studies found reduced expression of 
inhibitory molecules, including IL-10 and programmed death-ligand 1 (PD-L1), 
resulting in viral clearance and restoration of exhausted T cells (9, 43-45). Other 
chronic infections including hepatitis C virus (HCV) and Mycobacterium 
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tuberculosis (MTb) are also associated with increased IFN signatures, which 
correlate with disease severity (3, 5, 9, 12).  
Type 1 IFN is also produced during bacterial infections by activation of 
TLRs, but its role is not always beneficial. Type 1 IFN impaired clearance of 
Listeria monocytogenes and MTb (3, 5, 11). Although the exact mechanisms as 
to how IFN production can be detrimental during bacterial infection is still being 
studied, and may have multiple and unique roles based on the infecting 
pathogen, a few observations have been made. The detrimental effects of type 1 
IFN may be attributed to the induction of lymphocytes apoptosis, thus 
suppressing the adaptive response to the bacterial infection. Another hypothesis 
that is described identifies type 1 IFN inhibiting the IL-17 production, resulting in 
defective neutrophil recruitment and bacterial clearance (3, 4). Type 1 IFN-
induced upregulation of immunosuppressive cytokines and inhibitory molecules 
like IL-10 and PD-L1, may contribute to detrimental effects during some bacterial 
infections (3, 4, 12). IL-10 and PD-L1 may suppress T cell function, which could 
result in reduced pathogen clearance.  
In some cases, type 1 IFN production is beneficial during bacterial 
infections. IFNAR KO mice showed increased bacterial load and reduced survival 
in response to infection with Streptococcus pneumonia and Escherichia coli (3, 
4). Type 1 IFN can have beneficial effects during bacterial infections by 
upregulating some pro-inflammatory cytokines, including tumor necrosis factor 
(TNF), which has been shown to play a role in controlling infections (3, 14). The 
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diverse functions of IFN are not limited to bacterial infection, as fungal infections 
and certain parasitic infections also show different requirements for type 1 IFN in 
pathogen clearance (3, 9). Therefore, type 1 IFN can have either detrimental or 
protective roles in response to pathogenic infections. 
Type 1 IFN has been used to treat many types of cancers, including some 
types of leukemia, lymphomas, and some solid tumors (11, 46). In this case, IFN 
acted as a positive regulator of the immune system, in part by acting on DCs to 
enhance their ability to cross present antigens and activate CD8 T cells. Type 1 
IFN activation of NK cells may also contribute to control of tumor.  
Type 1 IFN plays a profound role in autoimmune disorders, and similar to 
effects seen during pathogenic infections, it can have a positive or negative 
effect. Some autoimmune disorders are improved if type 1 IFN is inhibited, 
whereas others will benefit from type 1 IFN treatment (4, 12). Patients affected 
with systemic lupus erythematosus (SLE) have increased levels of type 1 IFN in 
the blood compared to healthy donors (11). Type 1 IFN can positively activate T 
cells and B cell responses, which can ultimately contribute to autoimmune 
disorders associated with autoantibody production, similar to what is seen in 
SLE. SLE is not the only autoimmune disorder in which IFN has shown to play a 
pathogenic role. The skin inflammatory disorder psoriasis has also been linked to 
high levels of type 1 IFN (4). Similar to what is seen with patients with SLE, IFN 
is thought to activate the pathogenic T cells, which contribute to the immune-
mediated skin lesions (4). Blocking type 1 IFN in both SLE and in psoriasis 
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patients reduced severity of the diseases; however, IFN is not the only thing that 
contributes to these disorders and additional work needs to be done in order to 
develop new therapies for these disorders.  
Type 1 IFN therapy is prescribed for patients with relapsing-remitting 
multiple sclerosis (MS) and has generally shown positive effects with treatment 
(9, 11). In this situation, IFN is thought to have a suppressive role on the 
pathogenic T cells that mediate the disease, possibly by inhibiting the recruitment 
of T cells to the brain (4, 9). Additionally, type 1 IFN induction of IL-10 may 
contribute to suppression of the immune response thus limiting the auto-reactive 
cells and subsequent pathological consequences (4, 11). Because type 1 IFN 
can have both positive and negative effects on lymphocyte activation, it is 
conceivable that IFN may play different roles during various stages of 
autoimmune disorders.     
Even though type 1 IFN was discovered for anti-viral properties, it has a 
strong role in many other diseases and disorders. Depending on the infecting 
pathogen, or the autoimmune disorder, IFN can have detrimental or protective 
effects. The ability of IFN to have both stimulatory and inhibitory effects on 
lymphocytes allows for the wide range of results seen during disease.  
E. Effects of type 1 IFN on cells of the immune system 
Type 1 IFN regulates immune cell function and can have both direct and 
indirect effects on lymphocyte populations. Type 1 IFN is important in activation 
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of immature DCs, whereby it will promote the upregulation of Class I and Class II 
major histocompatibility complex (MHC) molecules and the costimulatory 
molecules CD80 and CD86 (B7.1 and B7.2) (32). Moreover, IFN increases the 
ability of DCs to present antigen, including cross presentation (32, 47). Migration 
of DCs to the lymph nodes is also affected by type I IFN. Section F, Type 1 IFN 
and dendritic cells, will discuss these details further.  
IFN can play both stimulatory and inhibitory roles in CD8 T cell activation. 
It can induce T cell apoptosis, but it can also promote development of effector 
function and clonal expansion. Section G, Type 1 IFN effects on CD8 T cells, 
provides further detail on this subject. 
Both indirect and direct effects of type 1 IFN are important for NK cell 
activation. Direct effects of IFN increase the cytolytic capability of NK cells by 
inducing cytotoxic effector molecules like perforin and granzymes, which promote 
cytolytic capability (8, 15, 32, 48-51). Some studies identified IL-12 production 
early after viral infections as the main driver of NK cell production of IFNγ, while 
type 1 IFN contributed more to NK cell cytotoxicity (52). However, studies with 
other infection models, including influenza, identified a direct role for IFN in NK 
cell production of IFNγ, not IL-12 (53). As mentioned earlier, IFN can mediate 
distinct functions in cells by acting through different downstream pathways. 
STAT1 was required for IFN mediated acquisition of cytolytic effector function, 
whereas STAT4 induced granzyme B and IFNγ expression in IFN-activated NK 
cells (52-54).  
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Type 1 IFN has indirect effects on NK cell activation. For example, IFN 
induces production of IL-15, which has positive effects on NK cell 
accumulation/proliferation (9). The positive effects of IFN-induced IL-15 mediated 
survival of NK cells were also shown to require STAT1 signaling (51). Activation 
of NK cells was also associated with increased blastogenesis, which was 
mediated by type 1 IFN acting through IL-15 (55). 
NK cells are widely recognized for their ability to kill virus-infected and 
tumor cells. However, recent studies showed that NK cells can play a regulatory 
role during virus infections by specifically lysing activated T cells (56, 57). Type 1 
IFN activation of NK cells was important for this regulatory phenomena. On the 
other hand, type 1 IFN was shown to act on CD8 T cells to prevent early NK cell 
mediated lysis (58, 59). The ability of IFN to both activate NK cells and inhibit T 
cells from NK cell lysis have important implications during infections. Although 
activated NK cells have the ability to specifically lyse activated T cells, killing of T 
cells may not be in the best interest of the host during infection.    
Both CD4 T cells and B cells are affected by direct type 1 IFN signaling. 
When T cells lacked the type 1 IFN receptor, mice immunized with chicken 
gamma globulin showed significant reductions in the antibody (Ab) response, 
suggesting that IFN signaling of T cells promotes B cell help (60). Type 1 IFN 
affected the differentiation of CD4 T cells where it promoted T helper (Th1) 
differentiation of CD4 T cells, resulting in increased IFNγ production (32, 61)  and 
it suppressed differentiation of Th2 and Th17 cells (62). Type 1 IFN did not 
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always enhance CD4 T cells proliferation. Direct IFN promoted CD4 T cell 
survival in response to LCMV infection, but bacterial infections did not show IFN-
induced enhanced clonal expansion of CD4 T cells (62, 63). In addition to CD8 T 
cells, IFN induced apoptosis of memory phenotype (CD44hi) CD4 T cells (64). 
Type 1 IFN signaling inhibited proliferation and activation of regulatory T cells 
(Tregs) during acute LCMV infections (65). Thus, IFN can have both stimulatory 
or inhibitory effects on CD4 T cell survival and clonal expansion, and either 
promote or suppress differentiation of T-helper subsets. The ability of IFN to 
mediate these differential effects on CD4 T cells may be attributed to the ability of 
type 1 IFN to activate multiple signaling pathways including JAK/STAT, MAPK 
and mTOR (3, 32).  
Although there has been evidence that IFN can decrease the survival of B 
cells, there is growing evidence that IFN also has stimulatory effects on B cells. 
Early work indicated that increased B cell function was due to indirect effects of 
IFN via activation of DCs (66). However, as stated earlier, type 1 IFN increased B 
cell responses by acting directly on CD4 T cells and B cells (60, 67). Antigen 
specific B cells showed increased activation and early activation markers upon 
type 1 IFN signaling (67). IFNAR KO B cells showed reduced activation and 
expansion compared to WT B cells in response to vesicular stomatitis virus 
(VSV) infection (68). Moreover, type 1 IFN increased antibody production and 
promoted class switching in B cells during IAV and VSV infection (68). Together, 
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these data indicate IFN may have more B cell stimulatory properties than 
previously thought.  
F. Type 1 IFN and dendritic cells 
 DCs are a type of professional APC that presents antigens to both CD4 
and CD8 T cells. DCs play an important role during viral infections, as they serve 
as a bridge between the innate and adaptive immune system.  
  DCs have the ability to present peptides on MHC Class I and Class II 
proteins, to provide recognition for CD8 and CD4 T cells respectively. DCs are 
one of only a few types of APCs, which have the ability to present antigens to 
both CD4 and CD8 T cells. Most cells have the ability to present antigens to CD8 
T cells, but only specialized APCs present to CD4 T cells. Class I and II MHC 
proteins present peptides from different compartments within the cell. Class I 
presented peptides are derived from the cytosol, whereas Class II presented 
peptides are from endocytic vesicles. Pathogens that replicate within the cytosol 
will have peptides presented on Class I MHC molecules to be presented to CD8 
T cells. Activated CD8 T cells that recognize cognate peptide-MHC (pMHC) 
complexes have the ability to specifically lyse those target cells. Extracellular 
pathogens are endocytosed and form vesicles where antigen can be loaded onto 
Class II MHC molecules for presentation to CD4 T cells. CD4 T cells help other 
cells, including B cells, to produce antibodies, and help CD8 T cells, often 
indirectly, by activating DCs. A specialized pathway called cross-presentation is a 
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way in which extracellular antigens can be processed and presented on MHC 
Class I molecules for CD8 T cell recognition.  
 Professional APCs, including DCs, macrophages and B cells, utilize MHC 
Class II molecules to present peptides derived from intracellular vesicles. Newly 
synthesized MHC Class II molecules from the endoplasmic reticulum (ER) will be 
transported and will associate with endosomal compartments (69). Antigens that 
are endocytosed are broken down by different proteases such that they can bind 
to MHC Class II molecules to be efficiently presented (69). MHC complexes that 
do not have a bound peptide are less stable and are rapidly degraded. Once 
peptide is bound, the pMHC complex can be presented on the surface of cells. 
 Class I MHC molecules present peptides derived from the cytosol. 
Pathogens and self-proteins in the cytosol are broken down by the proteasome, a 
large multiple subunit complex with protease activity (69). Essentially, proteins 
are fed into the active site of the proteasome and come out as short peptides. 
There are two distinct forms of the proteasome, the constitutive proteasome, 
which is present in all cells, and the immunoproteasome, which is only induced in 
cells stimulated by IFN. The immunoproteasome has three subunits that are 
induced upon IFN stimulation, β1i, β2i, and β5i (also known as LMP2, LMP7, and 
MECL-1 respectively) (70). By altering these catalytic subunits, the specificity of 
the peptide cleavage is altered, allowing the peptides that are released to be 
more efficiently presented on Class I MHC (70). Upon protein degradation, 
peptides derived from the cytosol are transported into the ER, mediated by two 
23 
 
enzymes, transporter associated with antigen processing 1 and 2 (TAP1 and 
TAP2). Peptides can then be loaded onto Class I MHC molecules for 
presentation on the surface of cells. Without associated peptides bound, empty 
Class I complexes will be retained in the ER and if a peptide does not bind, 
eventually Class I molecules will be degraded (69). Cells deficient in TAP1 and/or 
TAP2 show markedly reduced level of Class I MHC on the surface of cells. Only 
peptides that do not require TAP-mediated transport are able to be presented.  
 MHC Class I complexes also have the ability to present peptides from 
exogenous sources. This is referred to as cross-presentation, where exogenous 
proteins can be taken up via endocytosis, transferred into the cytosol for 
degradation by the proteasome, transferred to the ER via TAP and loaded onto 
Class I (69). Cross-presentation occurs in a number of cell types, but a subset of 
DCs, CD8α+ DCs, are specialized in the process (71). Cross-presentation is 
important for CD8 T cell activation in response to pathogens that do not 
productively infect antigen presenting cells (71).  
 DCs were originally placed into 2 different types; conventional DCs and 
non-conventional or plasmacytoid DCs (72). However, now there is evidence for 
significantly more DC heterogeneity in terms of function, location, and phenotype. 
Within conventional DC populations, there are migratory and lymphoid DCs. 
Migratory DCs are found in many locations in the body, including the skin, lungs, 
gastrointestinal tract and liver, and have the ability to migrate into lymphoid 
tissues (73). Lymphoid DCs are only found in lymphoid organs and are divided 
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further into subsets based on their expression of CD4 and CD8 (72, 73). All DCs 
express CD11c to some degree, and, based on expression of several key 
markers including CD4 and CD8α, DCs can be distinguished further (72, 73). 
DCs that express CD8α, are generally low in CD11b expression, and are termed 
CD8α DCs (71). As eluded to earlier, CD8α+ DCs have the ability to cross-
present antigens, thus promoting activation of CD8 T cells. CD8α+ DCs are also 
major producers of IL-12 as compared to some other DC subsets (71). pDCs, as 
previously mentioned, are major producers of type 1 IFN via activation of TLRs 7 
and 9. pDCs can be distinguished from other DC subsets by expressing lower 
levels CD11c, B220, and PDCA-1 (also known as BST2 and Tetherin) (47).  
Upon pathogen infection, DCs are activated by encountering PAMPs and 
take up and process antigens for presentation to T cells. The activation of PRRs 
results in increased antigen processing and presentation, upregulation of 
costimulatory molecules, and upregulation of chemokine receptors that are 
utilized for DC migration into secondary lymphoid organs (74, 75). After antigen 
is taken up at the site of infection, DCs migrate to the nearest peripheral 
lymphoid organ where they present antigen to T cells (75, 76). In some cases the 
original DC that picks up antigen may not be the DC that presents it to the T cell, 
as migratory DCs can transfer antigen to resident lymphoid DCs (75). As early as 
24 hours after infection with LCMV, CD11c+ DCs were found in T cell areas of 
the spleen (74).  
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As stated before, DCs are specialized APCs that can bridge the innate 
and adaptive immune system by activating T cells, both helper and cytotoxic. 
Naïve T cells require 3 distinct signals for their full activation: pMHC–T cell 
receptor (TCR) interaction (signal 1), costimulation between B7-CD28 (signal 2) 
and inflammatory cytokines (signal 3). DCs facilitate naïve T cell activation by 
expressing both Class I and Class II MHC molecules and by expressing a range 
of costimulatory molecules, including the canonical signal 2 molecules B7.1 
(CD80) and B7.2 (CD86). However, costimulatory molecules are not 
constitutively expressed by immature DCs; instead DCs must be activated to 
upregulated these molecules. The triggering of PRRs and subsequent production 
of IFN induces a positive feedback autocrine loop signaling through IFNAR 
leading to expression of costimulatory molecules like B7 and upregulation of both 
MHC Class I and Class II expression on the surface of cells. IFN can induce 
expression of immunoproteasome catalytic subunits to increase the likelihood of 
MHC Class I peptide presentation. Type 1 IFN, therefore, plays an important role 
in activating DCs, inducing differentiation of immature DCs into mature DCs, 
capable of presenting antigen, providing costimulatory signals and activating T 
cells.  
The costimulatory molecules DCs present can affect T cell activation in 
both positive and negative ways. B7:CD28 and CD40:CD40L interactions provide 
activation signals to T cells, whereas B7 interaction with cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4), PD-L1 and/or PD-L2 interacting with programmed 
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cell death 1 (PD-1) inhibit T cell function (77). In addition, when a naïve T cell 
encounters its cognate pMHC expressed on an APC without B7:CD28 
costimulation, T cell inactivation or deletion can occur. Therefore, the 
costimulatory molecules that APCs express, or lack of costimulatory molecule 
expression, can have dramatic effects on T cell activation. 
G. Type 1 IFN effects on CD8 T cells 
Type 1 IFN can exert effects on CD8 T cells both directly and indirectly. 
Indirectly, IFN acts on DCs to increase Class I presentation, increase 
costimulatory molecules and produce inflammatory cytokines, all of which help to 
promote CD8 T cell activation. On the other hand, type I IFN acts directly on CD8 
T cells as a signal 3 cytokine and promotes clonal expansion and differentiation 
(62, 78-81). Type 1 IFN can have both pro- and anti-apoptotic and proliferative 
effects on CD8 T cells.  
Type 1 IFN induced during the early stages of a virus infection will induce 
apoptosis of memory phenotype CD4 and CD8 T cells resulting in T cell attrition 
(64, 82-84). Naïve CD8 T cells are also susceptible to early attrition seen after 
viral infections. The inflammatory environment induced by administration of 
poly(I:C), mimicking an acute virus infection, also showed reduction in T cell 
number. Although the mechanism has not been fully identified, IFNAR KO mice 
were largely resistant to poly(I:C)-induced attrition of CD44hi CD8 T cells, 
implicating a role for type 1 IFN (82). IFN-induced TNF or TNF-related apoptosis 
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inducing ligand (TRAIL) upregulation was not contributing to early attrition of T 
cells. However, it was discovered that the IFN-induced attrition was partially 
mediated by Bim, as day 3 LCMV-infected Bim KO mice showed lower reduction 
in CD44hi CD8 T cells compared to WT mice (64). The loss of memory 
phenotype cells during the beginning of an infection may allow for a more diverse 
T cell response.  
Type 1 IFN has been shown to exert both pro-proliferative and anti-
apoptotic effects in CD8 T cells. Depending on how one defines proliferation, the 
meaning can be very different. Proliferation may refer to an increase in cell 
number, or simply as cell division, which does not always result in an increase in 
cell number. The literature showing IFN having pro-proliferative effects on T cells, 
mostly refers to proliferation as an increase in number. CD8 T cells that lacked 
IFNAR did not show defects in division, but rather in accumulation, suggesting 
that rather than promoting cell division, IFN has pro-survival effects on CD8 T 
cells (79). 
TCR and costimulation upregulate the anti-apoptotic molecules B-cell 
lymphoma 2 (Bcl-2) and B-cell lymphoma extra large (Bcl-xL) in T cells. 
Investigating the role of type 1 IFN in survival of activated CD8 T cells, in vitro 
studies revealed similar levels of Bcl-2 and Bcl-xl comparing CD8 T cells treated 
with or without IFN (85). Addition of adjuvants or IL-12 to activated T cells in vitro 
induced upregulation of B-cell lymphoma 3 (Bcl-3) expression (86, 87). Adjuvant–
induced survival of activated T cells correlated more with Bcl-3 expression than 
28 
 
with Bcl-2 or Bcl-xL expression (88). Therefore, the increase in Bcl-3 is thought to 
promote the increased accumulation of T cells stimulated with IFN vs. those 
without IFN signals. One study, however, suggests that IFN increases the 
number divisions activated CD8 T cells undergo by maintaining expression of the 
high affinity IL-2 receptor (89), thus contributing to enhanced accumulation.  
Interestingly, IFN can affect CD8 T cell expansion by acting through other 
T cell subsets. Type 1 IFN signaling in Tregs was found to be important for the 
expansion and function of virus-specific CD4 and CD8 T cells during LCMV 
infection, as IFN inhibited Treg proliferation and activation. IFN inhibition of Tregs 
resulted in reduced regulatory function, allowing for greater expansion of other T 
cell subsets. These data indicate that inhibition of Tregs by type 1 IFN during 
acute infections is important for generation of efficient T cell responses (65).  
These distinct and contradictory effects that type 1 IFN can have on CD8 
T cells are most likely mediated by the ability of IFN to activate multiple 
downstream signaling pathways, including JAK/STAT, PI3K, and mTOR (3, 32). 
The combination of STAT molecule(s) that are phosphorylated and translocated 
into the nucleus may control the outcome of CD8 T cell activation. Activation of 
STAT1 downstream of type 1 IFN receptor signaling generally has anti-
proliferative effects on CD8 T cells (54, 90-92). In contrast, type 1 IFN-mediated 
activation of STAT3 and/or STAT5 has anti-apoptotic and pro-mitogenic effects 
(93, 94). Type 1 IFN signaling via STAT4 promotes both the acquisition of 
effector function, including IFNγ production, and clonal expansion (52, 81, 95).  
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STAT1 is an IFN-inducible gene whose function in CD8 T cells is anti-
proliferative (39, 91). Therefore, how can type 1 IFN, a signal 3 cytokine, exert 
positive clonal expansion effects if it induces STAT1 and anti-proliferative 
effects? Recent studies showed that during LCMV infection, virus-specific CD8 T 
cells had decreased total STAT1 levels and increased STAT4 levels, thereby 
promoting effector T cell differentiation and clonal expansion over anti-
proliferative effects (95). Thus, type 1 IFN can have both inhibitory and 
stimulatory effects on CD8 T cell proliferation, and when type 1 IFN provides 
signal 3 cytokine activity, it has positive effects on CD8 T cell expansion.   
 
CD8 T cells 
H. CD8 T cells and virus infections – an overview 
During the course of an immune response to a pathogen, the innate and 
adaptive immune systems work together in order to control infections. The innate 
immune system initiates an inflammatory response, which helps to activate the 
adaptive immune response. CD8 T cells are especially important for clearing 
intracellular pathogens, including viruses and certain bacteria.   
There are several distinct phases of CD8 T cell activation during viral 
infections. Once naïve CD8 T cells see signals needed for full activation they 
undergo several rounds of division resulting in clonal expansion and 
differentiation into effector cells. CD8 T cell effectors comprise a heterogeneous 
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population of cells, most of which have the ability to produce multiple effector 
functions upon encountering cognate ligand. Effector CD8 T cells will produce 
multiple cytokines including IFNγ, TNF, and sometimes IL-2 (96). Effector CD8 T 
cells can also specifically lyse target cells through the activation and secretion of 
effector molecules including perforin and granzymes (97). After antigen is 
cleared, the majority of T cells die during the contraction phase, but there is a 
small but generally stable population that remains and forms memory. Memory T 
cells have reduced requirements for activation, in that they can respond 
immediately to encountering antigen again, without the need for costimulation or 
signal 3 cytokines, and produce effector functions prior to cell division. Rapid 
activation allows CD8 T cells to control and clear the infection faster, resulting in 
reduced pathology (98-103).   
I. Generation of CD8 T cells 
Similar to other hematopoietic cells, T cell development begins in the bone 
marrow. Progenitors develop in the bone marrow and migrate to the thymus 
where they proliferate and differentiate into mature T cells. TCRs are generated 
by V, D and J gene segment rearrangement with insertions or deletions at the 
junctions, resulting in a variety of distinct TCRs (104). The junctions form the 
highly variable regions of the TCR, termed complementarity determining regions 
(CDR), which bind the pMHC complex. T cells are positively selected in the 
thymus based on their ability to bind to self-peptide MHC complexes with a 
certain degree of affinity. During positive selection, CD4 and CD8 T cell lineage 
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commitment occurs based on the ability of TCRs to bind to Class I or Class II 
MHC molecules (105, 106). TCRs that bind to self-peptide MHC complexes with 
too high affinity will be deleted in a process termed negative selection (105, 106). 
The deletion of T cell clones that react with self with too high affinity result in self-
tolerance and therefore limit the potential for T cells to induce autoimmunity once 
T cells exit the thymus and migrate into the periphery. The majority of T cells die 
during thymic selection, but the select few that survive through positive and 
negative selection migrate to the periphery as a mature naïve T cells (105, 106) .  
The end result of thymic selection is the generation of a wide range of T 
cells with different specificities. T cells have different affinities for both self- and 
foreign-ligands. In the mouse, there are estimated to be ~ 2x106 clones (of about 
10 cells each) per spleen (107). Although this number is far lower than the 
possible receptor combinations, it still allows for a wide diversity. Studies 
identified that the number of precursors specific to an individual peptide to be 
anywhere from 80-1200 cells/mouse (108). Further studies identified that for a 
specific pathogen, containing multiple antigens, the precursor frequency was 
found to be quite high (~1 in 1,500 for vaccinia virus (VACV) and ~1 in 3000 for 
LCMV) (109). This suggests that there are ~14,000 T cells specific for VACV and 
~7,000 for LCMV in a naïve mouse. However, most of these studies may not be 
sensitive enough to detect lower affinity clones, and thus these numbers may be 
underestimates. Although TCRs are said to be specific for one antigen, they are 
in fact specific for multiple pMHC complexes, but with a varying degree of affinity 
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(110). T cells show “polyspecificity,” and therefore a larger number of them may 
be considered cross-reactive than once previously thought (111). 
The affinity of the TCR for the self-selecting pMHC is much lower than the 
affinity of the TCR for cognate pMHC. CD5 expression was shown to positively 
correlate with the strength of TCR reaction with self-pMHC during selection 
(112). In other words, the stronger a T cell reacts with self-peptide MHC, the 
more CD5 expression on the surface. TCR sensitivity to self-peptide affects its 
ability to respond to foreign antigen (113). It was shown that T cells with higher 
CD5 expression will preferentially expand in response to antigen over the CD5 
low expressing CD8 T cells. Consequently, the increased responsiveness to 
foreign antigen of CD5 high T cells, which have stronger reactivity to self pMHC, 
may have implications in autoimmunity.  
J. CD8 T cell priming and activation 
Naïve CD8 T cells require 3 distinct signals for their full activation and 
expansion: TCR engagement of pMHC (signal 1), costimulation CD28:B7 (signal 
2), and inflammatory cytokines (signal 3). The process in which naïve CD8 T 
cells first encounter antigen is often termed priming and is used to distinguish it 
from effector CD8 T cell encountering antigen presented on target cells. Naïve T 
cells are constantly circulating throughout the body from the blood to lymph 
nodes (LN) and spleen. Naïve CD8 T cells express CD62L, which allows them to 
enter lymphoid structures (114). T cells enter secondary lymphoid organs in 
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search of their cognate antigen presented on DCs (75). T cells that do not 
engage cognate antigen leave the LN and continue circulating. When a naïve T 
cell encounters cognate antigen on DCs and other appropriate activation signals, 
instead of re-entering circulation, it remains in the LN where it divides, clonally 
expands, and differentiates into effector subsets before recirculating in search of 
peripheral antigen (115-117). However, should a naïve T cell only encounter 
cognate antigen on APCs, without costimulation, it either becomes anergic or 
dies via apoptosis (98, 103). Therefore, cognate antigen encounter alone is not 
sufficient for T cells to divide, as costimulation and inflammatory cytokines are 
also required.  
The classical costimulatory molecules are between B7 on APCs and 
CD28 on T cells; however, some additional factors have been shown to either 
compensate in the absence of B7 or contribute to costimulatory effects on T cells 
(77). CD28 costimulation induces production of IL-2 and expression of the high-
affinity IL-2 receptor, thus allowing for autocrine signals to promote growth and 
survival. Multiple members of the TNF superfamily have been shown to 
contribute to T cell activation. CD27, a TNF receptor family member, is 
constitutively expressed on T cells, and when engaged by its ligand, CD70, on 
DCs, it provides stimulatory signals to T cells (77, 103). CD40:CD40L interaction 
between DCs and T cells provide activating signals for both the APC and the T 
cell (77). There has even been evidence that without CD28 and IL-2, other 
cytokine signals like IL-6 and TNF can compensate and still provide CD8 T cells 
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with sufficient costimulatory signals for full activation (118). The costimulatory 
pathways that are engaged contribute to the outcome of CD8 T cell activation. A 
CD28-related protein, CTLA-4, also binds to B7 expressed on APCs, but instead 
of providing stimulatory signals like CD28, it inhibits T cell activation (77).   
 CD8 T cells that encounter antigen and costimulation undergo 
programmed cell division, but these two signals alone are not sufficient for full 
effector cell differentiation and survival into memory (98, 100). CD8 T cells need 
a third signal, provided by cytokines, including IL-12 or type 1 IFN, for efficient 
clonal expansion, differentiation into various effector populations, acquisition of 
cytolytic effector functions, and memory formation (81, 119-122). The most well-
known cytokines to induce signal 3 cytokine activity are IL-12 and type 1 IFN (98, 
100). One in vitro study showed that without IL-12, CD8 T cells did not proliferate 
(defined as an increase in number) well or develop full effector function (123). 
Type 1 IFN, however, can evidently substitute for IL-12 as a signal 3 cytokine 
(81, 122). Additional cytokines have also been described to have similar 
stimulatory effects on CD8 T cell expansion and effector function, including IFNγ 
and IL-21 (124-128).  
Signal 3 cytokines are required for efficient clonal expansion in response 
to antigen, and the infecting pathogen and resulting inflammatory environment 
determine which cytokine(s) provide signal 3 activity (78, 129-131). LCMV-
specific CD8 T cells use type 1 IFN as the signal 3 cytokine for effective primary 
T cell expansion, whereas Listeria and VSV depend on both type 1 IFN and IL-12 
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(78-80, 129, 132, 133). Studies showed that IFNAR KO LCMV-specific 
transgenic P14 CD8 T cells divided similarly to WT P14 cells but had reduced 
survival, thereby limiting their overall clonal expansion (79). Costimulation 
induces expression of certain survival factors, including anti-apoptotic molecules 
like Bcl-2 and Bcl-xl, but in the presence or absence of signal 3 cytokines, levels 
of Bcl-2 and Bcl-xl were found to be similar between the two groups (88). This 
indicated that the enhanced survival was mediated by additional mechanisms. In 
other systems, the addition of adjuvants or IL-12 to activated CD8 T cells 
promoted their expansion by upregulating the inhibitor of κB (IκB) family member 
Bcl-3, which was found to prolong activated T cell survival (86-88).  
It is possible that naïve CD8 T cells acquire all three signals from an 
activated DC. In fact, in some infection models, CD4 T cells have been proven 
dispensable for efficient CD8 T cell expansion and effector function (103, 134, 
135). In the absence of CD4 help, “helpless” CD8 T cells function during the 
primary response, but have been found to have defects in secondary memory 
expansion (136). Thus, it is thought that under conditions where DCs can be 
activated directly by the pathogen, CD8 T cells do not require CD4 help; however 
under other conditions, CD4 T cells have to activate DCs for them to provide 
efficient stimulatory functions to mediate naïve CD8 T cell responses (128, 135). 
K. CD8 T cell differentiation  
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CD4 T cells are known for their ability to differentiate into various subsets 
upon activation, and CD8 T cells also generate a heterogeneous population of 
effector cells upon activation and expansion. After priming, changes in CD8 T cell 
phenotype occur during various stages of T cell activation and expansion. CD69, 
one of the earliest activation markers induced in CD8 T cells helps retain 
lymphocytes in lymphoid organs (137, 138). CD25, the high affinity IL-2 receptor 
is also induced early after T cell activation (139). Antigen experienced CD8 T 
cells upregulate the cellular adhesion molecule CD44 and high expression levels 
are retained throughout the remainder of the T cells life (140). Early activated T 
cells will also downregulate CD62L, which may serve to keep lymphocytes that 
have been sufficiently activated out of secondary lymphoid organs, increasing 
probability of encounter with antigen at the site of infection (141). After the 
transient upregulation of CD69 and CD25, activated CD8 T cells continue to 
differentiate into various effector populations. 
Based on expression of two different markers, killer cell lectin-like receptor 
subfamily G member 1 (KLRG1) and CD127, distinct effector populations 
including early effector cells (EEC), short lived effector cells (SLEC) and memory 
precursor effector cells (MPEC) can be identified (78, 100, 142-145). Naïve CD8 
T cells are CD127hi and KLRG1lo, and upon activation, many cells will 
downregulate CD127 and some upregulate KLRG1. T cells that are negative for 
both markers are termed EECs and retain the ability to differentiate into either 
SLECs or MPECs (100, 146). CD127lo, KLRG1hi cells are termed SLECs, and 
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are terminal effectors. The majority of this population die after antigen is cleared 
during the contraction phase. MPEC is a population of cells that has reacquired 
CD127 and preferentially survive the contraction phase and develop into memory 
cells (144, 147). Many of these effector populations were identified by sorting 
individual populations and determining their fate after transfer into new hosts.  
 A number of different factors have been associated with differentiation of 
CD8 T cells into effectors vs. memory precursors. TCR signal strength, TF 
induction, cytokine stimulation, chromatin accessibility, and metabolic regulation 
all contribute to T cell differentiation (77, 102, 103, 144, 148-151). Many models 
suggest that the balance between different TFs is important in differentiation. 
Two T-box TFs, Tbet and Eomesodermin (Eomes), regulate many of the same 
genes and are important for effector functions in CD8 T cells, including IFNγ 
production (103, 152-154). However, their roles are not redundant, as expression 
of Tbet is associated with terminal differentiation, and Eomes associates with 
memory formation (152, 153). The balance between other TFs are also 
differentially associated with the SLEC vs MPEC phenotype including inhibitor of 
DNA-binding (Id)2 and Id3, B lymphocyte induced maturation protein 1 (Blimp-1) 
and B-cell lymphoma 6 (Bcl-6), and STAT4 and STAT3, respectively (77, 102, 
149, 151, 155). T-cell factor 1 (TCF-1) is a TF that was found to be particularly 
important for memory cell formation (102, 151). Interestingly, expression of some 
of these TFs will actually negatively regulate the other. High expression of Blimp-
1 will suppress Bcl-6 expression, and vice-versa. The reciprocal nature of some 
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of these TFs suggests that once a cell is driven into a particular differentiation 
pathway, the TFs induced will only solidify the pathway, by actively repressing 
the other (102, 151).  
 Stronger TCR signaling has been associated with terminal effector 
differentiation (SLEC) rather than memory precursors (148). This may be partially 
due to the upregulation of the TF IRF4, which is induced and differentially 
regulated based on strength of TCR stimulation, where stronger TCR signals 
resulted in increased IRF4 expression (148). A recently identified TF, basic 
leucine zipper transcription factor, ATF-like (BATF), is required for effector 
differentiation of CD8 T cells in response to LCMV infection (156). IRF4 and 
BATF associate with one another, have similar downstream targets, and regulate 
many of the same genes (157, 158). 
TCR signal strength is not the only thing that governs effector fate; 
inflammatory cues also contribute to T cell effector differentiation. Signal 3 
cytokines play an important role in CD8 T cell differentiation into various 
phenotypic and functional effector populations (143, 145). Differences in CD8 T 
cell exposure to costimulatory molecules and cytokines can alter their 
differentiation into EECs, SLECs and MPECs (77). Recent studies investigating 
the role for signal 3 cytokines in primary CD8 T cell responses have shown that 
loss of IL-12R, IFNAR, or both receptors can alter CD8 T cell differentiation, 
showing reduced SLEC and increased MPEC formation (78, 100, 142, 143, 145). 
Increased inflammation, in the form of IL-12 production, induced higher levels of 
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Tbet and promoted terminal differentiation (143, 153). Conversely, IL-12 has 
been shown to inhibit Eomes induction thus inhibiting effector memory formation 
(159). This suggests that once a programming event is starting to take place, 
there are mechanisms that may result in the continuation of a specific pathway. 
L. CD8 T cell effector function 
In addition to cytolytic capability, CD8 T cells also can have 
immunoregulatory roles during infections, in part by secreting cytokines, which 
can activate other cells. Similar to CD4 T cells, CD8 T cells can also be 
distinguished as T cytotoxic (Tc)1, Tc2 and Tc17 cells, based on the cytokines 
produced (160). Although they may produce different cytokines, studies showed 
that they still retain cytolytic capability.  
Naïve CD8 T cells are functionally distinct from effector and memory CD8 
T cells. Naïve CD8 T cells stimulated with cognate antigen have the ability to 
produce TNF but not IFNγ (161, 162). After activation, division, and 
differentiation, naïve T cells gain the ability to produce IFNγ in response to 
antigen stimulation (141). Some activated CD8 T cells also retain the ability to 
produce TNF, and therefore will produce multiple cytokines. A small proportion of 
effector CD8 T cells have the capability of producing IL-2 in addition to IFNγ and 
TNF, although this function is seen more in memory CD8 T cells than effectors. 
IFNγ has anti-viral properties and increases Class I MHC on the surface of cells, 
making it easier for CD8 T cells to identify infected targets. IFNγ also actives 
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macrophages, which play an important role in pathogen clearance. TNF has the 
ability to bind to both TNF receptor (TNFR) 1 and TNFR2, and thus has 
differential effects on cells. TNFR1 is widely expressed, but TNFR2 is restricted 
to hematopoietic cells. TNF engagement of TNFR1 can induce apoptosis, but 
TNF also activates nuclear factor kappa-light-chain-enhancer of activated B cells 
(NFκB) and MAPK pathways and thus serves an immunoregulatory role. In fact, 
the anti-apoptotic effects of NFκB will often dominate over the apoptotic effects 
TNFR1 signaling can induce (77, 163). 
Activated CD8 T cells are known for their ability to specifically lyse 
antigen-specific target cells. Once activated, CD8 T cell upregulate effector 
molecules including perforin and granzymes, thus priming the T cell for rapid 
elimination of target cells (97). Studies have shown that activated effector CD8 T 
cells can lyse target cells in less than 5 minutes. Cytolytic function requires both 
perforin and granzymes, where perforin helps granzymes translocate into the cell 
(164). Granzymes are proteases that can cleave and activate effector caspase 3, 
thus inducing apoptosis (164). Effector CD8 T cells can also trigger apoptosis 
through TNF family members like FasL and TRAIL (164). Activated CD8 T cells 
upregulate FasL, which, upon engagement with Fas on target cells, induces cell 
death (164). The Fas:FasL mediated killing is important for immune cell 
homeostasis as mice deficient in either component develop severe 
lymphoproliferative disorders. TRAIL-mediated lysis of virus-infected cells is 
important for control of infections including IAV (165).  
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Many of the effector molecules that activated CD8 T cells express, 
including IFNγ, perforin and granzyme B, can be regulated by the T-box TFs Tbet 
and Eomes (153, 154, 166-168). Signal 3 cytokines, including IL-12, IL-21, and 
type 1 IFN, will augment the acquisition of CD8 T cell effector functions, including 
production of cytokines (IFNγ and TNF) and cytolytic activity (169). In vitro 
studies identified that deficiencies in type 1 IFN, IL-12 or IL-21, resulted in 
decreased lytic ability and low levels of granzyme B expression in CD8 T cells 
(79, 81, 169, 170). Additional in vivo studies showed reduced granzyme B 
expression in IFNAR KO transgenic P14 CD8 T cells compared to WT P14 CD8 
T cells (79). However, not all infection models showed the same requirements for 
the specific signal 3 cytokines in driving these effector functions (78, 79). 
M. Memory CD8 T cells  
After antigen is cleared the majority of the terminal effectors die during the 
contraction phase while a subset of effectors that expresses the IL-7R 
preferentially make it into the memory pool (147). CD8 T cell memory cells can 
be divided into three main categories, central memory (TCM), effector memory 
(TEM), and resident memory (TRM) (102, 149). Subsets can be distinguished 
based on phenotypic markers, functions, and their location within the body. 
Because memory T cell subsets are antigen experienced, they all express high 
levels of CD44. Central memory cells are CD62Lhi, which enables them to enter 
into secondary lymphoid organs. TCM generally proliferate more than other 
memory subsets and produce more IL-2, but have reduced effector functions 
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(102). TEM cells express low levels of CD62L and are mostly found in non-
lymphoid organs and can immediately produce cytolytic effector functions upon 
encountering antigen. Unlike TCM, TEM have reduced proliferative potential. The 
most recently identified subset of memory cells is the TRM population, also known 
as tissue-resident memory cells (102). These cells can be found in organs such 
as the skin, lungs, and gut, but are not found in the circulation or in any lymphoid 
organs. TRM cells are phenotypically distinct and show high expression of CD103, 
CD69, and low CD62L levels (102). TRM have very little proliferative and 
migratory potential; however, they have enhanced immediate effector function 
and some have been shown to express high levels of granzyme B (102).  
The effectiveness of memory is associated with increased frequencies of 
antigen specific cells and the ability to respond faster during subsequent antigen 
encounter. Besides differences in phenotype, memory CD8 T cells have 
differential requirements for activation when compared to naïve CD8 T cells. 
Where naïve T cells require 3 distinct signals for full acquisition of effector 
function and efficient clonal expansion, memory T cells have a reduced threshold 
for activation (171). Indeed, memory CD8 T cells were shown to have increased 
cytolytic effector function over naïve CD8 T cells, and produced cytokines (IFNγ 
and IL-2) much earlier than naïve CD8 T cells (172, 173). Additionally, memory 
CD8 T cells were activated in response to peptide concentrations 10-50 fold 
lower than naïve CD8 T cells (174). Unlike naïve CD8 T cells, which require cell 
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division prior to effector function acquisition, memory CD8 T cells do not need to 
divide before exhibiting effector function (123, 141, 154).  
 
Thesis objectives 
Efficient clonal expansion and differentiation of CD8 T cells are required to 
develop protective memory CD8 T cells. Efficient activation of CD8 T cells 
involves cell division, clonal expansion, differentiation into heterogeneous 
effector populations, and formation of a stable functional memory population.  
Priming of naïve T cells is therefore extremely important because it can affect all 
aspects of CD8 T cell activation. The priming of naïve T cells requires three 
distinct signals: a cognate peptide MHC-TCR interaction (signal 1), costimulation 
(signal 2), and infection-induced cytokines (signal 3). The requirements for signal 
3 cytokines have only been recently identified. However, the timing of exposure 
to these signals has yet to be investigated. T cell priming is generally described 
as a linear event, where T cells always encounter antigen first, then receive 
costimulation, and finally signal 3 cytokines (canonical T cell priming). In reality, 
some T cells will be exposed to signals 1, 2 and 3 out of order. If T cells are 
primed out-of-sequence, do they behave the same as canonical CD8 T cells?   
I sought to investigate how the timing of signal 3 cytokines affects CD8 T 
cell activation. During the course of an immune response, not all T cells see 
antigen, costimulation, and inflammatory cytokines at the same time. I 
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questioned how the order of these signals affects CD8 T cell priming and 
subsequent activation, expansion and differentiation. I investigated how out-of-
sequence signaling affects T cell activation immediately after cognate antigen 
stimulation (4-5 hours), and after prolonged exposure to cognate antigen (days-
weeks). 
CD8 T cells pre-exposed to type 1 IFN and costimulatory molecules in the 
presence of self-peptides gained the ability to respond immediately to cognate 
antigen stimulation. These T cells were termed primed because they produced 
immediate effector functions in response to antigen stimulation prior to cell 
division. Primed naïve CD8 T cells produced multiple cytokines in response to 
low-affinity, and low-density antigens, and gained ability to specifically lyse target 
cells. However, CD8 T cells that are pre-exposed to signal 3 cytokines and then 
exposed to cognate antigen stimulation in the context of a virus infection showed 
defects in clonal expansion, effector differentiation, effector function, and memory 
formation. 
The findings presented here may seem contradictory because out-of-
sequence signaling can prime T cells to produce immediate effector functions 
and cause defects in T cell expansion and effector differentiation. However, 
these two models assessed T cell function at different points after antigen 
exposure; one where functions were evaluated within hours after seeing cognate 
antigen, and the other showing T cell responses after days of antigen stimulation. 
Identifying how the order of activation signals during T cell priming can affect 
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subsequent T cell function is important to study. The discoveries presented here 
will enhance our understanding of T cell responses during infections and will 
provide useful information in developing better and more effective vaccines.   
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CHAPTER II: Materials and Methods 
A. Mice  
C57BL/6J (Ly5.2+), B6.129P2-B2mtm1Unc/J (β2Microglobulin KO) male 
mice were purchased from The Jackson Laboratory (Bar Harbor, ME).  
B6.IFNαβR KO (Muller 1994), TAP KO, B7 KO, 3 KO (70), and congenic B6.SJL 
(Ly5.1+) mice were bred in the Department of Animal Medicine at the University 
of Massachusetts Medical School (UMMS). Congenic Ly5.1 OT-I (106), P14 
(175), SMARTA (176) and Thy1.1 P14 TCR-transgenic mice were bred in the 
Department of Animal Medicine at the University of Massachusetts Medical 
School (UMMS). The P14 transgenic mice were bred onto the B6.IFNαβR KO 
background to generate P14 CD8 T cells that lacked IFNαβR.  
B. Viruses and inoculations 
Lymphocytic choriomeningitis virus (LCMV), strain Armstrong, was 
propagated in baby hamster kidney (BHK21) cells, as previously described (177, 
178). Mice were injected intraperitoneally (i.p.) with 5x104 pfu of LCMV. Mice 
were injected with 5x106 pfu of VACV-GP (recombinant vaccinia virus expressed 
glycoprotein from LCMV) i.p. Organ homogenate viral titers were determined by 
plaque assay using Vero cells. 
Poly(I:C) was purchased from InvivoGen (San Diego, CA) and diluted in 
HBSS for a concentration of 1 μg/μl. Mice were either inoculated with 200 μl 
HBSS or 200 μg poly(I:C) i.p. Anti-CD40L antibody (clone MR1) was a gift from 
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Dr. Michael Brehm, and mice received 500 μg/mouse in 200 μl i.p. To activate 
P14 CD8 T cells without a virus-induced inflammatory response, mice were 
inoculated intravenously (i.v.) with 5 μg (diluted in HBSS) of a 13-mer peptide 
(GP33-45) (KAVYNFATCGIFA) from the LCMV glycoprotein.  
C. Cytokines and peptides 
Mouse IFNβ was purchased from PBL Interferon Source. Cytokines: IL-2 
was purchased from BD Biosciences, IL-6 and IL-12 were purchased from R&D, 
and IL-7 and IL-15 were purchased from PeproTech, INC. Splenocytes were 
stimulated ex vivo with cytokine concentrations of 1000 U/ml IFNβ, or 10 μg/ml of 
IL-2, IL-6, IL-7, IL-12, or IL-15 at 37°C for ~30 minutes. For intracellular cytokine 
staining (ICS) P14 cells were stimulated with 1 μM of GP33 peptide 
(KAVYNFATC) (175) or altered peptide ligand (APL) F6L (KAVYNLATC) (179), 
OT-I cells were stimulated with 1 μM of OVA (SIINFEKL) (106) or OVA- APLs 
including Y3, T4, V4, and G4 (SIYNFEKL, SIITFEKL, SIIVFEKL, and SIIGFEKL) 
(180) and polyclonal CD8 T cells were stimulated with 1 μM of GP33, NP396 
(FQPQNGQFI), GP276 (SGVENPGGYCL), or NP205 (YTVKYPNL). Whole 
splenocytes or RMA cells were labeled with 1 μM of the minimal GP33 epitope or 
the vaccinia virus K3L epitope (YSLPNAGDVI). Peptides purchased from 21st 
Century Biochemicals (Marlboro, MA) unless otherwise noted. APLs were 
generously provided by Dr. Leslie Berg.  
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D. Adoptive transfers 
Spleens were harvested, single cell suspensions were made, and RBCs 
were lysed using 0.84% ammonium chloride. Where described, cells were 
resuspended at 1x107 cells/ml of 5 mM stock of CellTrace Violet (Molecular 
Probes) and incubated for 15 min in a 37°C water bath, mixing every 5 minutes. 
HBSS was used to wash and resuspended cells for transfer into recipients, each 
receiving 200 μl i.v. When transferring a specific number of P14 CD8 T cells, 
frequencies were determined via flow cytometry by staining for CD8α, Vα2, and 
the congenic marker Ly5.1 or Thy1.1 if applicable. The total number of cells was 
calculated to transfer equal numbers into each group.  
E. Surface staining 
Single cell suspensions were prepared by filtering cells through 190 
micron mesh. Red blood cells were lysed using 0.84% ammonium chloride and 
2-4x106 cells were plated per well in a 96 well round bottom plate in complete 
media. Fc receptors were blocked using anti-Fc (2.4G2) in FACS buffer (2% 
heat-inactivated FCS in HBSS) for 5 min at 4°C. Cells were washed with FACS 
buffer and stained with various combinations of fluorescently conjugated 
antibodies against surface proteins for 20 min at 4°C. Antibodies used include 
CD3ε (145-2C11), CD4 (RM4-5), CD8α (53-6.7), CD8β (YTS156.7.7) CD8β 
(eBioH35-17.2), CD44 (IM7), CD62L (MEL-14), CD127 (A7R34), CD27 
(LG.3A10), CD25 (PC61), CD43 (1b11), CD126 (D7715A7), CD132 (TUGm2), 
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CD122 (TM-BETA1), CD69 (H1.2F3), CD70 (FR70), CD28 (E18), ST2 (RMST2-
2), CD86 (GL1), CD80 (16-10A1), H2-Kb (AF6-88.5), H2-Db (KH95), I-Ab (AF6-
120.1), NK1.1 (PK136), IFNGR1 (2E2), IFNAR1 (MAR1-5A3), CD11a (M17/4), 
CD11b (M1/70), CD11c (HL3), B220 (RA3-6B2), CD19 (ID3), F4/80 (BM8), BST2 
(CD317) (eBio927), Ly5.1 (A20), Thy1.1 (OX-7), Thy1.1 (HIS51), CXCR3 
(CXCR3-173), CCR7 (4B12), KLRG1 (2F1), CD124 (mIL4R-M1) and Vα2 
(B20.1). After surface staining, cells were washed with FACS buffer and fixed 
using BD cytofix (BD bioscience) for 5 min at RT. After washing, cells were 
resuspended in FACS buffer and collected via flow cytometry. All antibodies used 
were from BD bioscience (San Jose, CA), eBioscience (San Diego, CA), or 
BioLegend (San Diego, CA) unless otherwise noted.  
F. Transcription factor and intracellular staining 
Cells were isolated, prepared and stained as described in surface staining 
section. Cells were permeablized using the Foxp3 staining buffer kit 
(eBioscience) or BD perm buffer III (BD bioscience) per manufactures 
instructions. A variety of fluorescently conjugated antibodies were used to stain 
for intracellular proteins including Eomes (Dan11mag), Tbet (eBio4B10), IRF4 
(3E4), BATF (MBM7C7), Ki67 (B56), Bcl-2 (3F11), and STAT1 (1/STAT1). 
Unconjugated antibodies including TCF1 (C63D9), Bcl-xl (54H6), Bcl-3 (C-14) 
(Santa Cruz Biotechnology Inc., Dallas, TX) Bim (C34C5), STAT3 (79D7), 
STAT4 (C46B10), STAT5 (3H7) and SOCS1 (A156) were stained with a 
secondary antibody FITC Donkey anti-rabbit IgG (Poly4046). Antibodies used 
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were from BD bioscience (San Jose, CA), eBioscience (San Diego, CA), 
BioLegend (San Diego, CA), or Cell Signaling Technology, Inc. (Danvers, MA).  
G. Intracellular cytokine staining 
Single cell suspensions were prepared, treated and plated as described in 
section E (surface staining). Cells were stimulated for 4-5 hours at 37°C 5% CO2 
in the presence of 1 μl/ml Golgi Plug (BD Bioscience), and 10 U/ml human rIL-2 
with either 250 ng/ml anti-CD3ε (145-2C11, BD Bioscience), 1 μM GP33, 50 
ng/ml PMA and 500 ng/ml ionomycin, or without additional stimulation. After 
stimulation, cells were stained for surface expression as described in section E. 
After surface staining, cells were permeabilized using either BD Cytofix/Cytoperm 
(BD bioscience), or Foxp3 Staining Buffer kit (eBioscience) per manufacturer’s 
instructions. After permeabilization, cells were stained with a combination of 
antibodies conjugated with different fluorophores including IFNγ (XMG1.2), TNF 
(MP6-XT22), IL-2 (JES6-5H4), and granzyme B (GB11, Invitrogen). To test if 
cells were actively degranulating, antibodies to CD107a (1D4B) and CD107b 
(ABL-93) were added during stimulation at 37°C. Cells were washed and 
resuspended in FACS buffer for acquisition. All antibodies used were from BD 
bioscience (San Jose, CA), eBioscience (San Diego, CA), or BioLegend (San 
Diego, CA) unless otherwise noted. 
H. Phosflow staining 
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To identify phospho-specific STATs, the BD Phosflow Alternative Protocol 
1 was used and slightly modified. Spleen leukocytes were isolated, stimulated 
(where appropriate), fixed, stained for surface molecules, permeabilized, and 
finally stained for intracellular proteins. Spleens were isolated, and single cell 
suspensions were prepared as described in Section E. Cells were incubated at 
37°C in 100 μl of media for the indicated times in the presence (stimulated) or 
absence (unstimulated) of cytokines. Cytokines tested included IL-2, IL-6, IL-7, 
IL-12, IL-15, IFNγ, and IFNβ. Total volume was brought up to 200 μl before 
spinning. Cells were fixed with BD cytofix (BD Bioscience) on ice for 20 min, and 
surface molecules were stained using the protocol described in Surface Staining. 
After surface staining, cells were permeablized with BD Perm buffer III (BD 
Bioscience) for 30 min on ice. Splenocytes were washed and then stained with a 
combination of fluorescently labeled Abs pY701 STAT1 (BD Bioscience), pY705 
STAT3 (BD Bioscience), pY693 STAT4 (BD Bioscience), or pY694 STAT5 (BD 
Bioscience) for 30 min at RT in the dark.  After intracellular staining, splenocytes 
were washed, resuspended in FACS buffer and acquired. 
I. Annexin V staining 
Single cell suspensions were made, and surface molecules were stained 
as described in section E. Cells were washed with Annexin binding buffer 
(eBioscience) and stained for Annexin V and 7AAD for 20 min at 4°C. Samples 
were collected with flow cytometer directly after staining.  
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J. RNA flow 
To detect RNA expression in a heterogeneous population of cells, we 
utilized QuantiGene FlowRNA (affymetrix, eBioscience). Overall procedure 
includes steps 1. Fixation and permeabilization, 2. Target probe hybridization, 
and 3. Signal amplification and detection. Single cell suspensions were prepared 
and stained according to protocol stated above. FlowRNA assay was performed 
according to manufactures protocol using type 1 probe SOCS1 (VB1-16311), and 
type 6 probe Rpl13a (VB1-15315). Samples were run on day 2 of the assay, 
immediately after the signal amplification and detection step.  
K. Flow cytometry 
Previously fixed samples (Cytofix, Cytofix/Cytoperm, and Foxp3 staining 
buffer kit) were run within 1 week of staining. Phosflow, Annexin V, Trogocytosis, 
and RNA flow staining procedures were acquired immediately after staining cells. 
All samples were acquired on a BD bioscience LSRII using FACS Diva software 
for data collection and FlowJo (Tree Star Inc., Ashland, OR) for data analysis.   
L. Trogocytosis assay 
Effector P14 cells were generated using adoptive transfers and poly(I:C) 
inoculation described in sections B and D. Targets were RMA cells cultured in 
complete RPMI and were un-pulsed, pulsed with an irrelevant peptide, K3L, or 
pulsed with cognate peptide, GP33, at 1 μM for ~ 90-120 minutes at 37°C 5% 
CO2. After incubation, target cells were labeled with fluorescent lipids SP-
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DiIC18(3) (Molecular probes) and diluted in Diluent C (Sigma Aldrich) using the 
protocol adapted from Daubeuf S. et al (181). Briefly, cells were incubated at 
room temp with 40 mM SP-DiIC18(3) lipid in Diluent C buffer for 5 min. Labeling 
was quenched by addition of FCS, and cells were washed a minimum of 3 times 
with complete media. Target cells (~7x105) were co-cultured with effector cells 
(1.5x106 total splenocytes) per well for 1 hour at 37°C 5% CO2. Cells were 
stained with surface antibodies of interest, and samples were acquired directly 
after staining.   
M. In vivo cytotoxicity assay 
Congenic P14 CD8 T cells were adoptively transferred into B6 mice as 
described in Section D. Mice were either inoculated with HBSS or poly(I:C) for ~ 
1 day followed by target cell transfer. Splenocytes from B6 mice were isolated, 
single cell suspensions were prepared as described earlier. Cells were pulsed 
with peptide at 37°C, 5% CO2 for 1 hour. After peptide labeling, cells were dual 
labeled with 1 μM CellTrace Far Red DDAO (Molecular Probes), and various 
concentrations of CellTrace violet (Molecular probes) to differentiate cells labeled 
with different peptides. Peptide-pulsed target cells were adoptively transferred 
into recipient mice, and splenocytes were harvested ~20 hours post transfer. 
Specific lysis was calculated based on the following formula: 
% specific lysis = 100 - ((Experimental/Control)/Control x 100)   
N. Plaque assay 
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Organs were harvested, ground, and supernatants were collected by 
spinning at 2000xg for ~20 minutes. Samples were stored at -80°C until plaque 
assay was performed. LCMV titers were determined by plaque assay using Vero 
cells. Vero cells, ~2x105 in 2 ml per well, were plated in 6 well plates on day -1 
and incubated overnight at 37°C, 5% CO2. Serial dilutions of organ supernatants 
were used with a minimum of 5 dilutions per organ. 100 μl of each virus dilution 
was added to 1 ml of media per well. Plates were rocked to distribute virus 
evenly and incubated at 37°C 5% CO2 for 1.5 hours, rocking plates every 45 
minutes. Plates were overlaid with 4 ml of 1:1 mix of 1% SeaKem-ME agarose 
and complete EMEM and left in incubator until stained 4 days later. Plates were 
stained with 2 ml of 1:1 mixture of 1% SeaKem-ME agarose and complete 
EMEM with ~15 μl of 1% Neutral Red per ml of mixture. Plates were counted for 
plaques the following day. 
O. Microarray and quantitative real time PCR 
Single cell suspensions of splenocytes were made, and red blood cells 
were lysed using 0.84% ammonium chloride. Naïve CD44lo CD8 T cells were 
sorted to 98-99% purity using MACS Naïve CD8α+ T cell Isolation Kit (Miltenyi 
Biotech). RNA was isolated from sorted naïve CD8 T cells with an RNeasy mini 
kit (Qiagen). cDNA was generated using the RT2 Easy First Strand Kit (Qiagen), 
and QuantiFast SYBR Green PCR Kit (Qiagen) was used to determine the 
relative mRNA concentrations by quantitative real-time PCR. Primers for Socs1 
(RefSeq Accession number NM_009896.2) and Actb (RefSeq Accession number 
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NM_007393.3) were used. MoGene 2.0 ST Array (Affymetrix) gene chip was 
used to identify differences in gene expression between naïve CD8 T cells from 
HBSS-treated mice and poly(I:C)-treated mice.  
P. Statistical analysis 
Where appropriate, Students t test or linear regression were calculated 
using GraphPad InStat software. Significance was set at a P value of 0.05; * 
indicates a P of <0.05, ** a P of <0.01, *** a P of <0.001, and **** a P of < 
0.0001.  All results are expressed as means of +/- standard deviations (SD), 
unless otherwise noted. 
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CHAPTER III: Out-of-sequence signal 3 suppresses CD8 T cell responses in 
vivo 
A. Introduction 
Efficient clonal expansion and differentiation of CD8 T cells are essential 
to develop protective memory CD8 T cells. This requires three signals: a cognate 
peptide MHC-TCR interaction (signal 1), costimulation (signal 2), and infection-
induced cytokines (signal 3) (98-100). CD8 T cells that encounter antigen and 
costimulation undergo programmed cell division, but these two signals alone are 
not sufficient for full effector cell differentiation and survival into memory (98, 100, 
142). CD8 T cells need a third signal, provided by cytokines, including IL-12 or 
type 1 IFN, for efficient clonal expansion, differentiation into various effector 
populations, acquisition of cytolytic effector functions, and memory formation (81, 
119-122).  
Signal 3 cytokines are required for efficient clonal expansion in response 
to antigen, and the infecting pathogen and resulting inflammatory environment 
determine which cytokine(s) provide signal 3 activity (78, 129-131, 133). LCMV-
specific CD8 T cells, for example, use type 1 IFN as the signal 3 cytokine for 
effective primary T cell expansion (78-80). Signal 3 cytokines also play an 
important role in CD8 T cell differentiation into various phenotypic and functional 
effector populations. Differences in CD8 T cell exposure to costimulatory 
molecules and cytokines can alter their differentiation into EECs, SLECs and 
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MPECs (78, 100, 143, 145). Signal 3 cytokines have also been shown to 
augment the acquisition of CD8 T cell effector functions, including production of 
cytokines (IFNγ and TNF) and cytolytic activity (79, 81, 170). However, not all 
infection models show the same requirements for the specific signal 3 cytokines 
in driving these effector functions (78, 79). 
Type 1 IFN can have both inhibitory and stimulatory effects on CD8 T cell 
proliferation, and when type 1 IFN provides signal 3 cytokine activity, it has 
positive effects on CD8 T cell expansion. Type 1 IFN signaling is complex in that 
it can activate multiple downstream pathways, including the JAK/STAT pathway. 
Engagement of the type 1 IFN receptor promotes phosphorylation of downstream 
STAT molecules, including STAT1, 3, 4, and 5 (32). The combination of STAT 
molecule(s) that are phosphorylated and translocated into the nucleus controls 
the outcome of CD8 T cell activation.  
Recent in vivo studies from our laboratory showed that type 1 IFN can be 
a profound and universal factor inducing suppression of T cell proliferation during 
viral infections if the T cells are exposed to type 1 IFN prior to encountering their 
cognate ligand (34, 182). The fact that virus infections can induce a transient 
state of immune suppression was first described over a century ago, and since 
then, infections with a number of other viruses have been shown to induce a 
transient state of immune suppression in humans and animal models (183-190). 
Although virus-induced immune suppression can affect many aspects of the 
immune system, it is often associated with a reduced ability of T cells to 
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proliferate in response to mitogens or antigen-specific stimulation (191, 192). It 
should be noted that the timing of exposure of CD8 T cells to activation signals is 
very important, as T cells exposed to virus-induced inflammatory environments 
prior to cognate antigen respond differently to signals 1 and 2 compared to CD8 
T cells from naïve environments (34, 182, 193). Under circumstances when CD8 
T cells see antigen and costimulation prior to or at the same time as inflammatory 
cytokines, IL-12 or type 1 IFN have positive effects on T cell differentiation and 
expansion. However, recent studies from our lab have shown that CD8 T cells 
pre-exposed to virus-induced inflammatory environments showed reduced 
proliferation when exposed to cognate antigen (182).  
Considering type 1 IFN can have both positive and negative effects on 
CD8 T cell activation, I sought to investigate the role type 1 IFN was playing in 
virus-induced immune suppression. Virus-induced impaired proliferation could be 
mimicked by the type 1 IFN-inducer poly(I:C). To eliminate any off target effects 
that an actively replicating virus could induce, I chose to use poly(I:C) to study 
the mechanism of virus-induced T cell suppression. Through these studies, 
several interesting features of the mechanism of virus-induced immune 
suppression of CD8 T cells were identified: 1) CD8 T cells pre-exposed to 
poly(I:C) show a transient state of immune suppression, in terms of clonal 
expansion. 2) There is a marked defect in the ability of poly(I:C)-pretreated CD8 
T cells to respond to IFNβ signaling in terms of phosphorylating downstream 
STAT proteins. 3) The inability of poly(I:C)-pretreated CD8 T cells to respond to 
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IFNβ signaling makes these cells behave more similar to T cells that only receive 
2 signals, rather than ones that receive all 3 signals in the appropriate order. 
Consequently, poly(I:C)-pretreated, or out-of-sequence, CD8 T cells were found 
to have defects in clonal expansion, effector differentiation and function, and 
memory generation, resulting in reduced efficacy of viral clearance.  
B. Poly(I:C)-induced suppression of CD8 T cell proliferation 
1. Impaired clonal expansion of poly(I:C)-pretreated CD8 T cells is a 
transient and intrinsic defect.  
Our lab showed that CD8 T cells exposed to exogenous cognate antigen 
after initiation of a virus infection proliferated poorly in response to a cognate 
antigen stimulus (182). To investigate the mechanism of this virus-induced 
suppression of T cell proliferation, the IFN-inducer poly(I:C) was used to prime 
CD8 T cells. Congenic transgenic LCMV-specific P14 CD8 T cells were used 
here to study virus-specific T cells exposed to the IFN-inducer poly(I:C) prior to 
infection. Ly5.1 or Thy1.1 P14 splenocytes were transferred into Ly5.2/Thy1.2 B6 
hosts. Recipients were untreated (control) or inoculated with poly(I:C), and 
spleens were harvested 1 day later. Equal numbers of P14 cells that were Ly5.1-
control and Thy1.1-poly(I:C) treated (Figure 3.1A-C) or Thy1.1-control and 
Ly5.1-poly(I:C) treated (Figure 3.1D-F) were transferred into recipients which 
were immediately infected with LCMV. Spleens and PECs were harvested at the 
peak of transgenic CD8 T cell expansion, day 7 post infection, and the proportion  
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Figure 3.1: Impaired clonal expansion of poly(I:C)-pre-exposed P14 cells 
when in direct competition with control-treated P14 cells 
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Figure 3.1: Impaired clonal expansion of poly(I:C)-pre-exposed P14 cells 
when in direct competition with control-treated P14 cells 
Congenic P14 cells (Ly5.1 or Thy1.1) were adoptively transferred into B6 mice, 
which were subsequently inoculated with poly(I:C) or remained untreated. One 
day after treatment, splenocytes were isolated and similar numbers of P14 CD8 
T cells that were untreated or poly(I:C) treated were transferred into the same 
WT B6 recipients. Immediately after P14 cell transfer, mice were infected with 
5x104 pfu LCMV Armstrong i.p. At day 7 post infection, spleens and PECs were 
harvested and frequency and number of donor P14 cells were determined. (A-C) 
Ly5.1 P14 cells were control treated and Thy1.1 P14 cells were poly(I:C) treated. 
(D-F) Thy1.1 P14 cells were control treated and Ly5.1 P14 cells were poly(I:C) 
treated (A, D) representative flow cytometry plots gated on CD8α+Vα2+ from 
spleen or PEC. Frequency (B, E) and number (C, F) of P14 cells that were 
control treated (open bars) and poly(I:C) treated (black bars) is graphed. Data 
are representative of at least 2 experiments with n = 3 mice per group. # 
indicates a p value of 0.0625 
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(Figure 3.1A-B and D-E) and total number (Figure 3.1C and F) of donor P14 
cells were determined. P14 cells pretreated with poly(I:C) (black bars) showed 
reduced proportions and total number of P14 cells compared to controls (open 
bars), regardless of congenic markers. That is, both Thy1.1 poly(I:C)-treated 
(Figure 3.1A-C) and Ly5.1 poly(I:C)-treated P14 cells (Figure 3.1D-F) showed 
suppression of proliferation when compared to control-treated P14 cells from the 
same mice. The reduced proportion and number of P14 cells was seen in both 
the PECs and the spleen, indicating defects in trafficking cannot account for the 
suppression seen.  
I wanted to investigate whether the suppressive effects of poly(I:C) 
pretreatment were only seen when cells were in direct competition with control 
treated cells. To test this, Thy1.1 P14 cells were transferred into mice which were 
untreated (control) or exposed to poly(I:C) for 1 day. Equal numbers of control- or 
poly(I:C)-treated P14 cells were determined by flow cytometry and transferred 
into separate hosts, which were subsequently inoculated with LCMV. Figure 3.2 
shows the proportion (A-B) and number (C) of donor P14 cells in the spleen at 
day 7 post infection. These data indicate impaired clonal expansion of poly(I:C)-
pretreated P14 cells occurs both with and without direct competition with control 
P14 cells. The reduced proliferation seen with direct competition suggests an 
intrinsic defect in the CD8 T cell expansion.  
To determine how long the suppressive effects last for, I utilized the 
poly(I:C)-induced impaired CD8 T cell proliferation model. Ly5.1 P14 cells were 
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Figure 3.2: Impaired proliferation of poly(I:C)-pretreated P14 CD8 T cells 
without direct competition with control P14 CD8 T cells  
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Figure 3.2: Impaired proliferation of poly(I:C)-pretreated P14 CD8 T cells 
without direct competition with control P14 CD8 T cells  
Thy1.1 P14 CD8 T cells were transferred into WT B6 mice. Mice were untreated 
or inoculated with poly(I:C), splenocytes harvested 1 day later and equal 
numbers of P14 cells from each group were transferred into different recipients. 
Mice were infected with 5x104 pfu LCMV i.p. and spleens were harvested at day 
7 post infection. (A) Representative flow plots gated on CD8α+ cells are 
depicted. Frequency (B) and number (C) of P14 cells pretreated with poly(I:C) 
(black bars) or untreated (open bars) is plotted. Data are from a representative 
experiment with n=4 mice per group.   
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transferred into B6 hosts that were inoculated with either HBSS (control) or 
poly(I:C). One to 3 days later, splenocytes were isolated, and equal numbers of 
P14 cells (enumerated by flow cytometry staining) were transferred into 
recipients that were immediately infected with LCMV. Spleens from recipient 
mice were harvested at day 7 post infection, and the proportion (Figure 3.3A-B) 
and total number (Figure 3.3C) of transgenic P14 cells were determined. 
Suppression of proliferation of poly(I:C)-pretreated P14 cells (black bars) was 
greatest at 1 and 2 days of treatment compared to control-treated cells (open 
bars). After 3 days of pre-treatment, clonal expansion of poly(I:C)-pretreated P14 
cells was almost comparable to that of the HBSS-pretreated control P14 cells, 
indicating that poly(I:C)-mediated suppression of proliferation is a transient effect.  
1. Direct effects of type 1 IFN are required for poly(I:C)-induced 
suppression of proliferation 
Because type 1 IFN is required for efficient clonal expansion of LCMV-
specific CD8 T cells, I investigated its role in the reduced proliferation seen in 
poly(I:C)-pretreated CD8 T cells. Using a similar experimental set up as 
described previously, congenic Thy1.1 IFNAR KO P14 CD8 T cells were 
transferred into Thy1.2 mice and 1 day later they were inoculated with either 
HBSS or poly(I:C). One day after inoculation, equal numbers of transgenic T cells 
were transferred into mice prior to LCMV infection. The proportion (Figure 3.4A) 
and total number (Figure 3.4B) of donor IFNAR KO P14 cells in recipient host  
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Figure 3.3: Poly(I:C)-induced suppression of CD8 T cell proliferation is 
transient, with 1 and 2 days of pre-treatment showing the greatest 
impairment 
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Figure 3.3: Poly(I:C)-induced suppression of CD8 T cell proliferation is 
transient, with 1 and 2 days of pre-treatment showing the greatest 
impairment 
Ly5.1 P14 splenocytes were transferred into WT B6 mice, which were untreated 
or inoculated with poly(I:C). Splenocytes were harvested 1, 2 or 3 days after 
inoculation, and equal numbers of control- or poly(I:C)-treated P14 cells were 
transferred into separate WT B6 mice and subsequently infected with 5x104 pfu 
LCMV. (A) Representative flow plots gated on CD8α+ cells are shown. 
Frequency (B) and total number (C) of donor P14 cells that were untreated (open 
bars) or poly(I:C) pretreated (black bars) is graphed. Data combined from 2 
independent experiments for a total n of 8 mice per group.  
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Figure 3.4: IFNαβR KO P14 cells are resistant to poly(I:C)-induced 
suppressive effects  
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Figure 3.4: IFNαβR KO P14 cells are resistant to poly(I:C)-induced 
suppressive effects  
Thy1.1 IFNαβR KO P14 cells were transferred in WT B6 hosts, which were 
inoculated with poly(I:C) or remained untreated (control). One day later, 
splenocytes were isolated, and equal numbers of IFNαβR KO P14 cells were 
transferred into separate mice, which were subsequently infected with 5x104 pfu 
LCMV. At days 7, 8, or 9 post infection spleens were isolated and total numbers 
of donor IFNαβR KO P14 cells were determined. (A) Representative flow plots 
gated on CD8α+ cells are shown. (B) Total number of IFNαβR KO P14 cells from 
control- (open bars) or poly(I:C)-pretreated mice (black bars) is graphed. Data 
combined from 3 individual experiments with n of 2-4 mice per group. 
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mice were determined at various times after LCMV infection. Poly(I:C)-pretreated 
IFNAR KO P14 cells proliferated to similar numbers as the control-treated 
counterparts at both day 7 and 8 post LCMV infection. The fact that these CD8 T 
cells lacked expression of the IFNAR and showed no difference in proliferation 
between HBSS- and poly(I:C)-primed groups suggested that there was a direct 
role for type 1 IFN on the CD8 T cells in this model of immune suppression.  
Early detection of viral RNA is essential for efficient control of pathogenic 
infections. TLR3, an innate immune receptor that recognizes dsRNA, is known to 
play a major role during infections and when triggered can induce type 1 IFN 
through downstream pathways (3, 4, 12, 23). To determine if TLR3-mediated IFN 
induction was required for the poly(I:C)-induced suppression of CD8 T cell 
expansion, I utilized TLR3 KO host mice during the priming period. Congenic P14 
splenocytes were transferred into WT B6 or TLR3 KO host mice, which were 
primed with poly(I:C) or HBSS (control) 1 day later. One day after inoculation, 
equal numbers of P14 cells from each treatment group were determined and 
transferred into WT B6 mice, which were subsequently infected with LCMV. At 
day 7 post infection, spleens were harvested and the total proportion (Figure 
3.5A) and number (Figure 3.5B) of donor cells were enumerated. Similar to WT 
controls, suppression of T cell expansion was also seen from the TLR3 KO-
primed cohort, indicating that TLR3 is not required for poly(I:C)-induced inhibition 
of CD8 T cell proliferation. However, because the donor P14 cells were TLR3 
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Figure 3.5: TLR3 is not required for poly(I:C)-induced suppression of CD8 T 
cell proliferation 
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Figure 3.5: TLR3 is not required for poly(I:C)-induced suppression of CD8 T 
cell proliferation 
Congenic P14 cells were transferred into WT B6 or TLR3 KO mice, which were 
treated with HBSS or poly(I:C) i.p. One day after treatment, equal numbers of 
P14 cells from each group were transferred into WT B6 hosts, which were 
subsequently infected with 5x104 pfu LCMV. Splenocytes were harvested at day 
7 post infection. Frequency (A) and total number (B) of donor P14 cells from 
HBSS- (open bars) or poly(I:C)- (black bars) pretreated mice are graphed. Data 
from experiment with n of 2-4 mice per group. 
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sufficient, this experiment does not determine if CD8 T cells themselves are 
responding to poly(I:C) inoculation and producing type 1 IFN.  
2. The priming hosts do not require Class I MHC to mediate 
poly(I:C)-induced CD8 T cell suppression of proliferation.  
Previous studies from our lab investigating bystander sensitization to rapid 
effector function indicated there was a direct requirement of Class I MHC to 
mediated sensitization (193). Prior studies showed that P14 mice could not be 
directly sensitized, which we attributed to the competition for self-MHC. We 
hypothesized that because of the overwhelming number of P14 cells in the P14 
host, the chance a particular T cell could see the self-MHC required for 
sensitization would be greatly reduced. 
Therefore, we questioned whether the poly(I:C)-induced suppression of 
proliferation also required Class I MHC. Ly5.1 P14 splenocytes were transferred 
into WT B6 or β2M KO hosts and primed with poly(I:C) for 1 day prior to transfer 
into WT hosts. Recipient mice were infected with LCMV, and splenocytes were 
harvested at day 7 post infection. Representative flow plots gated on CD8α+ 
lymphocytes (A) and total number of donor P14 cells (B) are shown in Figure 
3.6. Probably due to the large variability in this particular experiment, the 
difference in total number of poly(I:C)- (black bars) and HBSS- (open bars) 
pretreated P14 cells from β2M KO hosts does not reach statistical significance (# 
p=0.0901). However, there is a trend of poly(I:C)-induced suppression of CD8 T 
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Figure 3.6: Class I MHC is not required for poly(I:C)-induced suppression of 
proliferation 
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 Figure 3.6: Class I MHC is not required for poly(I:C)-induced suppression 
of proliferation 
Ly5.1 P14 splenocytes were transferred into WT B6 or β2M KO mice, which were 
inoculated with HBSS or poly(I:C) for 1 day. Equal numbers of poly(I:C) or control 
P14 cells were transferred into separate WT B6 hosts and infected with 5x104 pfu 
LCMV. Spleens were harvested at day 7 post infection. (A) Representative flow 
plots gated on CD8α+ cells are shown. (B) Total number of donor P14 cells is 
graphed. Data from experiment with n of 4 mice per group. # represents p value 
of 0.0901. 
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cell expansion, a trend similar to what is seen during poly(I:C)-priming in WT 
hosts. Since this phenotype is similar to what is seen when P14 cells are primed 
in a WT host, it suggests that Class I MHC is not required for poly(I:C)-induced 
suppression of CD8 T cell expansion, unlike IFN-induced sensitization of 
bystander CD8 T cells to acquire rapid effector function.  
After determining Class I MHC was not required for poly(I:C)-induced 
suppression of T cell responses, I questioned whether P14 mice could be primed 
directly, without the dual transfer model used in previous studies. I hypothesized 
that since Class I was not required, self-MHC would not be a limiting factor and 
P14 mice could therefore be sensitized directly, without the need for P14 CD8 
cells to be transferred into other hosts. Ly5.1 P14 mice were directly treated with 
HBSS (control) or poly(I:C) for 1 day prior to equal numbers of the transgenic 
cells being transferred into WT recipient hosts, which were subsequently infected 
with LCMV. Figure 3.7 shows that P14 mice can be directly treated with poly(I:C) 
to induce suppressive effects on T cell expansion. Reduced proportions (Figure 
3.7A-B) and total numbers (Figure 3.7C) of poly(I:C)-treated (black bars) P14 
cells at day 7 post LCMV infection compared to the HBSS controls (open bar) 
were found. Together with Figure 3.6, these data suggest that Class I and 
excess of specific self-antigen is not required for poly(I:C)-induced suppressive 
effects on CD8 T cells. 
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Figure 3.7: Suppression of proliferation occurs with direct treatment of P14 
mice with poly(I:C) 
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Figure 3.7: Suppression of proliferation occurs with direct treatment of P14 
mice with poly(I:C) 
Ly5.1 P14 mice were directly treated with HBSS or poly(I:C) for 1 day. Equal 
numbers of P14 transgenic cells were transferred into WT B6 hosts, which were 
inoculated with 5x104 pfu LCMV i.p. Spleens were harvested at day 7 post 
infection. (A) Representative flow plots gated on CD8α+ cells are depicted. 
Frequency (B) and total number (C) of P14 cells are graphed. Data are 
representative of at least 5 experiments with n of 3-5 mice per group.  
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3. Poly(I:C)-induced suppression of CD8 T cell expansion is seen in 
other models.  
Up until this point, poly(I:C)-induced suppression of proliferation had only 
been shown in P14 CD8 T cells in response to LCMV infection. I questioned 
whether or not poly(I:C) had suppressive effects on CD4 T cell expansion, or if it 
was specific to CD8 T cells. Therefore, I utilized transgenic SMARTA CD4 T 
cells, specific for the GP61 epitope of LCMV, to identify the effects of poly(I:C) 
pretreatment on CD4 T cell expansion (176). Congenic Ly5.1 SMARTA mice 
were inoculated with HBSS or poly(I:C) for 1 day. Equal numbers of CD4 
transgenic T cells, determined by flow cytometry, were transferred into separate 
host mice, which were subsequently infected with LCMV, and spleens were 
harvested at day 9 post infection. The HBSS- and poly(I:C)-treated SMARTA 
cells expanded to similar levels, in terms of both proportion (Figure 3.8A-B) and 
number (Figure 3.8C). Thus, CD4 T cells seem to be resistant to the suppressive 
effects of poly(I:C), indicating it does not have inhibitory effects on all T cell 
populations but instead may be more specific to CD8 T cells.  
I also wanted to determine if suppression of proliferation could be seen 
using other virus infection models in addition to LCMV. Transgenic P14 CD8 T 
cells were still utilized, but in addition to looking at the proliferative response to 
LCMV, the ability of poly(I:C)-pretreated cells to expand in response to VACV-GP 
infection was also investigated. VACV-GP is a recombinant vaccinia virus that 
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Figure 3.8: SMARTA CD4 T cells do not show suppression of clonal 
expansion if pre-exposed to poly(I:C)  
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Figure 3.8: SMARTA CD4 T cells do not show suppression of clonal 
expansion if pre-exposed to poly(I:C)  
Ly5.1 SMARTA mice were HBSS or poly(I:C) treated for 1 day. Equal numbers of 
SMARTA transgenic cells were transferred into WT B6 mice, which were 
subsequently infected with 5x104 pfu LCMV. Spleens were harvested at day 9 
post infection, with representative flow plots gated on CD4+ cells shown in (A). 
Frequency (B) and total number (C) of donor SMARTA cells are graphed. Data 
from experiment with n of 5 mice per group.  
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expresses the glycoprotein of LCMV. Ly5.1 P14 mice were inoculated with HBSS 
or poly(I:C) for 1 day, and equal numbers of P14 cells were transferred into mice, 
which were either infected with LCMV or VACV-GP. Because the peak of the 
CD8 T cell response is earlier in VACV infection (194), splenocytes were 
harvested and stained at day 6 post infection. The representative flow plots, 
gated on CD8α+ lymphocytes in Figure 3.9A show increased proportions of the 
HBSS- (control) treated P14 cells compared to the poly(I:C)-treated P14 cells in 
response to both LCMV and VACV-GP infection. The magnitude of P14 T cell 
expansion was much lower in the VACV-GP-infected animals compared to the 
LCMV-infected animals (Figure 3.9B-C), note the difference in y-axis in Figure 
3.9B, but suppression of clonal expansion was still seen in poly(I:C)-pretreated 
P14 cells. The suppression seen in response to both infections suggests the 
distinct inflammatory environments induced by each virus is not mediating the 
inhibition, and may be more intrinsic to the CD8 T cells.  
I wanted to determine if the suppression of proliferation was also seen in a 
polyclonal population and not just seen using a transgenic T cell system. In the 
present study, Ly5.1 mice were HBSS or poly(I:C) treated for 1 day, and total 
splenocytes were transferred into congenic WT B6 mice, which were 
subsequently infected with LCMV. At day 7 post infection, spleens were 
harvested and cells were stimulated ex vivo with LCMV specific peptides 
including GP276, NP205 and the co-dominant NP396 and GP33 epitopes. 
Figure 3.10 shows the Ly5.1 donor population on the left (A-E) and the host CD8 
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Figure 3.9: Impaired clonal expansion of poly(I:C)-pretreated P14 CD8 T 
cells in response to VACV-GP infection 
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Figure 3.9: Impaired clonal expansion of poly(I:C)-pretreated P14 CD8 T 
cells in response to VACV-GP infection 
Ly5.1 P14 mice were inoculated with HBSS or poly(I:C) i.p. One day later, 
splenocytes were harvested and similar numbers of HBSS- or poly(I:C)-
pretreated P14 cells were transferred into WT B6 mice, which were subsequently 
infected with 5x104 pfu LCMV or 5x106 VACV-GP i.p. Splenocytes were 
harvested at day 6 post infection. (A) Representative flow plots gated on CD8α+ 
cells are depicted. Frequency (B) and total number (C) of P14 CD8 T cells from 
HBSS- (open bars) or poly(I:C)-treated (black bars) mice are graphed. Data from 
experiment with n of 5 mice per group.  
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population on the right (A, and F-I). The total number of donor and host CD44hi 
CD8 T cells was calculated from HBSS-treated (open bars) and poly(I:C)-treated 
(black bars) groups and are shown in Figure 3.10A. Host mice receiving HBSS- 
or poly(I:C)-treated splenocytes showed similar numbers of CD44hi CD8 T cells 
(right), whereas donor cells (left) showed reduced numbers of poly(I:C)-
pretreated CD44hi CD8 T cells when compared to the HBSS-control CD44hi 
CD8 T cell number. To identify if the donor population had a skewed 
immunodominance hierarchy that may have been contributing to reduced 
number of CD44hi CD8 T cells seen in poly(I:C)-pretreated cells, multiple 
epitopes were tested. The donor population, regardless of the pretreatment 
regime, had similar proportions of the co-dominant NP396 (red) and GP33 
(yellow) specific cells compared to the host populations (B, C vs F, G). The 
donor population had slightly higher proportions of the sub-dominant epitopes 
GP276 (green) and NP205 (blue) compared to the host cells. However, the over-
all immunodominance hierarchy was not significantly skewed when comparing 
donor and host populations, regardless of the pretreatment regime. What was 
most striking was the absolute number of peptide-specific CD8 T cells from 
comparing HBSS- and poly(I:C)-pretreated donor populations (Figure 3.10D-E). 
Donor cells pretreated with poly(I:C) showed significantly lower numbers of 
peptide specific cells compared to the control-treated donor CD8 T cells. This is 
unlike what is seen in the host population, where both sets of mice receiving 
HBSS- or poly(I:C)-treated splenocytes showed similar numbers of peptide- 
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Figure 3.10: Polyclonal populations are also susceptible to poly(I:C)-
induced suppression of proliferation 
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Figure 3.10: Polyclonal populations are also susceptible to poly(I:C)-
induced suppression of proliferation 
Ly5.1 mice were treated with HBSS or poly(I:C) for 1 day. Similar numbers of 
CD44lo CD8 T cells were transferred into WT B6 mice, which were infected with 
5x104 pfu LCMV. At day 7 post infection, spleens were harvested and 
intracellular cytokine staining assay was performed. Mice receiving poly(I:C)-
treated splenocytes are shown as black bars, and control-treated splenocytes are 
shown as open bars. (A) Total number of CD44hi CD8 T cells per spleen from 
donors vs. host mice is graphed. Frequency (B-C, F-G) and total number (D-E, 
H-I) of CD44+IFNγ+ CD8 T cells after peptide stimulation (NP396 (red), GP33 
(yellow), GP276 (green) or NP205 (blue)) from donor (B-E) and hosts (F-G) are 
graphed. Frequency (C and G) and number (E and I) of peptide-stimulated 
CD44+IFNγ+ CD8 T cells from HBSS or poly(I:C) cohorts are graphed (additive). 
Data from experiment with n of 6 mice per group. # indicates p=0.0510. 
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specific CD8 T cells (Figure 3.10H-I). If poly(I:C)-pretreated cells were releasing 
suppressive factors, we would expect to see reduced expansion in the host 
population as well, but since we see no defect in host expansion it suggests that 
there is an intrinsic defect in clonal expansion in poly(I:C)-treated CD8 T cells, 
rather than poly(I:C) treatment inducing suppressive effects on other cell types. 
4. Summary 
Virus infections have been shown to induce a transient state of immune 
suppression, which can be mimicked by the dsRNA analog poly(I:C) (182). 
Poly(I:C) can induce transient suppressive effects on CD8 T cell clonal 
expansion in response to prolonged cognate antigen encounter. The greatest 
suppressive effects were seen at 1 day post poly(I:C) treatment. By 3 days post 
poly(I:C) treatment, the suppressive effects of pre-exposure are diminished 
(Figure 3.3).  
Our lab has previously shown that acute virus infections can affect 
bystander CD8 T cells whereby they acquire immediate effector function upon 
stimulation with cognate antigen (193). The mechanism of bystander 
sensitization was shown to require indirect effects of type 1 IFN and self-MHC. 
However, the poly(I:C)-induced CD8 T cell suppression shown here is mediated 
by a distinct mechanism. Impaired clonal expansion does not require Class I 
MHC in the sensitizing environment to mediate effects (Figure 3.6). Suppression 
of proliferation does, however, require type 1 IFN, but unlike what is seen in the 
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bystander sensitization to rapid effector function, the poly(I:C)-mediated impaired 
proliferation requires direct effects of type 1 IFN on CD8 T cells (Figure 3.4). P14 
mice directly treated with poly(I:C) may induce suppression (Figure 3.7) of 
proliferation but not rapid effector function because of the direct vs. indirect 
requirements for type 1 IFN, respectively.  
Although poly(I:C) induces suppressive effects on CD8 T cell expansion, 
not all lymphocyte subsets were susceptible to poly(I:C)-induced impaired 
proliferation, as CD4 T cells remained unaffected by IFN pretreatment (Figure 
3.8). Given that P14 T cells are a monoclonal population of GP33-specific cells, 
we wanted to identify if poly(I:C) induced suppressive effects on other polyclonal 
populations. Indeed, poly(I:C)-pretreated Ly5.1 splenocytes transferred into 
congenic hosts infected with LCMV showed reduced magnitude of antigen 
specific responses without skewing or altering the immunodominance hierarchy, 
or proportions of antigen-specific cells tested (Figure 3.10). These data suggest 
that poly(I:C) pretreatment affects more than just a monoclonal transgenic 
population, but also has suppressive effects on a polyclonal population.  Data 
indicate that during an acute viral infection, CD8 T cells may be exposed to these 
inflammatory-induced environments and this may be one mechanism that 
contributes to the transient state of immune suppression seen during acute viral 
infections.  
C. Poly(I:C)-induced lymphocyte refractoriness to IFN stimulation 
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1. Poly(I:C)-pretreated CD8 T cells are transiently refractory to IFNβ 
stimulation in terms of STAT phosphorylation  
Knowing that type 1 IFN delivered at an optimal time can provide a 
positive signal 3 to CD8 T cells and enhance their proliferation, I questioned 
whether an out of sequence early exposure to IFN would interfere with later 
attempts at IFN signaling, as seen in poly(I:C)-induced suppression of T cell 
proliferation. Type 1 IFN can activate multiple downstream STAT molecules, 
including STAT1, 3, 4, and 5 (32). Because type 1 IFN can have both positive 
and negative effects on T cell expansion, where recent studies have shown that 
the specific STAT(s) activated dictate the outcome, all of the aforementioned 
STAT molecules were tested (52, 54, 90, 93, 94). The phosphorylation of STAT 
molecules downstream of the type 1 IFN receptor was thus examined in CD8 T 
cells from mice pretreated with either HBSS or poly(I:C). Mice were inoculated 
with either HBSS or poly(I:C) for 1 day, and their splenocytes were isolated and 
stimulated ex vivo with murine recombinant IFNβ for ~30 min, followed by 
phosflow to examine downstream STAT phosphorylation (Figure 3.11). In 
unstimulated (non-IFNβ-treated) CD44lo CD8 T cells, there was very little 
phosphoSTAT staining, regardless of the pretreatment regimen (Figure 3.11A, 
shaded histograms). In T cells from HBSS-treated mice, the phenotypically naïve 
CD44lo CD8 T cells responded strongly to IFNβ stimulation and showed 
phosphoSTAT 1, 3, 4 and 5 staining well above the unstimulated controls (solid 
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Figure 3.11: Poly(I:C)-pretreated naïve CD44lo CD8 T cells are refractory to 
IFNβ stimulation as measured by STAT phosphorylation 
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Figure 3.11: Poly(I:C)-pretreated naïve CD44lo CD8 T cells are refractory to 
IFNβ stimulation as measured by STAT phosphorylation 
Mice were HBSS or poly(I:C) treated for 1 day. Splenocytes were isolated and 
either remained unstimulated or were stimulated ex vivo with IFNβ for 30 min and 
then stained for pSTAT1 (B), pSTAT3 (C), pSTAT4 (D) and pSTAT5 (E). (A) 
shows representative histograms gated on CD44lo CD8α+ (naïve) T cells 
showing pSTAT1, 3, 4 or 5 staining in HBSS– or poly(I:C)-pretreated naïve CD8 
T cells unstimulated (shaded histograms) or IFNβ stimulated (open histograms). 
HBSS-pretreated naïve CD8 T cells stimulated with IFNβ shown as solid line 
histograms, and poly(I:C)-pretreated naïve CD8 T cells stimulated with IFNβ 
shown as dotted line histogram. (B-E) pSTAT MFI of naive T cells from 
unstimulated vs. IFNβ-stimulated cells from HBSS- (open bars) or poly(I:C)- 
(black bars) pretreated mice are graphed. Data are representative of at least 4 
independent experiments with n of 3 mice per group. 
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line, open histograms in Figure 3.11A; open bars in Figure 3.11B-E). However, 
CD44lo CD8 T cells from mice pre-exposed to poly(I:C) for 1 day were unable to 
respond to IFNβ stimulation and did not phosphorylate any downstream STAT 
molecules tested (dashed line open histogram in Figure 3.11A; black bars in 
Figures 3.11B-E). Similar to naïve CD8 T cells, which represent most of the T 
cells and are the focus of this study, CD44hi memory phenotype CD8 T cells 
from poly(I:C)-pretreated mice also showed a reduced response to IFNβ 
stimulation in terms of downstream STAT phosphorylation (Figure 3.12). Similar 
to the naïve phenotype CD8 T cells, memory phenotype CD8 T cells did not 
phosphorylate any of the downstream STATs tested (STAT 1, 3, 4 or 5 (Figure 
3.12 A, B, C, and D) respectively) if pre-exposed to poly(I:C). Since STAT 
phosphorylation is a transient event, a kinetic analysis of STAT phosphorylation 
in cells from HBSS- or poly(I:C)-inoculated mice stimulated with IFNβ for times 
ranging from 5 minutes to 2 hours was performed. The poly(I:C)-pretreated CD8 
T cells did not phosphorylate downstream STATs above unstimulated controls at 
any time point tested (data not shown). The lack of IFNβ-induced phosphoSTAT 
staining in poly(I:C)-pretreated CD8 T cells suggests that the T cells are unable 
to respond to further IFN signals and therefore do not receive either the positive 
or the negative effects that type 1 IFN can have on lymphocytes.  
To test the duration of this unresponsiveness to IFNβ stimulation, mice 
were inoculated with HBSS or poly(I:C) and after 1, 2, or 3 days, their 
splenocytes were stimulated ex-vivo with IFNβ for ~30 min before staining for 
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Figure 3.12: Poly(I:C)-pretreated memory phenotype CD8 T cells are 
refractory to IFNβ-induced STAT phosphorylation 
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Figure 3.12: Poly(I:C)-pretreated memory phenotype CD8 T cells are 
refractory to IFNβ-induced STAT phosphorylation 
Mice were HBSS (open bars) or poly(I:C) (black bars) treated for 1 day. 
Splenocytes were isolated and either remained unstimulated or were stimulated 
ex vivo with IFNβ for 30 min and then stained for pSTAT1 (A), pSTAT3 (B), 
pSTAT4 (C) and pSTAT5 (D). Cells were gated on CD44hi CD8α+ lymphocytes, 
and the MFI of each respective pSTAT is graphed. Data are representative of at 
least 4 independent experiments with n of 3 mice per group. 
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phosphoSTATs. As shown in Figure 3.11, the phenotypically naive CD8 T cells 
from mice pretreated with poly(I:C) for 1 day did not respond to IFNβ stimulation 
in terms of STAT phosphorylation and this is also shown in Figures 3.13A-D 
(black bars). Similarly, naïve CD8 T cells from poly(I:C)-pretreated mice were 
also less responsive to IFN stimulation when treated 2 days previously compared 
to controls. However, by 3 days after pretreatment, the CD44lo CD8 T cells from 
poly(I:C)-treated mice started to regain the ability to respond to IFNβ stimulation 
and showed downstream STAT phosphorylation above unstimulated controls. In 
this particular experiment, at 3 days, the IFNβ-stimulated poly(I:C)-pretreated 
naïve CD8 T cells phosphorylated downstream STATs above unstimulated 
controls but were still significantly lower than pSTAT levels from IFNβ-stimulated 
HBSS-pretreated CD44lo CD8 T cells. However, in a separate experiment, at 3 
days, the poly(I:C)-pretreated CD8 T cells phosphorylated downstream STATs to 
similar levels as HBSS-pretreated CD8 T cells for all STATs tested except 
STAT4. Despite the slight variation from experiment to experiment, the data 
show that poly(I:C)-induced refractoriness to IFNβ stimulation is transient. 
Memory phenotype CD44hi CD8 T cells pretreated with poly(I:C) showed 
a similar transient unresponsiveness to IFNβ stimulation (Figure 3.13E-H) as the 
naïve CD44lo CD8 T cells did (Figure 3.13A-D). However, unlike the other 
STATs tested, CD44hi CD8 T cells did not show a strong reduction in 
phosphoSTAT5 staining in poly(I:C)-pretreated populations stimulated with IFNβ. 
That being said, pSTAT5 staining had the greatest background staining among 
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Figure 3.13: Poly(I:C)-mediated refractoriness to IFNβ-induced STAT 
phosphorylation is transient 
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Figure 3.13: Poly(I:C)-mediated refractoriness to IFNβ-induced STAT 
phosphorylation is transient 
Mice were HBSS (open bars) or poly(I:C) (black bars) treated once 1, 2, or 3 
days prior to isolation. Splenocytes were isolated, stimulated ex vivo with IFNβ 
for 30 min and then stained for phosphoSTATs. Cells were gated on CD44lo 
CD8α+ T cells (A-D) or CD44hi CD8α+ T cells (E-G) plotting pSTAT MFI after 
IFNβ stimulation. pSTAT1 (A, E), pSTAT3 (B, F), pSTAT4 (C, G) or pSTAT5 (D, 
H) MFI is graphed. Data are representative of 2 independent experiments with n 
of 3 mice per group.  
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all of the pSTATs tested (This can be seen in the representative histograms in 
Figure 3.11A) and therefore is the hardest to detect small changes in pSTAT 
levels. Combined, Figure 3.13 show that the refractoriness to IFNβ stimulation is 
transient, with kinetics similar to that of the poly(I:C)-induced impaired 
proliferation (Figure 3.3).   
To make sure that STAT molecules were available to be phosphorylated, 
total STAT protein levels in CD8 T cells after different days post HBSS or 
poly(I:C) inoculation were determined (Figure 3.14). After 1, 2, and 3 days of 
treatment, total STAT 1, 3, 4 and 5 levels in poly(I:C)-pretreated CD44lo (Figure 
3.14A-D) and CD44hi (Figure 3.14E-H) CD8 T cells were similar to, if not higher 
than, the control-treated cells. Total STAT1 expression was higher in poly(I:C)-
pretreated naïve CD8 T cells after 1 day and stayed high through day 3 of 
treatment, as compared to STAT1 levels in HBSS-treated CD8 T cells (Figure 
3.14A and E). Since STAT1 is an IFN-inducible gene (12, 39), higher STAT1 
protein expression in poly(I:C)-pretreated CD8 T cells was expected. These data 
indicate that the reduced phosphoSTAT staining found in IFNβ-stimulated 
poly(I:C)-pretreated CD8 T cells was not due to lower levels of total STAT 
protein. 
2. Poly(I:C)-pretreated lymphocytes are responsive to cytokines 
other than type 1 IFN 
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Figure 3.14: CD8 T cells express similar or increased levels of total STAT 
protein after poly(I:C) treatment 
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Figure 3.14: CD8 T cells express similar or increased levels of total STAT 
protein after poly(I:C) treatment 
Mice were HBSS (open bars) or poly(I:C) (black bars) treated once 1, 2, or 3 
days prior to isolation. Cells were gated on CD44lo CD8α+ T cells (A-D) or 
CD44hi CD8α+ T cells (E-H). STAT1 (A, E), STAT3 (B, F), STAT4 (C, G) or 
STAT5 (D, H) MFI is graphed. Data are representative of 2 independent 
experiments with n of 3 mice per group.  
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To test if the poly(I:C)-primed CD8 T cells were unresponsive to other 
cytokines, splenocytes were stimulated ex vivo with various cytokines for ~30 min 
before staining for the appropriate downstream phosphoSTATs. I tested IFNβ, IL-
2, IL-6, IL-7, IL-12, and IL-15, because these cytokines have positive effects on 
lymphocyte survival or proliferation. It should be noted that CD8 T cells are not 
the only lymphocyte populations that are affected by poly(I:C) pretreatment. CD4 
T cells and NK cells were also found to respond differently to cytokine stimulation 
induced STAT phosphorylation. Tables 3.1-3.4 show cytokine-induced pSTAT 
MFIs +/- SD for different cell types, including CD4, CD8 and NK cells. Values in 
bold represent a pSTAT MFI above the associated unstimulated control without 
any overlap in SD.  
 Table 3.1 shows pSTAT1 MFI of different lymphocyte populations after ex 
vivo stimulation without additional cytokine, with IFNβ, IL-2, or with IL-6. Not all 
lymphocyte populations phosphorylated STAT1 in response to all cytokine 
stimulations, regardless of the pretreatment regimen. As an example, CD4, CD8 
and NK cells did not phosphorylate STAT1 in response to IL-2 stimulation above 
the unstimulated control, but some cells did show response to IFNβ and IL-6. The 
variability in lymphocyte cytokine responsiveness was also seen looking at other 
STAT molecules, including STAT3 (Table 3.2), STAT4 (Table 3.3), and STAT5 
(Table 3.4). As an example, T cells responded to IL-6 stimulation and 
phosphorylated STAT3, but NK cells did not (Table 3.2).  
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Table 3.1 Cytokine-induced phosphorylation of STAT1 in lymphocytes after 
poly(I:C) treatment   
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Table 3.1 Cytokine-induced phosphorylation of STAT1 in lymphocytes after 
poly(I:C) treatment   
B6 mice were inoculated with HBSS or poly(I:C) and spleens were harvested 1 
day later. Splenocytes were stimulated individually ex vivo with various cytokines 
(none, IFNβ, IL-2 and IL-6) for ~30 min. Samples were fixed and stained for 
phosphoSTAT1. The MFI of pSTAT1 +/- SD for CD44hi vs CD44lo CD4 and CD8 
T cells and NK cells are shown. Numbers in bold indicate a MFI above respective 
unstimulated control without overlapping SD.  
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Table 3.2 Cytokine-induced phosphorylation of STAT3 in lymphocytes after 
poly(I:C) treatment   
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Table 3.2 Cytokine-induced phosphorylation of STAT3 in lymphocytes after 
poly(I:C) treatment   
B6 mice were inoculated with HBSS or poly(I:C) and spleens were harvested 1 
day later. Splenocytes were stimulated individually ex vivo with various cytokines 
(none, IFNβ, IL-2, IL-6, IL-7 and IL-15) for ~30 min. Samples were fixed and 
stained for phosphoSTAT3. The MFI of pSTAT3 +/- SD for CD44hi vs CD44lo 
CD4 and CD8 T cells and NK cells are shown. Numbers in bold indicate a MFI 
above respective unstimulated control without overlapping SD. 
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Table 3.3 Cytokine-induced phosphorylation of STAT4 in lymphocytes after 
poly(I:C) treatment   
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Table 3.3 Cytokine-induced phosphorylation of STAT4 in lymphocytes after 
poly(I:C) treatment   
B6 mice were inoculated with HBSS or poly(I:C) and spleens were harvested 1 
day later. Splenocytes were stimulated individually ex vivo with various cytokines 
(none, IFNβ and IL-12) for ~30 min. Samples were fixed and stained for 
phosphoSTAT4. The MFI of pSTAT4 +/- SD for CD44hi vs CD44lo CD4 and CD8 
T cells and NK cells are shown. Numbers in bold indicate a MFI above respective 
unstimulated control without overlapping SD. 
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Table 3.4 Cytokine-induced phosphorylation of STAT5 in lymphocytes after 
poly(I:C) treatment   
B6 mice were inoculated with HBSS or poly(I:C) and spleens were harvested 1 
day later. Splenocytes were stimulated individually ex vivo with various cytokines 
(none, IFNβ, IL-2, IL-7, and IL-15) for ~30 min. Samples were fixed and stained 
for phosphoSTAT5. The MFI of pSTAT5 +/- SD for CD44hi vs CD44lo CD4 and 
CD8 T cells and NK cells re shown. Numbers in bold indicate a MFI above 
respective unstimulated control without overlapping SD. 
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 It should be noted that the magnitude of pSTAT1 staining in response to 
cytokine stimulation was not equal in all lymphocyte populations; CD8 T cells 
induced more pSTAT1 staining in response to IFNβ stimulation than did CD4 T 
cells and NK cells (Table 3.1). Additionally, CD4 and CD8 T cells responded to 
IL-6 stimulation in terms of phosphorylating downstream STAT1 (Table3.1) and 
STAT3 (Table 3.2), but NK cells did not respond to IL-6 stimulation. On the other 
hand, NK cells responded robustly and phosphorylated STAT4 in response to IL-
12 stimulation whereas CD4 and CD8 T cells had a very low response (Table 
3.3). Not only did different lymphocyte populations respond to the same cytokine 
to a varying degree, but specific subsets of cells did not respond to all cytokine 
stimulations to the same extent. For example, CD4 T cells showed pSTAT5 
staining above unstimulated background in response to IFNβ, IL-2, and IL-15, but 
pSTAT5 MFI was greatest in response to IL-15 stimulation (Table 3.4). Different 
cell types respond to distinct cytokines to various extents. This may partially 
account for how one cytokine can affect diverse cell types in different ways.  
 Poly(I:C) treatment altered the ability of some cell subsets to respond to 
selected cytokines. Shown in bold in Table 3.1, all HBSS-treated lymphocyte 
subsets (CD44hi/lo CD4, CD44hi/lo CD8, and NK cells) responded to IFNβ 
stimulation and showed phosphoSTAT1 staining above their unstimulated 
controls, unlike the poly(I:C)-treated lymphocyte subsets stimulated with IFNβ, 
which did not show positive pSTAT1 staining above unstimulated controls. On 
the other hand, naive T cell populations induced phosphorylation of STAT1 
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above controls in response to IL-6 stimulation regardless of pretreatment-regime. 
Both CD44lo and CD44hi poly(I:C)-pretreated T cells stimulated with IL-6 (black 
bars, Figure 3.15A-B) or IL-15 (black bars, Figure 3.15C-D) responded just as 
well, in terms of phosphorylating downstream STAT3 and STAT5, respectively, 
as their control-treated counterparts. These results indicate that poly(I:C) 
pretreatment does not induce refractoriness to all cytokines, as CD4 and CD8 T 
cells were shown to respond to IL-6 and IL-15 stimulation and NK cells 
responded to IL-12 stimulation. Data shown here provide only a limited view on 
how complex cytokine receptor signaling can be, especially in terms of what cell 
types respond to what cytokines, the magnitude of the response of each cell type 
has to different cytokines, and how the pre-exposure of cytokines effects 
subsequent exposure to cytokine stimulation. 
3. Poly(I:C)-pretreated CD8 T cells have decreased IFNAR1 and 
increased SOCS1 expression 
Cytokine signaling must be tightly regulated in order to prevent over-active 
and prolonged immune activation. A number of different mechanisms are in place 
to limit cytokine signaling, including reducing cytokine receptor expression, 
downregulating expression of signaling protein components (JAK/STATs), and 
upregulating the expression of SOCS proteins (28, 31). I’ve shown that reduced 
STAT protein levels cannot account for the refractoriness to IFNβ simulation 
seen in the poly(I:C)-pretreated CD8 T cells (Figure 3.14).  
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Figure 3.15: Poly(I:C)-pretreated T cells can respond to other cytokines, 
including IL-6 and IL-15 
  
114 
 
Figure 3.15: Poly(I:C)-pretreated T cells can respond to other cytokines, 
including IL-6 and IL-15 
Mice were inoculated with HBSS (open bars) or poly(I:C) (black bars) for 1 day. 
Splenocytes were isolated and either unstimulated, stimulated with IL-6 (A-B) or 
IL-15 (C-D) and then stained for downstream pSTAT3 (A-B) or pSTAT5 (C-D). 
Splenocytes were gated on CD44lo or CD44hi CD8α+ T cells (A, C) or CD44lo or 
CD44hi CD4+ T cells (B, D) and pSTAT MFI was graphed. Data are 
representative of at least 2 independent experiments with n of 3 mice per group.  
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To investigate why naïve CD8 T cells pre-exposed to poly(I:C) were 
unresponsive to type 1 IFN, but not all cytokines, cytokine receptor expression 
was determined. At various days post HBSS or poly(I:C) treatment, naïve CD44lo 
CD8 T cells were assessed for cytokine receptor signaling components, including 
portions of the IL-2 (Figure 3.16A, B, E), IL-6 (3.16C), IL-7 (3.16D, E), IL-15 
(3.16 B, F), and IFNγ (3.16F) receptor complexes. Of the receptors tested, the 
majority of cytokine receptor expression did not change after poly(I:C) treatment. 
However, CD127, IL-7 receptor alpha chain, was decreased in naïve CD8 T cells 
1 day after poly(I:C) treatment but returned to control treated levels by 2 days 
post poly(I:C) treatment (Figure 3.16D). CD132, the common gamma chain, 
increased 1 day after inoculation with poly(I:C) in CD44lo CD8 T cells but this too 
was transient, as receptor levels were back to control treated levels after 2 days 
(Figure 3.16E). The minimal changes in cytokine receptor expression after 
poly(I:C) treatment in CD44lo CD8 T cells may explain why naïve CD8 T cells 
were able to phosphorylate downstream STATs in response to stimulation with 
some of these cytokines.    
To see if a decrease in the type 1 IFN receptor level contributed to 
reduced responsiveness of poly(I:C)-pretreated CD8 T cells to phosphorylate 
downstream STATs in response to further IFNβ signaling, IFN receptor 
expression was stained for. The type 1 IFN receptor is comprised of two 
components, IFNAR1 and IFNAR2 (32). Naïve CD8 T cells from mice inoculated 
with poly(I:C) (dashed line open histograms and black bars) for 1 day had   
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Figure 3.16: Cytokine receptor expression on naïve CD8 T cells after 
poly(I:C) treatment 
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Figure 3.16: Cytokine receptor expression on naïve CD8 T cells after 
poly(I:C) treatment 
Mice were HBSS (open bars) or poly(I:C) (black bars) treated once 1, 2, or 3 
days prior to isolation. Cells were gated on CD44lo CD8α+ T cells and cytokine 
receptor MFI is plotted. CD25 (A), CD122 (B), CD126 (C), CD127 (D), CD132 
(E) and IFNGR1 (F) is shown. Data are representative of 2 independent 
experiments with n of 3 mice per group.  
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much lower expression levels of IFNAR1, compared to the HBSS-treated cells 
(solid line open histograms and open bars) (Figure 3.17A-B). However, IFNAR1 
expression levels returned to control-treated levels by 2 days post treatment. The 
CD44hi CD8 T cells had similar kinetics of IFNAR1 expression as the naïve CD8 
T cells, showing slightly reduced receptor expression with 1 day treatment of 
poly(I:C) but not 2 or 3 days of treatment (Figure 3.17C). In fact, IFNAR1 
expression levels were modestly increased at later time points post poly(I:C) 
treatment in CD44hi and CD44lo CD8 T cells. Thus, unresponsiveness to type 1 
IFN at day 1 post poly(I:C) treatment may be partially due to the reduced 
expression of the type 1 IFN receptor. 
Since poly(I:C)-pretreated CD8 T cells were still less responsive to IFNβ 
stimulation (as measured by STAT phosphorylation) 2 days after poly(I:C) 
treatment (Figure 3.13), there were likely other suppressive mechanisms to limit 
IFNβ responsiveness in addition to the reduced receptor expression shown in 
Figure 3.17. SOCS proteins are known to inhibit cytokine receptor signaling by 
acting at many different steps in the JAK/STAT signaling pathway (28). SOCS1 
inhibits type 1 IFN signaling by binding to the receptor-associated JAK protein 
TYK2, thus blunting IFN receptor signaling (37). The well-established protocol for 
staining for phosphorylated proteins was utilized to identify intracellular levels of 
SOCS1. SOCS1 expression was determined in CD8 T cells from poly(I:C)- or 
HBSS-inoculated mice 1, 2, or 3 days after treatment (Figure 3.18). Indeed, at 
both 1 and 2 days after poly(I:C) treatment (dashed line open histograms and  
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Figure 3.17: CD8 T cells downregulate IFNAR1 expression 1 day after 
poly(I:C) exposure 
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Figure 3.17: CD8 T cells downregulate IFNAR1 expression 1 day after 
poly(I:C) exposure 
Mice were HBSS (open bars) or poly(I:C) (black bars) treated once 1, 2, or 3 
days prior to isolation. Cells were gated on CD44lo CD8α+ T cells (A-B) or 
CD44hi CD8α+ T cells (C). Representative histograms (A) and MFI of IFNAR1 
(B-C) are shown. Data are representative of at least 4 independent experiments 
with n of 3 mice per group.  
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black bars), naïve CD44lo CD8 T cells had higher expression of SOCS1 
compared to the control-treated cells (solid line open histograms and open bars) 
(Figure 3.18A-B). However, by 3 days of pretreatment, there was no longer a 
difference in SOCS1 expression between control- and poly(I:C)-treated CD8 T 
cells, although it was close to reaching statistical significance (p=0.0789). CD44hi 
CD8 T cells also showed increased SOCS1 protein levels (Figure 3.18C), with 
similar kinetics as CD44lo CD8 T cells. These data suggest that a combination of 
a decrease in IFNAR expression and an increase in SOCS1 expression may 
account for the observed refractoriness to IFNβ stimulation in poly(I:C)-pretreated 
CD8 T cells.  
4. Summary 
Knowing that type 1 IFN can provide stimulatory signals for CD8 T cells 
during acute viral infections and augment their proliferation, I investigated the 
role type 1 IFN had in the suppression of clonal expansion seen in poly(I:C)-
pretreated CD8 T cells. I tested the ability of poly(I:C)-pretreated CD8 T cells to 
respond to IFNβ stimulation and measured the phosphorylation status of 
downstream STATs. Both naïve (CD44lo) and memory (CD44hi) phenotype CD8 
T cells were refractory to IFNβ-induced STAT phosphorylation if pre-exposed to 
poly(I:C) (Figure 3.11-12). T cells were unresponsive to IFNβ stimulation and did 
not phosphorylate any of the STATs tested, including STAT 1, 3, 4, and 5. 
However, IFNβ refractoriness was not permanent, as CD8 T cells exposed to   
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Figure 3.18: CD8 T cells upregulate SOCS1 after poly(I:C) treatment 
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Figure 3.18: CD8 T cells upregulate SOCS1 after poly(I:C) treatment 
Mice were HBSS (open bars) or poly(I:C) (black bars) treated once 1, 2, or 3 
days prior to isolation. Cells were gated on CD44lo CD8α+ T cells (A-B) or 
CD44hi CD8α+ T cells (C). Representative histograms (A) and MFI of SOCS1 
(B-C) are shown. Data are representative of 2 independent experiments with n of 
3 mice per group.  
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poly(I:C) 3 days prior to ex vivo IFNβ stimulation were able to phosphorylate 
STATs above the unstimulated controls, indicating the IFN unresponsiveness 
was a transient event (Figure 3.13). CD8 T cells were not the only cell types 
found to be refractory to IFNβ-induced STAT phosphorylation after poly(I:C) 
treatment, as both CD4 T cells and NK cells also had a nonresponsive 
phenotype (Tables 3.1-3.4). Poly(I:C) pretreatment did not, however, render all 
cell types tested unresponsive to all cytokine stimulations; instead it was more 
specific to type 1 IFN.  
Poly(I:C)-pretreated CD8 T cells had reduced IFNAR1 expression levels 1 
day after inoculation but by 2 days post treatment, the receptor levels were back 
to control-treated levels (Figure 3.17). This indicated that a decrease in receptor 
expression level could not be the only factor contributing to the refractoriness to 
IFNβ-induced STAT phosphorylation because unresponsiveness was seen at 2 
and (to a small extent) 3 days post poly(I:C) treatment. SOCS1 expression was 
induced to the greatest degree at 1 day post treatment, but remained higher than 
controls through 3 days post poly(I:C) inoculation (Figure 3.18). These results 
correlated kinetically with refractoriness to IFNβ stimulation (Figure 3.11-3.12) 
and to the suppressed proliferation seen in poly(I:C)-pretreated CD8 T cells 
(Figure 3.3).  
 These data suggest that poly(I:C)-pretreated CD8 T cells, when put into 
hosts subsequently infected with LCMV, are not able to respond to the type 1 IFN 
induced by the virus, and thus are unable to receive positive signal 3 cytokine 
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signals. The reduced response to postitive type 1 IFN-induced signals may 
contribute to suppression of proliferation seen in T cells pre-exposed to poly(I:C)-
induced environments. 
D. Poly(I:C)-pretreated CD8 T cells behave similarly to 2-signal-stimulated 
rather than 3-signal-stimulated CD8 T cells 
1. Defects in clonal expansion are due to lack of receiving signal 3  
Because the suppression of proliferation of poly(I:C)-pretreated CD8 T 
cells correlated with refractoriness to IFNβ stimulation, I hypothesized that 
poly(I:C)-pretreated CD8 T cells were unable to receive the positive effects that 
type 1 IFN exerts as a signal 3 cytokine when delivered in the proper sequence. 
This hypothesis would suggest that poly(I:C)-pretreated P14 cells would behave 
similarly to 2-signal only CD8 T cells, rather than 3-signal CD8 T cells. Thus, I 
examined their effector phenotype and their abilities to divide, produce cytokines, 
degranulate, and express the survival protein Bcl-3 in response to antigen 
exposure. 
Studies have shown that 2-signal CD8 T cells divide similarly to 3-signal 
CD8 T cells but have defects in survival (79). I tested whether the impairment in 
proliferation seen in poly(I:C)-pretreated CD8 T cells was due to division or 
survival defects. A similar experimental setup as described previously was used, 
but after inoculation with HBSS or poly(I:C), congenic P14 CD8 T cells were 
labeled with CellTrace Violet and transferred together into the same recipients to 
126 
 
track cell division during LCMV infection. Cells were harvested at days 3 and 4 
post infection, and CellTrace Violet dilution was measured. Because we were 
looking at early days post infection, a larger number of transgenic cells was 
transferred than what would normally be considered physiologically relevant in 
order to quantify early cell division. Neither the poly(I:C)- nor the HBSS-
pretreated P14 cells diluted CellTrace Violet in naïve mice, indicating that they 
did not divide (Figure 3.19A). Two representative histograms are shown for day 
3 and day 4 post infection. The division profiles for each day post infection 
appear very different from one another despite being infected via the same route 
and with the same dose of virus and harvested at the same time. This is why it is 
important to have the HBSS- and poly(I:C)-pretreated P14 populations 
transferred into the same recipients when looking at cell division. At day 3 post 
infection, the control-treated P14 cells (Blue histograms) diluted more CellTrace 
Violet, indicating they had divided more compared to the poly(I:C)-pretreated P14 
cells (Red histograms) (Figure 3.19A). By day 4 post LCMV infection, the 
division profiles of both HBSS-and poly(I:C)-pretreated P14 cells appeared more 
similar. However, the day 4 LCMV example number 2 does show an increased 
HBSS-treated population on the left side of the histogram compared to poly(I:C)-
treated cells, where the CellTrace Violet has been diluted out. This may be due 
to an increased accumulation of this population, but because of the low division 
resolution, it cannot be said for sure that poly(I:C)-treated P14 cells divided less. 
The percentage of cells that divided was statistically similar between the two  
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Figure 3.19: Poly(I:C)-pretreated CD8 T cells have a delay in cell division 
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Figure 3.19: Poly(I:C)-pretreated CD8 T cells have a delay in cell division 
Congenic transgenic P14 mice were HBSS or poly(I:C) treated. One day after 
treatment P14 cells were labeled with CellTrace Violet, and similar numbers of 
HBSS- and poly(I:C)-pretreated cells were transferred into the same recipients, 
which were subsequently inoculated with 5x104 pfu LCMV. (A) Representative 
CellTrace Violet dilution profiles shown for different days post infection. Percent 
divided (B) and proliferation index (C) of P14 cells pretreated with HBSS (open 
bars) or poly(I:C) (black bars) at day 3 and 4 post infection are graphed. Data are 
representative of 2 independent experiments with n of 4-6 mice per group.  
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groups (Figure 3.19B), but the proliferation index of poly(I:C)-pretreated P14 
cells was lower compared to HBSS-treated cells at day 3 post infection (Figure 
3.19C). The proliferation index represents the average number of divisions of the 
cells that have undergone at least one division. These data indicate that the 
frequency of cells that have undergone division is similar, but poly(I:C)-treated 
cells divided, on average, fewer times compared to controls. These results show 
that poly(I:C)-pretreated CD8 T cells have a delay in cell divisions as compared 
to HBSS-treated CD8 T cells.   
If a delay in cell division were the only factor contributing to the 
suppression of proliferation, at later time points post infection the expansion of 
poly(I:C)-pretreated CD8 T cells might eventually reach the same level as the 
control-treated cells. Therefore, a time course of HBSS- or poly(I:C)-pretreated 
P14 CD8 T cell expansion in response to LCMV infection was performed. The 
peak of expansion of poly(I:C)-pretreated P14 CD8 T cells was delayed (day 9) 
compared to HBSS-pretreated P14 CD8 T cells (day 7), but the magnitude of the 
response was still reduced in the poly(I:C)-pretreated cells (Figure 3.20A-B). 
The poly(I:C)-pretreated, also described as “out-of-sequence,” P14 cells showed 
decreased memory proportions (Figure 3.20A) and number (Figure 3.20B) 
compared to their control-treated counterparts at multiple time points tested.  
When tracking congenic donor P14 populations at late time points post 
infection, there were some problems with P14 cells being rejected from the hosts.  
130 
 
Figure 3.20: Poly(I:C)-induced suppression of CD8 T cell proliferation 
occurs at multiple time points post infection 
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Figure 3.20: Poly(I:C)-induced suppression of CD8 T cell proliferation 
occurs at multiple time points post infection 
Equal numbers of HBSS- (open bars) and poly(I:C)- (black bars) pretreated P14 
CD8 T cells were transferred into the same or different recipients, which were 
subsequently infected with 5x104 pfu LCMV. Spleens were harvested at days 5, 
7, 9, 12, 15, 20, 30, 62, or 77 post infection, and the frequency (A, C) and 
number (B, D) of donor P14 cells are graphed. P14 cells were transferred into 
the same hosts when spleens were harvested from day 5 to day 20 post infection 
and different hosts when harvested at day 30 or later. Data are representative of 
2 individual experiments (A-B) or 3 experiments combined (C-D) with n of 3-5 
mice per group.  
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Rejections occurred in similar numbers between the control- and poly(I:C)-
treated groups (data not shown), but because of this, analyzing memory 
formation was difficult. However, with the few experiments looking at time points 
after 4 weeks post infection, poly(I:C)-pretreated P14 cells still showed reduced 
frequencies (Figure 3.20C) and numbers (Figure 3.20D) compared to control-
treated counterparts. The difference in expansion seemed to hold steady as time 
elapsed, suggesting that contraction rates are likely similar between both 
treatment groups. Thus, the relative difference seen at the peak of expansion can 
be carried through to memory formation. Because the magnitude of out-of-
sequence CD8 T cells never reached control-treated levels, it suggests that the 
defects in clonal expansion were not solely due to a delay in cell division but may 
also be due to other factors such as defects in cell survival. 
In vitro and in vivo studies by others found that survival of activated T cells 
in response to signal 3 cytokines and adjuvants was in part due to an increase in 
the IκB family member Bcl-3 and that cells lacking signal 3 cytokines have 
reduced expression of Bcl-3 (86-88). To determine if the poly(I:C)-treated virus-
stimulated T cells resembled 2-signal-only T cells in this respect, the expression 
of Bcl-3 was determined in HBSS- (control) or poly(I:C)-pretreated P14 CD8 T 
cells after LCMV infection. Indeed, a lower percent of poly(I:C)-pretreated P14 
cells upregulated Bcl-3 than HBSS-treated P14 cells at days 4, 5 and 6 post 
LCMV infection (Figure 3.21 A-B). Additionally, the Bcl-3 MFI of poly(I:C)-
pretreated P14 CD8 T cells was lower than in control-treated cells (Figure  
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Figure 3.21: Out-of-sequence P14 CD8 T cells have reduced Bcl-3 
expression at multiple time points post infection compared to controls 
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Figure 3.21: Out-of-sequence P14 CD8 T cells have reduced Bcl-3 
expression at multiple time points post infection compared to controls 
P14 mice were inoculated with HBSS (open bars) or poly(I:C) (black bars), 
spleens were harvested 1 day later, and equal numbers of transgenic T cells 
were adoptively transferred into B6 mice, which were subsequently infected with 
5x104 pfu LCMV. Spleens were harvested at days 4, 5, and 6 post infection. (A) 
Representative flow plots gated on donor P14 cells. The frequency of CD44hi 
P14 cells expressing Bcl-3 (B) and MFI of Bcl-3 expression gated on donor P14 
cells (C) are graphed. Representative of 2-4 experiments with n of 3-5 mice per 
group.  
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3.21C). Together, these results showed that, similar to 2-signal CD8 T cells, out-
of-sequence signal 3-stimulated P14 CD8 T cells had a delay in cell division 
when compared to CD8 T cells that receive all 3 signals in the correct order. 
Moreover, out-of-sequence P14 cells had defects in a survival protein that may 
limit the ability of these cells to clonally expand.   
To further support the hypothesis that out-of-sequence signal 3 CD8 T 
cells do not receive the positive effects that type 1 IFN can have as a signal 3 
cytokine during acute virus infection, and thereby contribute to suppression of 
proliferation, I determined the frequency of poly(I:C)- or HBSS-pretreated P14 
cells after cognate peptide stimulation. First, I wanted to make sure that WT cells 
did not have a proliferative advantage over IFNAR KO cells in response to 
peptide stimulation. WT B6 mice received equal numbers of Ly5.1 WT P14 cells 
and Thy1.1 IFNAR KO P14 cells in the presence or absence of the 13mer GP33-
45 peptide. Two and 3 days post peptide inoculation, splenocytes were harvested 
and the frequency and number of donor P14 cells were determined. Figure 3.22 
shows IFNAR KO (grey bars) expand to similar levels in terms of frequency of 
total CD8 T cell response (3.22A) and total number (3.22B) compared to WT P14 
cells (open bars). The stimulatory effects type 1 IFN can have on CD8 T cell 
expansion during LCMV infection have been shown by others, but this is also 
seen in Figure 3.22C, where WT P14 cells (open bars) expand >200 fold over 
the IFNAR KO P14 cells (grey bars) at day 7 post infection (note the log scale) 
(79). Type 1 IFN can have stimulatory effects on CD8 T cell expansion during 
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Figure 3.22: IFNAR KO P14 cells and out-of-sequence P14 CD8 T cells 
expand to similar levels as control P14 cells in response to GP33 peptide 
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Figure 3.22: IFNAR KO P14 cells and out-of-sequence P14 CD8 T cells 
expand to similar levels as control P14 cells in response to GP33 peptide 
(A-B) Ly5.1 WT P14 cells (open bars) and Thy1.1 IFNAR KO P14 cells (grey 
bars) were transferred into the same recipients. Mice received 5 μg GP33 13mer 
peptide i.v. or no peptide, and spleens were harvested at days 2 and 3 post 
peptide administration. The frequency (A) and number (B) of donor P14 cells 
were determined and graphed. (C) WT P14 cells (open bars) or IFNAR KO P14 
cells (grey bars) were transferred into WT recipients, which were inoculated with 
5x104 pfu LCMV i.p. Splenocytes were harvested at day 7 post infection and total 
number of donor P14 cells is graphed. (D) Congenic P14 mice were HBSS 
treated (open bars) and Thy1.1 P14 mice (black bars) were poly(I:C) treated for 1 
day. Equal numbers of each P14 population were transferred into the same 
recipient. Mice remained untreated (naïve), received 5 μg GP33 peptide i.v. or 
were inoculated with 5x104 pfu LCMV i.p. At various time points post inoculation, 
spleens were harvested and fold expansion (over naïve) was calculated and 
graphed (A-B). Data from 1 experiment with 5 mice per group (C) Data 
representative of 2 individual experiments with 1 naive or 4-5 LCMV mice per 
group (D) Data were combined from 3 individual experiments with n of 4-5 mice 
per group. 
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acute infections, but during settings without type 1 IFN production, IFNAR-
competent T cells do not have any advantage over IFNAR-deficient T cells in 
response to cognate antigen stimulation, and this is represented in Figures 
3.22A-C.  
To test whether or not out-of-sequence CD8 T cells expanded to similar 
levels as control-treated CD8 T cells, congenic P14 mice were directly treated 
with HBSS or poly(I:C) for 1 day. Splenocytes were transferred together into the 
same recipients that were naive, that received 13mer GP33-45 peptide or that were 
inoculated with LCMV. Here the LCMV infection should induce high levels of type 
1 IFN, whereas the peptides would be poor type 1 IFN inducers. Figure 3.22D 
shows that at all time points tested, poly(I:C)-pretreated P14 cells (black bars) 
expanded to similar levels as HBSS-pretreated P14 cells (open bars) in mice that 
only saw antigen (13mer GP33-45) and did not have a major inflammatory 
response. However, poly(I:C)-pretreated P14 cells had defects in expansion in 
response to the IFN-inducing LCMV infection compared to control treated cells 
(note the different axis for GP33 peptide or LCMV inoculation). Given that 
poly(I:C)-pretreated P14 cells expanded to similar levels in response to antigen 
only but had defects in expansion in response to antigen and inflammation (i.e. 
live virus infection), and IFNAR KO P14 cells expand to similar levels as WT P14 
cells in response to antigen, but have defects in clonal expansion in response to 
infection, these results further support the hypothesis that out-of-sequence CD8 
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T cells are unable to receive positive effects of signal 3 cytokines (i.e. type 1 IFN) 
during acute infections.   
2. Poly(I:C)-pretreated CD8 T cells have defects in short lived 
effector cell differentiation 
Signal 3 cytokines have been shown to regulate the differentiation of CD8 
T cells into distinct effector populations including EEC, SLEC and MPEC (78, 
100, 143-145). Therefore, I examined the ability of poly(I:C)-pretreated CD8 T 
cells to differentiate into EEC, SLEC and MPEC populations, which can be 
distinguished based on expression of KLRG1 and CD127 (100, 146, 147). A 
similar experimental model was used as described previously, where WT or 
IFNAR KO P14 cells were transferred into mice for 1 day of treatment with 
poly(I:C) or HBSS prior to a second transfer into congenic hosts that were 
subsequently inoculated with LCMV. At different days post infection, splenocytes 
were isolated and stained for KLRG1 and CD127. At day 7 post infection, the 
IFNAR KO P14 CD8 T cells had similar proportions of SLEC (KLRG1hi, 
CD127lo), MPEC (KLRG1lo, CD127hi) and EEC (KLRG1lo, CD127lo), 
regardless of the pretreatment regimen (Figure 3.23A). Importantly, control 
IFNAR KO P14 cells had reduced SLEC proportions compared to control WT 
P14 cells (open bars). This is consistent with other results showing that type 1 
IFN is important for SLEC differentiation in various infection models (78, 100, 
143, 145). Consistent with our hypothesis, poly(I:C)-pretreated WT P14 CD8 T 
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Figure 3.23: Poly(I:C)-pretreated P14 cells and IFNAR KO P14 cells have 
similar proportions of SLECs at day 7 post LCMV infection 
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Figure 3.23: Poly(I:C)-pretreated P14 cells and IFNAR KO P14 cells have 
similar proportions of SLECs at day 7 post LCMV infection 
WT or IFNAR KO P14 cells were transferred into mice, which were inoculated 
with poly(I:C). One day later, splenocytes were isolated and equal numbers of 
WT or IFNAR KO P14 cells were transferred into mice subsequently infected with 
5x104 pfu LCMV. Spleens were harvested at day 7 post infection. (A) 
Representative flow plots gated on donor P14 cells. (B) Frequency of control- 
(open bars) or poly(I:C)- (black bars) treated WT or IFNAR KO P14 cells 
expressing SLEC phenotype is graphed. Data are representative of 2 individual 
experiments with n of 2-4 mice per group.  
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cells (black bars) had reduced proportions of SLEC populations compared to the 
HBSS-pretreated WT P14 CD8 T cells (open bars) (Figure 3.23). Moreover, the 
poly(I:C)-pretreated WT P14 cells (black bars) had similar proportions of SLECs 
as compared to control IFNAR KO P14 cells (open bars) (Figure 3.23B). These 
data support the idea that the out-of-sequence CD8 T cells behave more similar 
to 2-signal only CD8 T cells (IFNAR KO P14 cells) in terms of effector cell 
differentiation. 
  The defect in SLEC differentiation in poly(I:C)-treated cells can be seen as 
early as day 5 post infection. However, because effector cell differentiation is 
only beginning, and antigen-specific CD8 T cells have only started to expand, it 
can be difficult to see differences at this early time point. The defect in 
differentiation is more dramatic at days 6 and 7 post infection and is seen in both 
proportion of the donor P14 response (Figure 3.24B) as well as total number of 
P14 SLECs (Figure 3.24C). The proportion of MPECs were generally similar to 
or slightly elevated in poly(I:C)-pretreated P14 cells as compared to control-
treated counterparts at days 5-7 post infection (Figure 3.24D). However, despite 
having increased proportions of MPECs, the reduced clonal expansion seen in 
out-of-sequence CD8 T cells was still seen. Consequently, the total number of 
P14 MPECs was still lower in the poly(I:C)-pretreated cohort as compared to the 
control-treated P14 population despite the higher proportions (Figure 3.24E).  
Not only did IFNAR KO P14 cells show defects in SLEC differentiation at 
day 7 post infection, consistent with what others have shown for 2-signal only T  
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Figure 3.24: Out-of-sequence CD8 T cells have defects in short-lived 
effector cell differentiation 
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Figure 3.24: Out-of-sequence CD8 T cells have defects in short-lived 
effector cell differentiation 
Congenic P14 mice were inoculated with HBSS (open bars) or poly(I:C) (black 
bars), and spleens were harvested 1 day later. Equal numbers of P14 cells were 
transferred into congenic WT host mice, which were subsequently infected with 
5x104 pfu LCMV. Spleens were harvested at days 5, 6, and 7 post infection. (A) 
Representative flow plots gated on donor P14 cells showing SLEC/MPEC 
profiles at days 6 and 7 post infection. Frequency (B) and number (C) of P14 
SLECs at days 5-7 post infection are graphed. Frequency (D) and number (E) of 
P14 MPECs at days 5-7 post infection are graphed. Data are from a 
representative experiment with 5 mice per group from more than 5 individual 
experiments with 3-5 mice per group. 
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cells, but out-of-sequence CD8 T cells also show defects in differentiation. 
Defects were seen early and continued through the peak of expansion. These 
data show that in addition to CD8 T cells requiring signal 3 cytokines for proper 
effector cell differentiation into various subsets, they also need to see the signals 
in the appropriate order.   
3. Out-of-sequence CD8 T cells have defects in effector function 
In some infection models, 2-signal CD8 T cells can produce similar 
proportions of cytokines as compared to 3-signal CD8 T cells (VSV), but other 
infection models show reduced cytokine production (Listeria) (78, 79). Therefore, 
I compared poly(I:C)- and HBSS-treated cells for their ability to produce the 
effector cytokines TNF and IFNγ. A similar experimental model was used as 
described previously, where P14 cells were transferred into mice for 1 day of 
treatment with poly(I:C) or HBSS or P14 mice were treated directly with poly(I:C) 
or HBSS prior to transferring cells into congenic hosts that were subsequently 
inoculated with LCMV. At day 5 post infection, splenocytes were isolated and 
stimulated ex vivo with or without cognate peptide (GP33) for 5 hours. Using 
naïve CD8 T cells, isotype controls and fluorescent minus one (FMO) staining to 
distinguish positive vs. negative staining, the poly(I:C)-pretreated P14 cells 
produced similar proportions of TNF and IFNγ compared to control-treated P14 
cells after in vitro GP33 peptide stimulation (Figure 3.25A). Plotting the 
proportion of single cytokine producers (IFNγ- 3.25B, TNF- 3.25D) and double 
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Figure 3.25: Poly(I:C)-pretreated P14 cells produce similar proportions of 
IFNγ and TNF as control-treated P14 cells 
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Figure 3.25: Poly(I:C)-pretreated P14 cells produce similar proportions of 
IFNγ and TNF as control-treated P14 cells 
P14 mice were inoculated with HBSS (open bars) or poly(I:C) (black bars), and 
splenocytes were harvested 1 day later. Equal numbers of P14 cells were 
transferred into mice, which were subsequently infected with 5x104 pfu LCMV. At 
day 5 post infection, splenocytes were stimulated ex vivo with GP33 in an ICS. 
(A) Representative flow plots gated on donor P14 cells are depicted. The 
frequency of P14 cells producing IFNγ (B), TNF (D), or both IFNγ and TNF (F) 
after GP33 stimulation are graphed. The MFI of IFNγ (C) and TNF (E) of P14 
cells are graphed. Data are representative of 3 individual experiments with n of 2-
5 mice per group.  
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cytokine producers (TNF and IFNγ) (Figure 3.25F) revealed no significant 
difference in the ability of poly(I:C)-pretreated P14 cells (black bars) to produce 
effector cytokines. The MFI of IFNγ (3.25C) and TNF (3.25E) of HBSS- (open 
bars) and poly(I:C)-pretreated (black bars) P14 cells indicates that on a per cell 
basis there is no difference in the ability of these cells to produce effector 
cytokines. However, because of impaired clonal expansion, the number of cells 
producing IFNγ, TNF or both is reduced in out-of-sequence CD8 T cells 
compared to control CD8 T cells.  
Using CD107a and b as markers for degranulation, poly(I:C)-pretreated 
P14 cells stained to a similar extent, if not slightly more, than HBSS-treated cells 
in response to GP33 peptide stimulation (Figure 3.26A-B). However, poly(I:C)-
pretreated P14 CD8 T cells had substantially lower levels of granzyme B 
expression than control-treated cells at day 5 post infection (Figure 3.26A, C). 
Reduced granzyme B expression in the out-of-sequence CD8 T cells was seen 
as early as day 4 post infection and lasted at least until day 6 post infection 
(Figure 3.26D). Out-of-sequence CD8 T cells were shown to have defects in 
ability to differentiate into SLECs and now showed reduced granzyme B 
expression, and I questioned whether these characteristics correlated with one 
another. KLRG1 expression in CD8 T cells is often associated with effector 
function, and indeed, there was a positive correlation between KLRG1 
expression and granzyme B expression (R square = 0.8563, p < 0.0001) (Figure 
3.26E). These data showing similar cytokine production but reduced granzyme B  
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Figure 3-26: Out-of-sequence P14 CD8 T cells have reduced granzyme B 
expression after LCMV infection 
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Figure 3-26: Out-of-sequence P14 CD8 T cells have reduced granzyme B 
expression after LCMV infection 
P14 mice were inoculated with HBSS (open bars) or poly(I:C) (black bars), and 
splenocytes were harvested 1 day later. Equal numbers of P14 cells were 
transferred into mice, which were subsequently infected with 5x104 pfu LCMV. 
Spleens were harvested at day 5 post infection (A-D) and days 4, 5 and 6 post 
infection (E). Splenocytes were stimulated ex vivo with or without GP33 peptide 
(A-D) or stained directly ex vivo (E). Data are representative of at least 3 
Individual experiments with n of 3-5 mice per group.  
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expression are consistent with published phenotypes for CD8 T cells that only 
receive 2 signals (78, 79).  
Since granzyme B expression has been used as a correlative marker for 
cytotoxic capability, data shown here suggest that poly(I:C)-pretreated CD8 T 
cells have reduced cytolytic function compared to HBSS-treated CD8 T cells. A 
new method to study effector cell function is the trogocytosis assay, whereby 
target cells are labeled with a membrane dye, mixed with cytotoxic effector cells 
for 1 hour, and then examined for the transfer of dye to a flow cytometry-defined 
effector cell population (181, 195). Trogocytosis is the process by which plasma 
membrane segments are transferred from one cell to another through cell-cell 
interactions. T cell engagement and formation of immunological synapse with 
target cells and APCs can result in trogocytosis, where T cells acquire segments 
of the plasma membrane of the target cell. The trogocytosis analysis protocol 
(TRAP) assay can measure the amount of lipid bilayer exchange between T cells 
and targets, where an increase in acquisition may be due to interacting with more 
targets, or with a single target more aggressively. 
  HBSS- or poly(I:C)-pretreated P14 cells were transferred into congenic 
hosts, which were subsequently inoculated with LCMV. At day 5 post infection, 
splenocytes were harvested and a TRAP assay was performed using RMA cells 
pulsed with various peptides as targets, including a no peptide control, irrelevant 
K3L peptide, and cognate GP33 peptide. Representative flow plots gated on 
donor P14 cells showing dye incorporation in response to different targets is 
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shown in Figure 3.27A. The MFI of P14 cells pretreated with HBSS (open bars) 
or poly(I:C) (black bars) expressing Sp-DiI18(3) was normalized to control-treated 
cells for either K3L targets or GP33-pulsed targets is graphed (Figure 3.27B). 
The poly(I:C)-pretreated P14 cells, 5 days after LCMV infection, had modest but 
statistically significant reduced ability to acquire the dye from GP33-pulsed RMA 
cells, when compared to the HBSS-pretreated donor T cells. Reduced 
incorporation of the lipid dye can be an indicator of reduced effector cell function 
(196, 197).  
I questioned whether these donor poly(I:C)-pretreated T cell responses, 
which were dramatically reduced in number and modestly reduced in effector 
function, would affect viral load differently than that in mice receiving HBSS-
treated cells. Mice receiving either HBSS-pretreated or poly(I:C)-pretreated P14 
CD8 T cells were subsequently infected with LCMV, and viral titers were 
examined at different time points post infection. As early as day 4 post infection, 
mice receiving poly(I:C)-pretreated P14 cells had modest but statistically 
significant increased viral titers compared to mice receiving control-treated P14 
cells in the fat pad (4.7 ± 0.1 vs. 4.3 ± 0.08 log pfu, two independent experiments 
combined for n=10 per group) respectively (p = 0.0082). One individual 
experiment determining viral titers on day 6 post infection showed modest but 
significant increased viral loads in the fat pad and spleen in mice receiving 
poly(I:C)-pretreated P14 CD8 T cells compared to mice receiving HBSS-
pretreated P14 cells (Figure 3.28A). Viral titers in the liver did not reach 
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Figure 3.27: Reduced trogocytosis of poly(I:C)-pretreated P14 cells co-
cultured with GP33 pulsed RMA cells  
  
154 
 
Figure 3.27: Reduced trogocytosis of poly(I:C)-pretreated P14 cells co-
cultured with GP33 pulsed RMA cells  
A TRAP assay was performed using day 5 HBSS- or poly(I:C)-pretreated P14 
CD8 T cells as effectors and RMA cells pulsed with peptides as targets. Effectors 
were developed by poly(I:C) or HBSS treating a P14 transgenic mouse, 
transferring ~10,000 P14 cells from each group into separate mice 1 day after 
treatment and infecting the recipient mice with LCMV. At day 5 post infection, 
splenocytes containing the donor P14 CD8 T cells were isolated and used as 
effectors. Target cells were RMA cells that were not pulsed with peptide (no 
peptide), pulsed with an irrelevant peptide (K3L), or pulsed with the specific 
peptide (GP33). Target cells were labeled with fluorescent lipid molecule SP-
DiIC18(3) that can be detected if it is transferred to a different cell through 
trogocytosis. Target cells were in excess and were co-incubated with effectors for 
1 hour, stained with surface antibodies and ran on a flow cytometer. (A) 
Representative flow plots gated on donor P14 cells that were HBSS or poly(I:C) 
pretreated co-incubated with 1. No targets, 2. No peptide pulsed targets, 3. K3L 
pulsed targets, or 4. GP33 pulsed targets, looking at P14 cell incorporation of 
SP-DiIC18(3) are depicted. Data are representative of 2 independent experiments 
with n of 3-5 mice per group. (B) MFI of SP-DiIC18(3) gated on donor P14 cells, 
normalized to HBSS control for K3L and GP33 pulsed targets. HBSS-pretreated 
P14 cells are in the open bars and poly(I:C)-pretreated P14 cells represented as 
black bars. Data are combined from 2 independent experiments with a total n of 
8 mice per group.    
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statistical significance (p=0.0711), but still showed a similar trend as titers in the 
other organs tested, where mice receiving poly(I:C)-pretreated P14 cells had 
increased titers as compared to mice who received HBSS-treated P14 cells. 
These differences in viral titer are admittedly small, but they are statistically 
significant and occur in environments where normal endogenous host T cell 
responses are simultaneously occurring. By day 8 post infection the viral titers 
were reduced to the limit of detection in all organs tested in both treatment 
groups. 
Since out-of-sequence P14 cells were found to have reduced KRLG1 
expression compared to controls, I questioned whether KLRG1 expression 
correlated with viral load. After plotting the frequency of KLRG1+ P14 cells at 
days 4, 6, and 8 post infection vs. corresponding viral titer, a negative correlation 
between viral titer and frequency of KLRG1+ P14 cells in all three organs tested 
was revealed (Figure 3.28B). The greater the frequency of KLRG1+ P14 cells, 
the lower the viral load. In addition, and perhaps not surprising, there was also a 
negative correlation between viral titer and total number of P14 cells per spleen 
(Figure 3.28C). Based on these data, a combination between reduced effector 
function, and impaired clonal expansion may have negative consequences on 
the ability to control antigen load.  
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Figure 3.28: Mice receiving poly(I:C)-pretreated P14 cells have higher viral 
titers compared to mice receiving HBSS-pretreated P14 cells 
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Figure 3.28: Mice receiving poly(I:C)-pretreated P14 cells have higher viral 
titers compared to mice receiving HBSS-pretreated P14 cells 
Mice received equal numbers of HBSS- (open bars) or poly(I:C)- (black bars) 
pretreated P14 cells and were infected with 5x104 pfu LCMV. (A-C) At days 4, 6 
and 8 post infections, spleens, fat pad and livers were harvested, viral titers were 
determined, and splenocytes were stained. (A) Viral titers at day 6 post infection 
are graphed. Viral titers from spleen, fat pad and liver from days 4, 6, and 8 were 
correlated with frequency of KLRG1+ P14 cells (B) or total number of P14 CD8 T 
cells (C) per spleen. Data representative of 2-3 individual experiments per time 
point with n of 4-6 mice per group.  
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4. Summary 
Because the suppression of proliferation of poly(I:C)-pretreated CD8 T 
cells correlated with refractoriness to IFNβ stimulation, I hypothesized that 
poly(I:C)-pretreated CD8 T cells were unable to receive the positive effects that 
type 1 IFN exerts as a signal 3 cytokine when delivered in the proper sequence. 
This hypothesis would suggest that poly(I:C)-pretreated P14 cells would behave 
similarly to 2-signal only CD8 T cells, rather than 3-signal CD8 T cells.  
Indeed, I found that out-of-sequence CD8 T cells behaved more like to 2-
signal only CD8 T cells rather than T cells that received all 3 signals in the 
appropriate order. Poly(I:C)-pretreated CD8 T cells were found to have a delay in 
their ability to divide at 3 days post infection, but division profiles eventually 
mimicked that of control-treated cells by day 4 post infection (Figure 3.19). If a 
delay in cell division was the only factor contributing to the suppression of clonal 
expansion seen, we would have expected to see the out-of-sequence CD8 T 
cells catch up to control-treated cells at late enough time. However, despite a 
delay in the peak expansion of poly(I:C)-pretreated CD8 T cells, the magnitude of 
the response never reached the same levels as controls (Figure 3.20), 
suggesting that additional factors were contributing to the reduced expansion 
seen in poly(I:C)-pretreated CD8 T cells.  
Signal 3 cytokines had been shown to prolong the survival of activated 
CD8 T cells by upregulating the IκB family member Bcl-3 (86-88). Although the 
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exact mechanism of how Bcl-3 mediates survival is not known, loss of Bcl-3 
resulted in reduced clonal expansion of CD8 T cells (86-88, 198). Reduced Bcl-3 
expression is another hallmark of 2-signal CD8 T cells, and here we show that 
the out-of-sequence T cells behave more like to the 2-signal CD8 T cells in this 
regard. We identified lower levels of Bcl-3 in the out-of-sequence CD8 T cells at 
multiple time points post infection when compared to control-treated cells (Figure 
3.21). Therefore it is conceivable that lower Bcl-3 levels caused the poorer 
survival of out-of-sequence CD8 T cells, resulting in reduced clonal expansion.  
I showed that in response to peptide only, IFNAR KO P14 cells expanded 
to similar levels as WT P14 cells. Likewise poly(I:C)-pretreated CD8 T cells 
expanded to similar levels as HBSS-treated CD8 T cells in response to peptide 
only. However, IFNAR KO P14 cells and poly(I:C)-pretreated P14 CD8 T cells 
both showed impaired expansion compared to their appropriate controls in 
response to an LCMV infection (Figure 3.22). This shows how type 1 IFN can 
have such positive effects on T cell expansion. Results here suggest it is a lack 
of the response to signal 3 cytokines that contributes to suppression of 
proliferation seen in out-of-sequence CD8 T cells.  
Previously studies identified CD8 T cells lacking signal 3 cytokines signals 
had defects in T cell differentiation where they showed reduced SLEC 
proportions compared to T cells which received all 3 signals (78, 100, 143, 145). 
Consistent with these results, I have shown here that IFNAR KO P14 cells had 
lower proportions of SLECs and increased MPECs compared to WT P14 cells in 
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response to LCMV infection (Figure 3.23). Poly(I:C)-pretreated P14 cells had 
comparable changes as the IFNAR KO P14 cells, showing reduced SLEC 
proportions, and increased MPEC proportions as compared to control-treated 
P14 cells after LCMV infection (Figure 3.24). 
In addition to signal 3 cytokines being important for T cell subset 
differentiation, CD8 T cell function has also been shown to be affected. Each 
infection model may require different factors for efficient T cell activation and 
acquisition of effector function. My findings show that out-of-sequence T cells 
behave in a consistent manner with those of 2-signal only T cells. The poly(I:C)-
pretreated CD8 T cells could produce similar proportions of IFNγ and TNF, and 
similar levels on a per cell basis (Figure 3.25); however poly(I:C)-pretreated CD8 
T cells expressed less granzyme B (Figure 3.26). The combination of reduced 
granzyme B expression and impaired clonal expansion may have contributed to 
the higher viral titers seen in mice, which received out-of-sequence P14 CD8 T 
cells (Figure 3.28). 
Thus, studies here have shown that not only do CD8 T cells require 
distinct signal 3 cytokines for efficient activation, acquisition of effector function, 
differentiation into effector subsets, and efficient clonal expansion, but CD8 T 
cells also need to see these signals in a specific order. Out-of-sequence CD8 T 
cells that receive signal 3 first actually behave more like a 2-signal only CD8 T 
cell rather than one that receives all 3 signals in the more conventional order.  
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E. Conclusions 
Demonstrated in this chapter are three main findings: 1) poly(I:C)-
pretreated CD8 T cells have reduced clonal expansion, 2) pretreatment with 
poly(I:C) renders T cells transiently refractory to IFNβ induced STAT 
phosphorylation, and 3) out-of-sequence CD8 T cells behave more similar to 2 
signal only CD8 T cells. A model is shown in Figure 3.29. 
Acute virus infections induce a transient state of immune suppression 
often associated with impaired T cell responses to antigen exposure. We 
demonstrate here a universal mechanism of IFN-induced suppression of T cell 
response associated with the inability to receive positive effects of IFN acting as 
a signal 3 cytokine, resulting in impaired T cell responses. Virus-induced 
suppression of T cell responses could be mimicked by pre-exposure to the 
dsRNA analogue, poly(I:C) (Figures 3.1-3.10). The suppression of clonal 
expansion of poly(I:C)-pretreated CD8 T cells was found to require direct effects 
of type 1 IFN on the CD8 T cells (Figure 3.4).  
Because the poly(I:C)-induced suppression of CD8 T cell expansion to 
required direct effects of type 1 IFN, I hypothesized that poly(I:C)-pretreated CD8 
T cells may have had a different pattern of STAT phosphorylation in response to 
IFNβ signals. It could have been conceived that poly(I:C)-pretreated CD8 T cells 
may phosphorylate more STAT1 than STAT4, considering that type 1 IFN 
signaling through STAT1 has more anti-proliferative effects, and acting through  
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Figure 3.29: Model: Out-of-sequence signal 3 suppresses CD8 T cell 
responses in vivo  
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Figure 3.29: Model: Out-of-sequence signal 3 suppresses CD8 T cell 
responses in vivo  
 
Under normal circumstances when naïve T cells see antigen and costimulation 
first (top), type 1 IFN will have positive effects as a signal 3 cytokine. IFN 
augments clonal expansion by promoting survival of activated CD8 T cells, in 
part by upregulating Bcl-3. Efficient clonal expansion and differentiation of T cells 
results in control of antigen load. Naïve CD8 T cells that see signal 3 cytokines 
prior to antigen and costimulation (bottom) are refractory to further IFN 
stimulation and do not receive the positive effects IFN normally has as a signal 3 
cytokine. Out-of-sequence T cells have a delay in cell division and lower Bcl-3 
levels, which may reduce survival of T cells, resulting in impaired clonal 
expansion. Impaired clonal expansion and differentiation may lead to reduced 
ability to control antigen load.  
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STAT4 promotes more clonal expansion (90, 91, 95). However, this was not the 
case, as poly(I:C)-pretreated CD8 T cells did not phosphorylate any downstream 
STATs tested (Figures 3.11-3.12). CD8 T cells eventually gained the ability to 
respond to further IFN signals, indicating the refractoriness to IFN-induced STAT 
phosphorylation is a transient event (Figure 3.13). Downregulation of the type 1 
IFN receptor and upregulation of the suppressor protein SOCS1 were identified 
in poly(I:C)-pretreated CD8 T cells (Figures 3.17-3.18) and are thought to be 
contributing to the refractoriness to IFNβ stimulation. The refractoriness to IFNβ 
stimulation correlated kinetically with the poly(I:C)-induced impairment in clonal 
expansion seen (Figures 3.13 and 3.3). Since IFN has been shown to have such 
a profound effect on T cell expansion during acute infections, the correlations 
suggest that the lack of responsiveness to IFN signals may contribute to the 
suppression of clonal expansion seen in poly(I:C)-pretreated CD8 T cells.  
We show here that poly(I:C)-pretreated CD8 T cells are refractory to IFNβ 
signaling in terms of downstream STAT phosphorylation, suggesting that they 
are unable to receive positive effects that signal 3 cytokines normally provide 
during acute infections. Indeed, these out-of-sequence signal 3 CD8 T cells were 
found to behave more like 2-signal only CD8 T cells rather than T cells that 
receive all 3 signals in the proper order. The poly(I:C)-pretreated CD8 T cells 
were shown to behave similar to 2-signal T cells in a number of ways; they were 
associated with impaired expansion, which may have been attributed to a 
combination between delayed cell division (Figure 3.19) and reduced levels of 
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the survival protein Bcl-3 (Figure 3.21). Poly(I:C)-pretreated T cells also had 
defects in effector cell differentiation, showing reduced proportions of SLECs 
(Figures 3.23-3.24), and were also associated with reduced effector function 
(Figure 3.25-3.27). Consequently, the combination between reduced effector 
function and impaired clonal expansion resulted in increased viral loads during 
the acute infection (Figure 3.28), and reduced memory formation (Figure 3.20). 
Therefore, the inability to respond to signal 3 cytokines, as seen in out-of-
sequence T cells, limits CD8 T cell expansion and suggests a causative 
mechanism for reduced vaccine efficacy when administered during acute 
infections.   
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CHAPTER IV: Interferon primes naïve T cells to exhibit immediate effector 
function upon antigen stimulation 
A. Introduction  
During an acute virus infection, antigen-specific CD8 T cells undergo 
clonal expansion and differentiation into effector cells in order to control the 
infection. Antigen-specific cells require 3 distinct signals for their full activation: 
TCR engagement of pMHC (signal 1), costimulation resulting from interaction 
between B7 and CD28 (signal 2), and inflammatory cytokines including IL-12 or 
type 1 IFN (signal 3) (98-100). Without any one of these signals, dramatic 
differences in CD8 T cell activation can occur. Without signal 3 cytokines, CD8 T 
cells can divide but with defects in clonal expansion and/or effector function (79). 
If CD8 T cells are only exposed to pMHC without costimulation or inflammatory 
cytokines, they can be driven into apoptosis or become anergic (98). Identified in 
the previous chapter, out-of-sequence signal 3 was found to have a profound 
effect on CD8 T cell clonal expansion and effector differentiation when exposed 
to antigen for a prolonged period of time. We questioned if there might be an 
effect of out-of-sequence signaling on CD8 T cells prior to cell division and clonal 
expansion.  
During the course of an immune response there are multiple stages of 
CD8 T cell activation: expansion and differentiation, contraction, and memory 
formation. Much work has been done trying to identify and differentiate naïve vs. 
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effector vs. memory CD8 T cell populations based on their phenotype. A 
heterogeneous population of CD8 T cells exists at each stage of activation. 
Nevertheless, the general activation status of CD8 T cells can be identified using 
several key molecules. Naïve CD8 T cells are generally classified as being 
CD44lo, CD62Lhi, and CD127hi (199). During the earliest stages of activation, 
CD8 T cells will become CD44hi, upregulate CD69 and CD25 and downregulate 
CD127 and CD62L (138, 172, 200). Closer to the peak of CD8 T cell expansion, 
T cells lose expression of CD25 and CD69, which are early activation markers, 
but remain CD44hi (140). A small proportion of CD8 T cells will upregulate 
KLRG1, an effector-associated surface marker. A specific population of effectors 
will re-express CD127; these cells, have been shown to preferentially transition 
into the memory pool (147). Memory T cells, although a heterogeneous 
population, remain CD44hi, and while the majority are CD127hi, some express 
CD62L, depending on the subset (199). Therefore, the relative differentiation 
state of CD8 T cells can be identified by staining for a subset of surface markers. 
Recent work has attempted to identify the specific TFs that are associated 
with effector vs. memory T cells. Numerous TFs are associated with T cell 
differentiation, but two primary TFs play a major role in effector CD8 T cells are 
the T-box TFs, Tbet and Eomes (151-154). These TFs regulate a number of 
effector genes in CD8 T cells including IFNγ, granzyme B, and perforin (154, 
168). These two TFs do not have completely redundant roles, as Tbet is more 
associated with effector T cells and Eomes with memory T cells (153, 154). In 
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addition, effector CD8 T cells are associated with Tbet and Blimp-1 expression, 
whereas memory CD8 T cells are associated with Eomes and TCF1 expression 
(152, 154). More recently, the TFs BATF and IRF4 have been shown to be 
important for CD8 T cell effector differentiation and proliferation. BATF is 
upregulated in effector cells in response to LCMV infection, and (156) IRF4 is 
induced through TCR stimulation. IRF4 and BATF cooperate with each other 
during CD8 T cell differentiation and, in fact, regulate many of the same genes 
including effector-associated TFs, such as Tbet, Eomes, and Blimp-1 (157, 158).  
Once activated, CD8 T cells have the ability to produce multiple cytokines 
in response to cognate antigen and acquire ability to specifically lyse target cells. 
Naïve CD8 T cells require all 3 signals in order to acquire multiple effector 
functions. Without signal 3 cytokine stimulation, T cells can have defects in 
cytotoxic capability, and cytokine production (78, 79, 98). If CD8 T cells receive 
all the appropriate signals, they can produce multiple cytokines including TNF, 
IFNγ, and sometimes IL-2 in response to cognate antigen. Activated CD8 T cells 
will upregulate granzyme B and perforin, which enables them to specifically lyse 
target cells (97). However, CD8 T cells normally need to divide at least once 
before they acquire specific effector functions, including the ability to directly lyse 
target cells and rapidly produce certain cytokines (141). Naïve CD8 T cells have 
the capacity to produce TNF upon stimulation with cognate ligand or anti-CD3, 
but they do not produce IFNγ (161, 162). Traditionally, acquisition of IFNγ 
production upon stimulation with ligand is seen only after CD8 T cells divide 
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several times (141, 154, 162). Other studies have found that naïve T cells 
produce a short burst of IFNγ within the first 24 hours after cognate antigen 
stimulation and costimulation or infection, but this may have more regulatory 
effects (201, 202).  
Recent discoveries from our lab have shown that bystander CD8 T cells, 
which are non-antigen specific for the infecting pathogen, can acquire rapid 
effector function if pre-exposed to type 1 IFN-inducing environments (193). 
Bystander CD8 T cell sensitization to rapid effector function required indirect 
effects of type 1 IFN and self-MHC. This suggested that if CD8 T cells are 
exposed to activation signals in an unconventional order, they may behave 
differently in response to antigen stimulation. We sought to determine how CD8 T 
cells responded to cognate antigen stimulation if they were pre-exposed to signal 
3 cytokines. By using the dsRNA analog, poly(I:C), to induce type 1 IFN, we 
discovered poly(I:C)-induced naïve CD8 T cells to acquire immediate effector 
function, prior to cell division and prior to acquiring an effector cell phenotype. 
Through these studies, several distinct discoveries were made: 1) Poly(I:C)-
pretreated naïve CD8 T cells acquired an early-activated phenotype associated 
with alterations of transcription factors and surface markers; 2) Priming with 
poly(I:C) induced naive CD8 T cells to exhibit effector functions immediately upon 
stimulation with high-density cognate antigen, reduced affinity APLs, and in 
response to reduced concentrations of cognate antigen; 3) Poly(I:C) priming 
requires hematopoietic cells, self-MHC, and costimulatory B7 molecules; 4) 
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Primed naïve CD8 T cells specifically lyse target cells; 5) Acquisition of 
immediate effector function in poly(I:C)-primed naïve CD8 T cells occurs before 
cell division. These studies identified how the timing of activation signals can 
dramatically affect the acquisition of CD8 T cell effector function. 
B. Poly(I:C)-primed naïve CD8 T cells acquire immediate effector function  
1. Naïve CD8 T cells adopt an early-activated phenotype after 
poly(I:C) priming in vivo. 
Naïve CD8 T cells are phenotypically distinct from effector T cells and 
memory T cells. Naïve CD8 T cells can be identified as being CD44lo, CD127hi, 
and CD62Lhi (100). Upon cognate antigen stimulation, CD8 T cells undergo 
clonal expansion, differentiation and memory formation associated with 
alterations in CD8 T cell phenotype. In the present study, the phenotype of naïve 
CD8 T cells changed in the absence of cognate antigen. Upon in vivo stimulation 
with the dsRNA analog, poly(I:C), naïve CD44lo CD8 T cells adopt an early, 
intermediate-activated phenotype. Antigen-specific cells were tracked by using 
CD8 T cell congenic Ly5.1 transgenic cells, including OT-I and P14 CD8 T cells. 
Transgenic CD8 T cells were adoptively transferred into Ly5.2 hosts, which were 
inoculated with HBSS or poly(I:C). Representative histograms in Figure 4.1A 
show naïve CD8 T cells (host, donor OT-I and donor P14) upregulated the early 
activation markers CD69 and CD86, and downregulated IFNAR1, CD127, with 
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some downregulating  CD62L, one day after poly(I:C) treatment (open 
histograms). The HBSS-treated controls (open bars) were used to normalize the  
Figure 4.1: Poly(I:C) induces naive CD8 T cells to adopt an early-partial 
activated phenotype 
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Figure 4.1: Poly(I:C) induces naive CD8 T cells to adopt an early-partial 
activated phenotype 
Ly5.1 OT-1 or P14 T cell transgenic splenocytes were adoptively transferred into 
WT B6 mice, which were inoculated with HBSS or poly(I:C). Spleens were 
harvested 1 day later and stained for activation markers. A) Representative 
histograms gated on CD44lo host, CD44lo OT-I, or CD44lo P14 CD8 T cells from 
HBSS- (shaded histograms) or poly(I:C)- (open histograms) inoculated mice. B-
E) MFI of poly(I:C)- (black bars) treated CD44lo CD8 T cell populations were 
normalized to HBSS- (open bars) treated CD44lo CD8 T cell populations 
depicting CD69 (B), CD127 (C), IFNAR1 (D), and CD86 (E). Data are 
representative of 2 individual experiments (OT-1) or at least 5 individual 
experiments (P14) with n of 2-5 mice per group.  
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MFI of poly(I:C)-pretreated naïve CD8 T cells (black bars). The normalized MFI 
of CD69 (B), CD127 (C), IFNAR1 (D) and CD86 (E) of the naïve host, OT-I and 
P14 CD8 T cell populations are graphed (Figure 4.1). Irrespective of the 
specificity of the naïve T cell population, each adopted a similar change in 
phenotype. However, both of the transgenic populations showed higher 
expression of CD69 when compared to the endogenous polyclonal population. 
Nevertheless, the poly(I:C)-treated host population still showed CD69 MFI ~20 
fold higher compared to HBSS-treated controls.  
These results were further corroborated by microarray data. CD44lo 
CD8α+ T cells were isolated from HBSS- or poly(I:C)-inoculated mice after 1 day. 
Naïve T cells were purified to >98.5% purity, and a microarray analysis was 
performed. The fold expression of poly(I:C)-treated/HBSS-treated T cells of 
selected genes are shown in Table 4.1. Both CD86 and CD69 were found to be 
upregulated in naïve CD8 T cells from poly(I:C)-treated over control-treated cells 
in microarray data, and this was confirmed with protein expression shown in 
Figure 4.1.   
The upregulation of both CD69 and CD86 required type 1 IFN signaling. 
Splenocytes from Ly5.1 P14 mice were transferred into WT B6 or IFNAR KO 
hosts followed by inoculation with HBSS or poly(I:C) for 1 day. Donor CD44lo 
P14 cells showed reduced upregulation of the early activation marker CD69 
(Figure 4.2A), and this upregulation was completely abrogated in the host 
CD44lo CD8 T cell population (Figure 4.2C). This indicated that type 1 IFN must  
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Table 4.1: Microarray analysis of selected genes differentially expressed 
from CD44lo CD8α+ T cells after 1-day inoculation with HBSS or poly(I:C) 
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Table 4.1: Microarray analysis of selected genes differentially expressed 
from CD44lo CD8α+ T cells after 1-day inoculation with HBSS or poly(I:C) 
WT B6 mice were inoculated with HBSS or poly(I:C). One day later, splenocytes 
were harvested, and CD44lo CD8α+ T cells were isolated to > 98.5% purity. 
MoGene 2.0 ST Array (Affymetrix) gene chip was used. Data were analyzed 
using Genespring software. Fold change of poly(I:C)-treated CD8 T cells relative 
to HBSS-treated CD8 T cells of selective genes are listed in the table. Data are 
from an individual experiment.   
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Figure 4.2: Early activated phenotype requires type 1 IFN  
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Figure 4.2: Early activated phenotype requires type 1 IFN  
Congenic P14 cells were transferred into WT B6 hosts or IFNAR KO hosts, which 
were inoculated with HBSS or poly(I:C). One day later splenocytes were 
harvested and stained. MFI of CD44lo donor P14 cells expressing CD69 (A) and 
CD86 (B) is graphed. MFI of CD44lo host CD8 T cells expressing CD69 (C) and 
CD86 (D) is graphed. Individual experiment with n of 3-4 mice per group. 
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act directly on the CD8 T cell for its upregulation of CD69. CD86 was similarly 
found to require IFN signaling on CD8 T cells, as host CD44lo CD8 T cells from 
IFNAR KO mice did not upregulate CD86 after poly(I:C) treatment (Figure 4.2D), 
but donor P14 cells upregulated CD86 after poly(I:C) treatment (Figure 4.2B).  
Previous studies from our lab found that P14 cells in a bystander setting 
maintained a naïve phenotype and remained CD44 and CD43 low at day 5 post 
Pichinde virus (PV) infection (non-cross-reactive with the P14 cells) and modestly 
increased CD122 expression (193). However, in the system shown here, 1 day 
after poly(I:C) treatment, CD122 expression was not increased over controls. 
Additional effector molecules were surveyed, including a number of different 
cytokine receptors, activation markers, and adhesion molecules, most of which 
showed no significant difference between control and poly(I:C)-pretreated 
groups. CD25 is one of the earliest markers upregulated after naïve CD8 T cell 
activation, but its expression was unaffected by poly(I:C) treatment. Another 
important effector CD8 T cell activation marker, KLRG1, was also unaltered by 
pretreatment with the dsRNA analogue.  
To identify when poly(I:C)-primed naïve CD8 T cells alter their phenotype, 
mice were inoculated with poly(I:C) for 12, 18 or 24 hours. CD44lo P14 cells 
upregulated CD69 within the first 12 hours after exposure to poly(I:C)-induced 
environments (black bars) (Figure 4.3A). However, the downregulation of both 
CD127 (Figure 4.3B) and CD62L (Figure 4.3C) occurred in a stepwise fashion 
over time. There were very few CD44lo P14 cells that had downregulated CD127  
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Figure 4.3: Early activated phenotype of naïve CD8 T cells seen as early as 
12 hours post poly(I:C) inoculation 
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Figure 4.3: Early activated phenotype of naïve CD8 T cells seen as early as 
12 hours post poly(I:C) inoculation 
Congenic P14 cells were transferred into WT B6 mice, which were inoculated 
with HBSS or poly(I:C) for 12, 18, or 24 hours. Splenocytes were harvested and 
stained ex vivo. Frequencies of CD44lo P14 cells expressing CD69 (A), CD127 
(B), and CD62L (C) are graphed. Data are representative of 2 individual 
experiments with n of 3 mice per group. 
  
181 
 
or CD62L at 12 hours post poly(I:C) treatment (black bars), but by 24 hours, a 
significant frequency of naïve P14 cells had reduced expression of these surface 
proteins when compared to controls (open bars) (Figure 4.3B-C).  
The duration over which the altered phenotype of naïve CD8 T cells pre-
exposed to poly(I:C)-induced environments was also determined. The modified 
phenotype, showing CD127 and CD62L downregulation and CD69 upregulation 
in CD44lo CD8 T cells, occurred through 2 days post-inoculation, but by 3 days 
post-treatment, the phenotype mostly resembled that of the control-treated 
counterparts (data not shown). These data indicate that poly(I:C) transiently 
induces naïve CD8 T cells to acquire an intermediately activated phenotype. 
2. Poly(I:C)-primed naïve CD8 T cells upregulate effector-associated 
transcription factors 
Upon activation, CD8 T cells express various transcription factors, which 
will allow for their differentiation into effector cells and ability to produce effector 
functions upon stimulation with cognate antigen. In the present study, I sought to 
determine the TF phenotype of poly(I:C)-primed naïve CD8 T cells. 
Representative histograms gated on CD44lo CD8α+ T cells are shown in Figure 
4.4A, with HBSS-treated cells shown by shaded histograms and poly(I:C) by 
open histograms. The TCR-stimulated transcription factor IRF4 was found to be 
upregulated in CD44lo CD8 T cells after poly(I:C) treatment (Figure 4.4B). 
However, the CD8 effector-associated T-box TF Tbet remained largely   
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Figure 4.4: Naïve CD44lo CD8 T cells upregulate effector-associated 
transcription factors after poly(I:C) inoculation 
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Figure 4.4: Naïve CD44lo CD8 T cells upregulate effector-associated 
transcription factors after poly(I:C) inoculation 
WT B6 mice were inoculated with HBSS (shaded histograms) or poly(I:C) (open 
histograms), and splenocytes were harvested and stained for transcription 
factors 1 day later. A) Representative histograms gated on CD44lo CD8 T cells 
depicting IRF4, Eomes, Tbet, or TCF1 expression. B-E) CD44lo CD8 T cell MFI 
of IRF4 (B), Tbet (C), Eomes (D) and TCF1 (E). Data are representative from 2-5 
individual experiments with n of 3-5 mice per group.  
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unchanged (Figure 4.4C),  while the memory-associated TF Eomes was 
dramatically upregulated in naïve CD44lo CD8 T cells after poly(I:C) treatment 
(Figure 4.4D). Microarray data also showed expression of Eomes transcripts 
from poly(I:C)-treated CD44lo CD8 T cells was increased 3-fold over HBSS-
treated controls (Table 4.1). Poly(I:C) treatment also induced a small reduction in 
TCF1 expression in naïve CD8 T cells (Figure 4.4E).  
Our lab previously showed that indirect effects of type 1 IFN were required 
for bystander T cell sensitization to rapid effector function. Therefore, I wanted to 
identify if the upregulation of effector-associated TFs had similar requirements for 
IFN. Congenic P14 CD8 T cells were transferred into WT or IFNAR KO host 
mice, which were subsequently inoculated with HBSS or poly(I:C). After 1 day of 
in vivo treatment, the CD44lo donor P14 cells transferred into the IFNAR KO host 
did not upregulate IRF4 and Eomes to the same extent as P14 cells that were 
poly(I:C)-primed (black bars) in WT hosts (Figure 4.5 A-B). Moreover, host naïve 
CD8 T cells showed no increase in frequency of cells expressing the effector-
associated TFs IRF4 or Eomes after poly(I:C) inoculation (Figure 4.5 C-D). 
These data indicate that IFN acts directly on CD8 T cells to upregulate IRF4 and 
Eomes. That being said, interpretations of these results may be more 
complicated, considering that in the IFNAR KO hosts, less IFN is being induced, 
and this may be a contributing factor to the observed phenotype. 
Combined, these results are somewhat perplexing, considering that IRF4 
has been shown to promote Tbet expression and inhibit Eomes induction   
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Figure 4.5: Type 1 IFN is required for upregulation of effector-associated 
transcription factors IRF4 and Eomes 
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Figure 4.5: Type 1 IFN is required for upregulation of effector-associated 
transcription factors IRF4 and Eomes 
Congenic P14 cells were transferred into WT B6 hosts or IFNAR KO hosts, which 
were inoculated with HBSS or poly(I:C). One day later splenocytes were 
harvested and stained. Frequencies of CD44lo P14 cells expressing IRF4 (A) or 
Eomes (B) and frequencies of CD44lo host CD8 T cells expressing IRF4 (C) or 
Eomes (D) are graphed. Individual experiment with n of 3-4 mice per group. 
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(148, 151, 153, 156). Therefore, I wanted to determine if IRF4 was upregulated 
before or after Eomes induction. Mice that had received congenic P14 cells were 
inoculated with HBSS (open bars) or poly(I:C) (black bars), and splenocytes were 
harvested at 12, 18 and 24 hours post-treatment. In donor CD44lo P14 CD8 T 
cells, Eomes expression was greatest at the earliest time point tested, whereas 
IRF4 expression, albeit upregulated, was lowest at the 12-hour time point 
(Figure 4.6 A-B). The kinetics of Eomes and IRF4 expression in donor naïve 
P14 cells was recapitulated in the endogenous host CD44lo CD8 T cell 
population (Figures 4.6C-D), where at 12 hours post poly(I:C) treatment, the 
lowest frequencies of IRF4+ cells were observed, but the highest frequencies of 
Eomes+ cells were observed. Considering that the frequency of Eomes+ cells 
declined slightly at later time points, but IRF4 levels increased, these data are 
consistent with previous findings that IRF4 expression can repress Eomes 
expression (203). However, because we did not see a difference in Tbet 
expression, results are inconsistent with IRF4 regulating Tbet in this setting. 
However, some experiments performed showed that a small proportion of 
CD44lo CD8 T cells upregulated Tbet after poly(I:C) treatment, but results were 
not very consistent, and expression levels were very low. However, it should be 
noted, that IRF4 is not the only TF that has been linked to Eomes and Tbet 
expression.  
3. Poly(I:C)-primed naïve CD8 T cells produce immediate effector 
functions upon stimulation with cognate antigen stimulation 
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Figure 4.6: CD44lo CD8 T cells upregulate IRF4 and Eomes as early as 12 
hours post poly(I:C) priming 
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Figure 4.6: CD44lo CD8 T cells upregulate IRF4 and Eomes as early as 12 
hours post poly(I:C) priming 
Congenic P14 cells were transferred into WT B6 mice, which were inoculated 
with HBSS (open bars) or poly(I:C) (black bars). Splenocytes were harvested and 
stained 12, 18, or 24 hours later. Frequencies of CD44lo IRF4- (A) or Eomes- (B) 
expressing donor P14 cells are graphed. Frequencies of CD44lo IRF4- (C) or 
Eomes- (D) expressing host CD8 T cells are graphed. Data are from at least 1 
experiment with 3 mice per group.  
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Recent studies from our lab showed that bystander CD8 T cells could 
rapidly produce effector functions in response to cognate antigen stimulation if 
pre-exposed to virus-induced inflammatory environments (193). The present 
study confirms previous results where P14 CD8 T cells produced immediate 
effector function in response to cognate antigen stimulation if pre-exposed to 
poly(I:C) in vivo. First, microarray data show that granzyme B expression is 
highly induced (>25 fold) in naïve CD8 T cells after poly(I:C) inoculation 
compared to control-treated naïve CD8 T cells (Table 4.1). Additional cytolytic-
associated effector molecules were found to be increased in poly(I:C)-treated 
cells over controls including granzyme A, granulin, and TRAIL (or Tnfsf10). 
However, not all of the changes observed at the transcript level have been 
corroborated at the protein level, but granzyme B protein levels were elevated. 
Congenic P14 splenocytes were transferred into B6 mice, which were inoculated 
with HBSS or poly(I:C) for 1 day, and stimulated ex vivo with GP33 for 4-5 hours 
during an ICS assay. Figure 4.7A-C depicts poly(I:C)-treated CD44lo P14 CD8 T 
cells degranulating and secreting granzyme B upon ex vivo stimulation with their 
cognate ligand GP33. Representative histograms of poly(I:C)-treated CD44lo 
P14 cells (open histograms) show increased degranulation, as measured by 
CD107a/b staining, and release of granzyme B, over control-treated cells 
(shaded histograms) (Figure 4.7A). Quantification of the frequency of CD44lo 
P14 cells (control-treated represented as open bars and poly(I:C)-treated 
represented as black bars) producing CD107a/b and granzyme B are shown in   
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Figure 4.7: Poly(I:C)-pretreated CD44lo P14 CD8 T cells produce immediate 
effector functions upon stimulation with cognate ligand  
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Figure 4.7: Poly(I:C)-pretreated CD44lo P14 CD8 T cells produce immediate 
effector functions upon stimulation with cognate ligand  
Congenic P14 splenocytes were transferred into WT B6 mice, which were 
subsequently inoculated with HBSS or poly(I:C). One day later spleens were 
harvested, and cells were stimulated ex vivo with no peptide or GP33 for ~4-5 
hours, then stained for effector molecules. A) Representative flow plots gated on 
donor CD44lo P14 CD8 T cells from HBSS- (shaded histograms) or poly(I:C)- 
(open histograms) treated mice showing CD107a/b and granzyme B expression. 
Frequencies of CD44lo P14 T cells producing CD107a/b (B) and granzyme B (C) 
from poly(I:C)- (black bars) and HBSS- (open bars) treated mice are graphed. D) 
Representative flow plots gated on CD44lo P14 T cells are depicted. 
Frequencies of CD44lo P14 T cells from HBSS- (open bars) and poly(I:C)- (black 
bars) treated mice producing IFNγ (E) and TNF (F) are graphed. Data are 
representative of 3-7 individual experiments with n of 3-5 mice per group.  
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Figures 4.7B and C, respectively. It should be noted that poly(I:C)-treated naïve 
P14 cells without ex vivo stimulation (No stim) show enhanced granzyme B 
expression, and upon stimulation with high-affinity ligand show a significant loss 
in granzyme B staining. Combined with the increased degranulation markers, this 
suggests that granzyme B is being released or secreted.   
In addition to degranulation, poly(I:C)-pretreated CD44lo P14 cells also 
produced IFNγ and enhanced TNF in response to ex vivo stimulation with 
cognate ligand (Figure 4.7 D-E). Representative flow plots gated on CD44lo P14 
cells from HBSS- or poly(I:C)-pretreated mice that remained unstimulated, or 
stimulated with GP33 ex vivo, are illustrated (Figure 4.7D). The proportion of 
CD44lo P14 cells expressing IFNγ (Figure 4.7E) or TNF (Figure 4.7F) from 
control- (open bars) or poly(I:C)- (black bars) pretreated mice are graphed. The 
pre-exposure of naïve CD8 T cells to IFN-induced environments primes them to 
be immediate effectors upon stimulation with high affinity cognate ligand such 
that they produce multiple cytokines.  
To ensure that the enhanced effector function of naïve CD8 T cells from 
inflammatory environments was not due to an artifact of the P14 transgenic 
population, other transgenic T cells and endogenous polyclonal T cells were 
observed. Congenic OT-I splenocytes were transferred into B6 hosts and were 
assessed in a similar manner as P14 cells in Figure 4.7. Upon stimulation with 
high affinity cognate ligand (OVA), increased frequencies of poly(I:C)-pretreated 
CD44lo OT-I cells (black bars) produced IFNγ (Figure 4.8A) and enhanced TNF 
194 
 
(Figure 4.8B) compared to their control-treated counterparts (open bars). OT-I 
cells are another transgenic monoclonal population, therefore, I wanted to 
determine if polyclonal CD44lo CD8 T cells also showed immediate effector 
function. The endogenous host naïve CD44lo CD8 T cells were stimulated ex 
vivo with anti-CD3 and assessed for IFNγ and TNF production. Figure 4.8C 
shows increased frequencies of CD44lo CD8 T cells producing IFNγ in response 
to anti-CD3 stimulation in poly(I:C)-pretreated populations (black bars) compared 
to controls (open bars). Naïve CD8 T cells had already been shown to produce 
TNF in response to anti-CD3 stimulation or cognate Ag stimulation ex vivo (161). 
Data shown here depict increased proportions of TNF-producing CD44lo CD8 T 
cells from poly(I:C)- vs HBSS-pretreated mice (Figure 4.8D). Combined, these 
data show that transgenic P14 and OT-I CD8 T cells along with polyclonal 
CD44lo CD8 T cells are susceptible to poly(I:C)-induced priming and acquire the 
ability to produce effector functions immediately upon cognate antigen 
stimulation.  
Previous studies in our lab showed that indirect effects of type 1 IFN were 
important for P14 cell production of IFNγ after poly(I:C) inoculation. To 
recapitulate these studies, and also to identify if degranulation and/or additional 
effector functions have similar requirements, WT P14 cells were transferred into 
WT B6 or IFNAR KO hosts and primed with poly(I:C). After in vivo treatment, 
splenocytes were harvested, and an ICS was performed. Unstimulated CD44lo 
P14 cells primed in WT host mice showed increased frequencies of granzyme B+   
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Figure 4.8: Naïve CD44lo CD8 T cells acquire immediate effector function 
after poly(I:C) priming  
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Figure 4.8: Naïve CD44lo CD8 T cells acquire immediate effector function 
after poly(I:C) priming  
OT-I splenocytes were transferred into WT B6 mice, which were subsequently 
inoculated with HBSS or poly(I:C). One day later, spleens were harvested and 
cells were stimulated ex vivo with no peptide, anti-CD3, or OVA for ~4-5 hours 
and stained for cytokines. Frequency of donor CD44lo OT-I CD8 T cells from 
HBSS- (open bars) and poly(I:C)- (black bars) inoculated animals producing IFNγ 
(A) and TNF (B) are graphed. C-D) Frequencies of host CD44lo CD8 T cells from 
HBSS- (open bars) and poly(I:C)- (black bars) inoculated animals producing IFNγ 
(C) and TNF (D) are graphed. Data are representative of at least 4 experiments 
with n of 3-5 mice per group. 
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P14 cells, but if P14 cells were primed in the IFNAR KO host, granzyme B was 
not upregulated (Figure 4.9A). The ability of CD44lo P14 cells to degranulate, as 
measured by CD107a/b staining, and to produce IFNγ was also reduced if T cells 
were primed in IFNAR KO hosts compared to WT hosts (Figure 4.9B-C). 
Because there was still some degranulation and IFNγ production from poly(I:C)-
primed CD44lo P14 cells from IFNAR KO hosts, this suggests that in addition to 
type 1 IFN indirectly activating cells, that it may also have some direct effects. 
However, these studies may be difficult to interpret because of the assumed 
reduced levels of type 1 IFN in the KO hosts.  
We then questioned how early naïve CD8 T cells acquire the immediate 
effector function after exposure to poly(I:C)-induced inflammatory environments. 
P14 cells were transferred into mice that were inoculated with HBSS or poly(I:C) 
and harvested at 12, 18, or 24 hours post-inoculation. Directly ex vivo, poly(I:C)- 
expressed high levels of granzyme B compared to control-treated P14 cells 
(open bars) at all time points tested (Figure 4.10A). Upon stimulation with high 
affinity cognate ligand during an ICS assay, poly(I:C)-pretreated P14 cells (black 
bars) produced significant amounts of IFNγ as early as 12 hours post-inoculation 
(Figure 4.10B). 
Previous studies conducted by our lab determined that the poly(I:C) 
priming of naïve T cells into immediate effectors is a transient effect (193). T cells 
were in the poly(I:C)-primed environment for 1, 2, or 3 days before assessing 
their capability of producing IFNγ to cognate antigen stimulation. Effector function   
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Figure 4.9: Poly(I:C)-induced immediate effector function requires type 1 
IFN signaling in the priming environment 
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Figure 4.9: Poly(I:C)-induced immediate effector function requires type 1 
IFN signaling in the priming environment 
Congenic P14 cells were transferred into WT B6 hosts or IFNAR KO hosts, which 
were inoculated with HBSS or poly(I:C). One day later splenocytes were 
harvested and were either stimulated without peptide (A) or with GP33 (B-C) for 
~5 hours. Frequency of CD44lo P14 cells expressing granzyme B (A), CD107a/b 
(B), or IFNγ (C) are graphed. Individual experiment with n of 3-4 mice per group. 
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Figure 4.10: Naïve CD8 T cells acquire immediate effector function as early 
as 12 hours post poly(I:C) inoculation  
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Figure 4.10: Naïve CD8 T cells acquire immediate effector function as early 
as 12 hours post poly(I:C) inoculation  
Congenic P14 cells were transferred into WT B6 mice, which were inoculated 
with HBSS or poly(I:C) for 12, 18, or 24 hours. Splenocytes were harvested and 
stained ex vivo (A, C) or stimulated with GP33 for an ICS assay (B). Frequencies 
of CD44lo P14 cells expressing granzyme B (A), or IFNγ (B) from HBSS- (open 
bars) or poly(I:C)- (black bars) treated mice are graphed. Representative flow 
plots gated on P14 CD8 T cells expressing Ki67 from poly(I:C)- or HBSS-treated 
mice are graphed (C). Data are representative of 1-2 individual experiments with 
3 mice per group.  
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was greatest with 1 day of priming, and decreased thereafter, where by day 3 
post priming with poly(I:C), donor P14 cells only modestly induced IFNγ in 
response to GP33 stimulation ex vivo.  
Our lab also identified that bystander P14 CD8 T cells did not divide 
during a PV infection shown by using CFSE dilution assays. To identify if 
poly(I:C) treatment induced division of CD8 T cells, the proliferation marker Ki67 
was used. Ki67 can be detected in cells that are in a non-resting state or that are 
actively at some point in the cell cycle. However, the phase of the cell cycle in 
which a Ki67 positive cell exists is not known. Figure 4.10C shows that poly(I:C)-
treated P14 cells do not upregulate Ki67 at 12, 18, or 24 hours post treatment, 
indicating that they are not dividing, nor have they exited the resting G0 state. 
 
4. Summary 
During the course of an immune response, antigen-specific CD8 T cells 
will divide, clonally expand, and differentiate into effector cells. Effector cells have 
the capability of producing multiple cytokines in response to antigen simulation. 
However, the acquisition of those effector functions is thought to require CD8 T 
cell division. In the present study, we find that naïve CD8 T cells gain the ability 
to respond immediately to cognate antigen stimulation and produce effector 
functions if they are pre-exposed to a poly(I:C)-induced inflammatory 
environment. Naïve CD8 T cells exposed to poly(I:C) for as little as 12 hours will 
upregulate surface proteins associated with early activated T cells including 
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CD69 and CD86 while remaining CD44lo (Figure 4.1-4.3). Moreover, poly(I:C)-
pretreated CD44lo CD8 T cells downregulated IFNAR1, CD127 and to a lesser 
extent CD62L (Figure 4.1-4.3). This change in phenotype of poly(I:C)-primed 
CD8 T cells resembles an early, intermediately activated CD8 T cell, whilst still 
remaining CD44lo, and having never seen cognate antigen. 
 In addition to altering the phenotype of naïve CD8 T cells, pre-exposure to 
poly(I:C) alters the TF profile of naïve CD8 T cells (Figure 4.4). IRF4 was 
upregulated in poly(I:C)-treated naïve CD8 T cells, indicating TCR signaling 
occurred, even without the presence of cognate antigen (Figure 4.4-4.6). The T-
box TF Eomes, which is normally associated with memory CD8 T cells, was 
upregulated in poly(I:C)-primed CD44lo CD8 T cells as early as 12 hours post 
poly(I:C) treatment (Figure 4.6). Upregulation of Eomes is thought to be one 
factor that allows for the immediate cytokine secretion in primed naïve CD8 T 
cells. 
 Poly(I:C)-pre-exposed naïve CD8 T cells gained the ability to respond 
immediately to cognate antigen stimulation and showed signs of degranulation, 
release of granzyme B, production of IFNγ, and enhanced TNF production 
(Figure 4.7-4.10). Poly(I:C) “primes” naïve CD44lo CD8 T cells to respond to 
cognate antigen immediately, without the need to divide (Figure 4.10). The 
poly(I:C)-pretreated CD8 T cells maintained a naïve phenotype but behaved 
more similar to a memory T cell rather than a naïve CD8 T cell.  
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C. Cell types that mediate IFN priming 
1. Hematopoietic cells mediate poly(I:C)-induced priming 
The present study addressed the cell type that was mediating poly(I:C)-
induced priming. Bone marrow chimeras were generated in which either WT B6, 
or H2-Db KO mice were lethally irradiated (950rads) and then received BM from 
the opposite recipient. WT B6 mice received H2-Db KO BM (KO BM), so that in 
these mice only the radio-resistant cells will have H2-Db on the surface, and cells 
of the hematopoietic compartment will lack surface H2-Db. H2-Db KO mice 
receiving WT BM (WT BM), conversely, will have surface H2-Db on cells of the 
hematopoietic lineage. After ~6 weeks of re-constitution, congenic transgenic 
P14 cells were transferred into each of the chimeric mice, which were inoculated 
with either HBSS or poly(I:C) the following day. After 1 day of in vivo treatment, 
splenocytes were harvested and stained. P14 cells from the mice that received 
KO BM did not upregulate the early activation marker CD69 to the same extent 
as P14 cells from mice that received WT BM (Figure 4.11A). Since CD69 was 
one of the phenotypic markers associated with primed naïve effectors, this 
suggested that self-MHC was required in the hematopoietic compartment to 
mediate priming. Additionally, P14 cells from mice receiving KO BM also showed 
lower upregulation of the T-box TF Eomes (Figure 4.11B), a TF shown to be 
upregulated in primed naïve T cells. Together, these data suggest that H2-Db  
  
205 
 
Figure 4.11: WT hematopoietic cells mediate poly(I:C)-induced CD8 T cell 
priming  
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Figure 4.11: WT hematopoietic cells mediate poly(I:C)-induced CD8 T cell 
priming  
Bone marrow chimeras were generated in which either WT BM was transferred 
into irradiated β2M KO hosts, or β2M KO BM was transferred into irradiated WT 
B6 hosts. After reconstitution for >6 weeks, congenic P14 cells were transferred 
into chimeras, which were control-treated with HBSS, or treated with poly(I:C). 
One day later splenocytes were harvested and stained. The frequency of CD44lo 
P14 cells expressing CD69 (A) and Eomes (B) from HBSS- (open bars) or 
poly(I:C)- (black bars) treated BM chimeras is graphed. Data are representative 
of 2 individual experiments with n of 2-3 mice per group.  
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expression on cells of the hematopoietic compartment mediates poly(I:C)-
induced priming of naïve CD8 T cells. 
2. B7 costimulation is required for poly(I:C)-induced priming of 
naïve CD8 T cells 
After identifying that self-MHC on hematopoietic cells is important, we 
wanted to identify the cell type that was mediating poly(I:C)-induced priming. We 
hypothesized that professional APCs were required for poly(I:C)-induced priming. 
Because expression of costimulatory molecules can distinguish APCs from other 
cell types that express class I MHC, I determined whether or not the CD40-
CD40L interaction was required for T cell priming. P14 cells were transferred into 
WT B6 hosts and mice either received an anti-CD40L blocking antibody (MR1) or 
did not receive the antibody treatment. After 1 day, mice were primed with 
poly(I:C) or control treated with HBSS for 1 day prior to splenocytes isolation and 
staining. The frequencies of CD44lo P14 cells that upregulate Eomes were 
similar between mice irrespective of blocking the CD40-CD40L interaction after 
poly(I:C) treatment (Figure 4.12A). In addition, similar frequencies of CD44lo 
P14 cells upregulated granzyme B after priming with poly(I:C), whether or not 
they were treated with MR1 blocking antibody (Figure 4.12B). Lastly, upon 
stimulation with cognate antigen, poly(I:C)-primed naïve P14 cells degranulated 
(Figure 4.12C), produced IFNγ (Figure 4.12D), and enhanced TNF (Figure 
4.12E) despite blocking the CD40-CD40L interaction. Together these results  
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Figure 4.12: Blocking CD40-CD40L does not affect poly(I:C)-induced naïve 
CD8 T cell acquisition of immediate effector function 
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Figure 4.12: Blocking CD40-CD40L does not affect poly(I:C)-induced naïve 
CD8 T cell acquisition of immediate effector function 
P14 CD8 T cell splenocytes were transferred into WT B6 mice, which either did 
or did not receive anti-CD40L blocking antibody (MR1). One day after treatment, 
mice were control treated (HBSS) or inoculated with poly(I:C), and spleens were 
harvested 1 day later. Splenocytes remained unstimulated ex vivo (A-B) or were 
stimulated ex vivo with GP33 for ~4-5 hours (C-E). Frequencies of donor CD44lo 
P14 cells from HBSS-treated (open bars) or poly(I:C)-treated (black bars) mice 
expressing Eomes (A), granzyme B (B), CD107a/b (C), IFNγ (D) or TNF (E) are 
depicted. Data are representative from 4 individual experiments with n of 3-4 
mice per group.   
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indicate that the costimulation between CD40 and CD40L is not required for 
naïve T cell priming.  
  Since naïve CD8 T cells require both TCR and costimulation in order to 
gain effector function and to avoid becoming anergic (99), I questioned whether 
the canonical signal 2 costimulation was required for naive CD8 T cell priming. 
To determine if B7-CD28 costimulation is required for poly(I:C)-induced T cell 
priming, WT congenic P14 cells were transferred into B7.1/B7.2 KO mice 
(referred to as B7 KO) or WT B6 mice. Mice were inoculated with HBSS or 
poly(I:C) and harvested 1 day later. Naïve P14 CD8 T cell upregulation of Eomes 
was variable from experiment to experiment. In one experiment (exp #1), P14 
cells from B7 KO showed no difference in Eomes upregulation compared to P14 
cells from WT host after poly(I:C) treatment. However, in other experiments (exp 
#2), poly(I:C)-treated P14 cells from B7 KO hosts had lower levels of Eomes 
compared to poly(I:C)-treated P14 cells from WT hosts (Figure 4.13A). CD44lo 
P14 cells primed in the B7 KO environment did not produce IFNγ like cells 
primed in the WT environment (Figure 4.13B). To confirm that lack of 
costimulation during the ex vivo stimulation was not the reason for reduced IFNγ 
production in poly(I:C)-primed cells from KO mice, B7-sufficient cells were added 
to the ex vivo stimulated cultures. The frequencies of CD44lo IFNγ+ P14 cells 
from WT or KO priming environments that either did not receive any additional 
cells during ICS (No cells), received HBSS-treated splenocytes, or received 
poly(I:C)-treated splenocytes during the ICS assay are shown in Figure 4.13C.  
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Figure 4.13: Poly(I:C) priming of naive CD8 T cells requires B7 
costimulation  
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Figure 4.13: Poly(I:C) priming of naive CD8 T cells requires B7 
costimulation  
Congenic P14 cells were transferred into WT B6 mice or B7 KO mice, which 
were inoculated with HBSS or poly(I:C). One day later, splenocytes were isolated 
and stained directly ex vivo (A) or stimulated with GP33 (B-C). Frequency of 
CD44lo P14 cells expressing Eomes (A) or IFNγ (B-C) is graphed. (C) 
Splenocytes were stimulated in the absence of extra cells, the presence of WT 
HBSS-pretreated splenocytes or WT poly(I:C)-pretreated splenocytes. Data are 
representative of 3 Experiments (A-B) with n of 3-4 Mice per group or an 
individual experiment with n of 3-4 mice per group (C).  
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The presence of B7-sufficient cells during ex vivo stimulation did not allow for 
P14 cells primed in the B7 KO host to immediately synthesize IFNγ. Thus, B7 
costimulation may play a minor role in Eomes upregulation, but it is required for 
IFNγ production from poly(I:C)-primed naïve CD8 T cells. Therefore, Eomes 
upregulation may be only part of the equation that allows naïve CD8 T cells to 
elicit immediate effector function.  
3. Poly(I:C)-induced priming of naïve CD8 T cells requires TAP  
Self-MHC was determined to be required for sensitization of T cells to 
exert rapid effector function (193). However, the specificity of the particular 
peptides presented was never addressed. I questioned whether any peptide 
could meditate poly(I:C)-induced priming or whether more specific peptides were 
required for this process. I studied two different KO strains, which limited the 
peptide repertoire that was presented. First, I made use of immunoproteasome 
KO mice (3 KO), in which the 3 catalytic subunits of the Immunoproteasome 
(LMP2, LMP7, and MECL-1) are knocked out (70). Therefore, any peptide that 
requires these specific catalytic subunits to be processed and presented will not 
be expressed. 3 KO mice have ~50% reduced MHC Class I expression on the 
cell surface and a different peptide repertoire compared to WT mice (70). If a 
specific peptide that is processed by the immunoproteasome was required for 
poly(I:C)-induced priming, CD8 T cells would not be primed in the 3 KO 
environment. To limit the peptide repertoire even further, TAP1/TAP2 KO (TAP 
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KO) mice were used. During MHC Class I presentation, TAP assists in peptide 
trafficking into the ER for loading onto MHC Class I complexes (204). Therefore, 
without TAP, only peptides that can be transported and loaded in the absence of 
TAP will be presented on the cell surface. Since the majority of MHC Class I 
peptides require TAP for presentation, this severely limits the repertoire of 
peptides presented and also limits the total amount of Class I on the cell surface.  
First, I determined if CD44lo P14 cells would upregulate the priming-
associated early activation markers and the transcription factors shown in 
Chapter IV, Section B. Representative histograms gated on CD44lo P14 cells 
from WT, 3 KO, and TAP KO mice treated with HBSS (shaded histograms) or 
poly(I:C) (open histograms) expressing CD69, Eomes, and IRF4 are depicted in 
Figure 4.14A.  The frequency of CD44lo P14 cells expressing these poly(I:C)-
induced markers are shown in Figures 4.14B-D, where poly(I:C)-pretreated cells 
are shown as black bars, and HBSS-treated cells are shown as open bars. 
CD44lo P14 cells primed in 3 KO hosts upregulated CD69, Eomes, and IRF4 to a 
similar extent as those primed in WT hosts. However, priming in TAP KO hosts 
resulted in impaired upregulation of CD69 (Figure 4.14B), Eomes (Figure 
4.14C), and IRF4 (Figure 4.14D) compared to P14 cells primed in the WT hosts 
(statistics comparing WT B6 poly(I:C) vs. TAP KO poly(I:C)).  
An ICS assay using GP33 peptide stimulation was performed to determine 
if poly(I:C)-primed CD44lo P14 cells could produce immediate effector function if 
primed in either the 3 KO or TAP KO environments. Representative flow plots  
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Figure 4.14: Poly(I:C)-induced early activation phenotype requires TAP 
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Figure 4.14: Poly(I:C)-induced early activation phenotype requires TAP 
Congenic P14 cells were transferred into WT B6, 3 KO, or TAP KO mice, which 
were inoculated with HBSS or poly(I:C). One day later, splenocytes were isolated 
and stained. (A) Representative histograms gated on CD44lo P14 cells are 
shown with MFI ± SD of poly(I:C) treated group. Significance comparing 
poly(I:C)-treated WT to poly(I:C)-treated TAP KO. Frequencies of CD44lo P14 
cells expressing CD69 (B), Eomes (C), and IRF4 (D), are graphed. Data are 
representative of 2-3 individual experiments with n of 2-4 mice per group.   
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gated on CD44lo P14 cells from each group are depicted in Figure 4.15A. 
Frequencies of CD44lo P14 cells producing IFNγ (Figure 4.15B) or TNF (Figure 
4.15C) after poly(I:C) treatment (black bars) in WT, 3 KO or TAP KO hosts are 
graphed. Naïve P14 cells inoculated with poly(I:C) from TAP KO hosts did not 
exhibit immediate effector functions, whereas poly(I:C)-pretreated naïve P14 
cells from WT or 3 KO hosts did. The frequency of CD44lo IFNγ+ T cells was 
significantly lower if from TAP KO hosts than if from WT hosts (Figure 4.15B). 
P14 cells from TAP KO hosts treated with poly(I:C) did exhibit enhanced 
production of TNF over HBSS controls from TAP KO hosts, but had slightly lower 
levels when compared to P14 cells treated with poly(I:C) from WT mice (Figure 
4.15C).  
 These results could be interpreted in a few different ways. TAP KO mice 
may not have enough Class I on the surface to prime naïve CD8 T cells, 
suggesting that the amount of self-MHC on the surface, not the specificity of the 
peptides, is the important factor. On the other hand, the specific peptides 
presented may not be those that are required for T cell priming to immediate 
effector function, suggesting that in order for naïve T cells to be primed, they 
need to see specific self-peptides, and the amount may not be as crucial.  
After identifying that P14 cells are not primed in B7 KO or TAP KO host 
mice, I wanted to quantify levels of self-MHC and costimulatory molecules after 
poly(I:C) priming. We hypothesized that professional APCs were mediating the 
priming of naïve T cells to become immediate effectors and chose to focus on   
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Figure 4.15: Poly(I:C) priming of CD8 T cells to immediate effector function 
requires TAP  
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Figure 4.15: Poly(I:C) priming of CD8 T cells to immediate effector function 
requires TAP  
Congenic P14 cells were transferred into WT B6, 3 KO, or TAP KO mice, which 
were inoculated with HBSS or poly(I:C). One day later, splenocytes were isolated 
and stimulated with GP33 ex vivo. (A) Representative flow plots gated on CD44lo 
P14 cells are shown. Frequencies of CD44lo P14 cells expressing IFNγ (B), and 
TNF (C) are graphed. Data are representative of 2-3 individual experiments with 
n of 2-4 mice per group.   
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DCs. I assessed expression levels of Class I (H2-Db) and Class II (I-Ab) 
expression and of the costimulatory molecules CD80 and CD86 on DCs from WT 
B6, IFNAR KO and TAP KO host mice after HBSS or poly(I:C) treatment (Figure 
4.16). Although a number of different subsets of DCs have been described, each 
with their own unique properties, for simplification data from heterogeneous bulk 
DCs (identified as CD3e- and CD11c+) are shown.  
It has been shown by others that type 1 IFN can upregulate both MHC 
Class I and Class II expression, and indeed this is also seen in our poly(I:C)-
priming model (32, 74, 205). DCs from WT B6 mice upregulate H2-Db and I-Ab 
expression after poly(I:C) treatment. The expression level of MHC Class II I-Ab 
was similarly found to increase after poly(I:C) treatment on DCs from the TAP KO 
hosts (Figure 4.16B). However, the same cannot be said for Class I H2-Db 
expression. Although there is a slight upregulation of H2-Db on DCs from IFNAR 
KO mice, levels were still significantly lower than those from WT DCs. As 
expected, H2-Db expression levels on DCs from TAP KO mice were extremely 
low, and they did not increase after poly(I:C) treatment (Figure 4.16A). In terms 
of upregulating costimulatory molecules, DCs from each host - WT, IFNAR KO, 
and TAP KO - upregulated B7.1 (CD80) after 1 day of in vivo poly(I:C) treatment 
(Figure 4.16C). However, B7.2 (CD86) expression (similar to what was found on 
CD44lo CD8 T cells from IFNAR KO hosts) did not show poly(I:C)-induced 
upregulation in the IFNAR KO host DCs, as opposed to DCs from WT and TAP 
KO mice (Figure 4.16D). It should be noted that various subsets of DCs followed   
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Figure 4.16: Poly(I:C)-induced MHC Class I and costimulatory CD86 
upregulation are mediated by type 1 IFN 
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Figure 4.16: Poly(I:C)-induced MHC Class I and costimulatory CD86 
upregulation are mediated by type 1 IFN 
Phenotype of CD11c+ DCs from WT B6, IFNAR KO, and TAP KO hosts was 
assessed after HBSS or poly(I:C) treatment for 1 day. Gated on CD3e-, CD11c+ 
DCs, the MFI of H2-Db (A), I-Ab (B), CD80 (C), and CD86 (D) is graphed. 
Individual experiment with n of 3-4 mice per group. 
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similar changes in MHC and costimulatory molecule expression, as shown in 
Figure 4.16. That being said, some DC subsets showed stronger requirements 
for IFN signaling with regard to upregulation of I-Ab and CD80 (data not shown). 
In summary, type 1 IFN is important for the upregulation of MHC Class I and 
CD86, but is not as important for Class II and CD80 after poly(I:C) treatment in 
DCs. TAP KO DCs do not show defects in upregulating costimulatory molecules 
or Class II MHC after poly(I:C) treatment, but, as expected, had extremely low 
levels of MHC Class I.  
4. Summary 
We wanted to look further into the mechanism that mediates naïve T cell 
priming. BM chimeras where self-MHC was absent on hematopoietic cells did not 
induce the early activation marker CD69 or TF Eomes associated with poly(I:C)-
induced priming of naïve CD8 T cells (Figure 4.11). These data do not directly 
identify a role for professional APCs but are consistent with the idea that 
hematopoietic cells are important for poly(I:C)-induced priming. 
P14 cells primed in B7 KO hosts did not exhibit immediate effector 
function (i.e. IFNγ production) upon stimulation with cognate ligand ex vivo 
(Figure 4.13) indicating that B7-CD28 costimulatory effects are required for 
poly(I:C)-induced priming of naïve T cells. A deficiency in costimulation during 
the ICS could not account for the absence of IFNγ production in poly(I:C)-
pretreated P14 cells from B7 KO hosts, because when B7-sufficient cells were 
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added to the cultures, IFNγ production was still lacking. Costimulatory molecules, 
including B7, are found on APCs, supporting the hypothesis that professional 
APCs are mediating naïve T cell priming.  
Lastly, studies depicted here identify the requirement of either TAP-
dependent peptides to be presented, or a certain amount of self-MHC on the 
sensitizing cells to mediate poly(I:C)-induced T cell priming (Figures 4.14-4.15). 
Our working hypothesis is that poly(I:C) induces upregulation of Class I MHC and 
costimulatory molecules on APCs, which can interact with naïve CD8 T cells. The 
reduced Class I on the surface of DCs in TAP KO host mice contributes to the 
idea that both MHC and costimulatory molecules are necessary for priming of 
naïve CD8 T cells to immediate effectors (Figure 4.16). DCs did not upregulate 
CD86 from IFNAR KO host mice after poly(I:C) inoculation and showed a 
reduced ability to prime naïve T cells. Combined, data presented here suggest 
that both MHC Class I and costimulation contribute to poly(I:C)-induced priming.    
D. Poly(I:C)-primed naïve T cells have a reduced threshold required for 
effector function production  
1. Poly(I:C)-primed naïve CD8 T cells produce immediate effector 
functions in response to lower concentrations of high affinity 
ligand 
I questioned whether poly(I:C)-primed naïve CD8 T cells only responded 
to high-affinity, high-density antigen, or if they were able to respond to reduced 
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affinities or densities. Congenic P14 cells were transferred into WT B6 mice, 
which were HBSS- or poly(I:C)-treated for 1 day. Splenocytes were harvested 
and stimulated ex vivo with different concentrations of GP33 peptide and 
assayed for effector function. Due to the fact that CD69 is one of the first 
activation markers to be induced in activated T cells, I determined the frequency 
of CD44lo P14 cells that expressed CD69 after stimulation with various 
concentrations of GP33 (Figure 4.17A). The majority of poly(I:C)-pretreated P14 
cells already expressed CD69, but only a small proportion of the HBSS-treated 
P14 cells upregulated CD69, even when stimulated with the highest 
concentrations of cognate ligand. Because T cell receptor signaling is essential 
for CD8 T cell activation, IRF4, a TF known to be induced downstream of T cell 
receptor signaling was measured (Figure 4.17B). Poly(I:C)-pretreated naïve P14 
cells (black bars) showed higher proportions of IRF4+ T cells in the absence of 
exogenous ex vivo stimulation, compared to HBSS-treated P14 cells (open bars) 
(NO stim). Upon ex vivo stimulation with the lowest concentrations of cognate 
ligand tested, poly(I:C)-primed CD44lo P14 cells upregulate significantly more 
IRF4 than their control treated counterparts (16 nM and 64 nM). IRF4 expression 
has been associated with many aspects of CD8 T cell effector function. These 
results show that poly(I:C)-pretreated naïve CD8 T cells upregulate IRF4 in 
response to a lower density antigen compared to control-treated CD8 T cells, and 
this increased IRF4 expression may play a role in the acquisition of immediate 
effector function.   
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Figure 4.17: CD44lo P14 CD8 T cells primed with poly(I:C) produce 
immediate effector functions in response to lower concentrations of 
cognate ligand 
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Figure 4.17: CD44lo P14 CD8 T cells primed with poly(I:C) produce 
immediate effector functions in response to lower concentrations of 
cognate ligand 
P14 splenocytes were transferred into B6 mice, which were inoculated with 
HBSS (open bars) or poly(I:C) (black bars). Splenocytes were harvested 1 day 
later and stimulated ex vivo with different concentrations of GP33 peptide. The 
frequencies of CD44lo P14 cells expressing CD69 (A), IRF4 (B), granzyme B 
(C), IFNγ (D), or TNF (E) are graphed. Data are representative of 2 individual 
experiments with n of 4-5 mice per group.   
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To assess effector function, granzyme B expression levels were 
determined in poly(I:C)- and HBSS-pretreated naïve P14 cells after ex vivo 
stimulation with different concentrations of GP33 (Figure 4.17C). The frequency 
of poly(I:C)-primed CD44lo P14 cells expressing granzyme B was greatest 
without any ex vivo stimulation (NO), and upon increasing concentrations of 
GP33 stimulation, the proportion of granzyme B+ P14 cells decreased. Based on 
work shown earlier (Figure 4.7), in which primed CD8 T cells were shown to 
degranulate in response to cognate antigen, these data suggest that granzyme B 
is secreted upon stimulation with cognate ligand. It should be noted that at low 
concentrations, such as 64 nM (compared to 1 μM of stimulation), significant 
changes in granzyme B expression were seen in the poly(I:C)-primed groups, 
suggesting release of granzyme B with lower densities of high-affinity cognate 
ligands. In contrast, control-treated naïve P14 cells (HBSS-open bars) did not 
express granzyme B. The frequencies of IFNγ producing (Figure 4.17D) and 
TNF producing (Figure 4.17E) CD44lo P14 cells stimulated with varying 
concentrations of GP33 peptide were also determined. As shown previously, 
poly(I:C)-primed naïve P14 cells can produce IFNγ and enhanced TNF in 
response to high-affinity, high-density antigen (1000 nM). Moreover, primed 
CD44lo P14 cells were also found to produce these effector cytokines in 
response to lower concentrations of ligands (250 nM and 64 nM) to a significant 
level over HBSS-treated controls. At the lowest concentration tested (16 nM), a 
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small, but significant difference was observed in IFNγ and TNF production, when 
comparing poly(I:C)-primed and unprimed counterparts.  
2. CD8 T cells primed with poly(I:C) produce effector functions in 
response to lower affinity ligands  
After showing that poly(I:C)-primed naïve T cells could produce immediate 
effector functions in response to low-density cognate antigen, I questioned 
whether they could also produce immediate effector function in response to lower 
affinity antigens. P14 transgenic CD8 T cells were used in a similar poly(I:C)-
priming experimental design as used previously, but peptides used for ICS 
included an APL (F6L) which reduces the affinity of the TCR for the pMHC 
complex ~5 fold compared to the high affinity GP33 pMHC complex. 
Representative flow plots gated on CD44lo P14 cells from HBSS- or poly(I:C)-
treated mice stimulated ex vivo without peptide, APL (F6L), or cognate ligand 
(GP33) are shown in Figure 4.18A. Poly(I:C)-primed naïve P14 cells produced 
TNF (quantified in Figure 4.18B) and IFNγ (quantified in Figure 4.18C) in 
response to cognate antigen stimulation. Additionally, upon stimulation with the 
lower affinity APL, F6L, poly(I:C)-primed naïve P14 cells also produced 
significantly more IFNγ and TNF than HBSS treated naïve counterparts.  
To identify if increased response to APLs occurs in other systems, a 
similar experimental design was performed with the OT-I transgenic T cells. 
Congenic OT-I cells were transferred into B6 mice that were inoculated with   
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Figure 4.18: Poly(I:C)-primed naïve P14 cells produce IFNγ and TNF in 
response to low-affinity altered peptide ligand 
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Figure 4.18: Poly(I:C)-primed naïve P14 cells produce IFNγ and TNF in 
response to low-affinity altered peptide ligand 
Congenic P14 cells were transferred into B6 hosts. Mice were treated with HBSS 
or poly(I:C) for 1 day, and splenocytes were stimulated with high-affinity cognate 
ligand (GP33) or altered peptide ligand (F6L). A) Representative flow plots gated 
on donor P14 cells expressing IFNγ and TNF are shown. The frequencies of 
CD44lo P14 cells producing TNF (B) or IFNγ (C) are graphed. Data from 
experiment with n of 4 mice per group.   
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HBSS or poly(I:C) for 1 day. Cells were stimulated with a variety of APLs for 
which OT-I T cells have a varying degree of affinity (180). The order of peptide 
affinity is as follows from highest affinity to lowest affinity: OVA>Y3>T4>V4>G4. 
Representative flow plots gated on CD44lo OT-I T cells from HBSS- or poly(I:C)-
treated mice, stimulated ex vivo with different peptides are shown in Figure 
4.19A. The frequency of CD44lo TNF+ OT-I (Figure 4.19B), IFNγ+ OT-I (Figure 
4.19C) and granzyme B+ OT-I (Figure 4.19D) from HBSS-treated (open bars) or 
poly(I:C)-treated (black bars) mice stimulated ex vivo with different peptides are 
graphed. Similar to results shown in Figure 4.18 with naïve P14 T cells and the 
F6L APL, naïve OT-I CD8 T cells also produced multiple effector functions in 
response to APL stimulation to a significant level over control-treated cells 
stimulated ex vivo with the same APL. Poly(I:C)-priming induced more naïve OT-I 
cells to produce TNF to all of the APLs tested, including G4 which has a > 200 
fold reduction in TCR affinity for the pMHC compared to OVA (180), when 
compared to HBSS-treated naïve OT-I T cells (Figure 4.19B). Not only was there 
an increased proportion of poly(I:C)-pretreated naïve OT-I T cells that produced 
TNF in response to APLs, but of the cells that produced TNF, poly(I:C)-
pretreated OT-I T cells had higher MFIs than HBSS-treated OT-I cells, indicating 
they produced more TNF on a per cell basis (data not shown). This also holds 
true for IFNγ production, where an increased frequency of naïve OT-I T cells 
produce IFNγ to all of the APLs tested, including the lowest affinity, albeit to a 
very low level, if primed with poly(I:C), compared to control OT-1 T cells (Figure   
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Figure 4.19: Poly(I:C)-primed CD44lo OT-I cells produce effector functions 
in response to low-affinity altered peptide ligands 
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Figure 4.19: Poly(I:C)-primed CD44lo OT-I cells produce effector functions 
in response to low-affinity altered peptide ligands 
Congenic OT-I splenocytes were transferred into B6 hosts, which were 
inoculated with HBSS or poly(I:C). Splenocytes were isolated 1 day later and 
stimulated without peptide (NO), with high affinity cognate ligand (OVA), or an 
altered peptide ligand (Y3, T4, V4, or G4). A) Representative flow plots gated on 
donor CD44lo OT-1 cells expressing IFNγ and TNF are shown. The frequencies 
of CD44lo OT-I cells producing TNF (B), IFNγ (C) or granzyme B (D) are 
graphed. Data are representative of 2 independent experiments with n of 3-5 
mice per group.  
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4.19C). Moreover, of the cells that produced IFNγ in response to peptide 
stimulation with the lowest affinity APL, G4, poly(I:C)-pretreated naïve OT-1 T 
cells showed increased IFNγ MFI than their HBSS-treated counterparts 
(1810±231 vs. 615±79, p<0.0001), indicating more IFNγ production on a per cell 
basis.  
The loss of granzyme B staining in the poly(I:C)-pretreated CD44lo OT-I T 
cells after APL stimulation, as compared to unstimulated counterparts, indicates 
that granzyme B is secreted and/or released in response to even the lowest 
affinity APL tested here (Figure 4.19D). Together, these data demonstrate that 
priming with poly(I:C) enables naïve T cells to produce immediate effector 
functions, even in response to lower affinity ligands. Thus, the poly(I:C)-primed 
naïve CD8 T cells appear to have a reduced threshold for production of cytokines 
and release of granzyme B compared to naive T cells that are not primed.  
3. Poly(I:C)-primed naïve CD8 T cells specifically lyse target cells 
The process of trogocytosis can be a surrogate for functional activation, in 
terms of cytolytic effector function. CD8 T cells engaging in trogocytosis have 
been found to be more active and may have increased cytolytic capability (196, 
197). To determine if trogocytosis is similar between primed T cells and control T 
cells, a TRAP assay using fluorescently-labeled RMA peptide-pulsed targets was 
performed. P14 cells were transferred into B6 recipients that were inoculated with 
HBSS or poly(I:C) for 1 day prior to harvesting spleens. Single cell suspensions 
236 
 
were prepared, and P14 effectors were incubated with either: 1) No target cells, 
2) K3L-pulsed RMA cells, or 3) GP33-pulsed RMA cells. Target cells were 
labeled with a fluorescent lipid that can be detected on effector cells if 
trogocytosis has occurred. Poly(I:C)-primed CD44lo P14 cells (black bars) 
incorporated more of the fluorescent dye (Figure 4.20A) compared to control-
treated P14 cells (open bars) during incubation with GP33-pulsed target cells. 
Although the difference is small, it is statistically significant. It should be noted 
that there is a difference between dye incorporation of poly(I:C)-treated P14 cells 
when co-incubated with the irrelevant peptide K3L vs. the specific peptide GP33, 
demonstrating the specificity of the assay.  
I questioned whether during this short 1 hour incubation with GP33 target 
cells, if primed cells could also downregulate CD62L. Indeed, there were 
increased frequencies of CD44lo CD62Llo P14 cells from poly(I:C)-inoculated 
host mice compared to P14 cells from control-treated host mice when incubated 
with GP33-pulsed target cells for only 1 hour (Figure 4.20B). This 
downregulation of CD62L is specific, as there is not a significant difference if we 
examine P14 cells when incubated with K3L-pulsed targets.  
The increase in trogocytosis and release of granzyme B in poly(I:C)-
primed naïve T cells lead us to question whether or not naïve CD8 T cells primed 
with poly(I:C) could exert cytolytic effector function. The current study utilizes the 
in vivo cytotoxic assay to determine if poly(I:C)-pretreated P14 cells could 
specifically lyse target cells. Congenic P14 cells were transferred into B6 hosts   
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Figure 4.20: Increased trogocytosis of poly(I:C)-primed P14 cells  
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Figure 4.20: Increased trogocytosis of poly(I:C)-primed P14 cells  
A TRAP assay was performed using HBSS- or poly(I:C)-pretreated P14 CD8 T 
cells as effectors and RMA cells pulsed with peptides as targets. Effectors were 
developed by poly(I:C) or HBSS treating B6 mice that had previously received 
congenic P14 cells. One day after inoculation, splenocytes containing the donor 
P14 CD8 T cells were isolated and used as effectors. Target cells were RMA 
cells that were pulsed with an irrelevant peptide (K3L) or pulsed with the specific 
peptide (GP33). Target cells were labeled with fluorescent lipid molecule SP-
DiIC18(3), which can be detected when transferred to a different cell through 
trogocytosis. Target cells were in excess and were co-incubated with effectors for 
1 hour, stained with surface antibodies and ran on a flow cytometer. Frequency 
of CD44lo P14 cells incorporating the fluorescent lipid SP-DiIC18(3) from HBSS- 
(open bars) or poly(I:C)-treated (black bars) mice incubated with separate targets 
are graphed in (A). Frequency of CD44lo P14 cells downregulating CD62L from 
each group is graphed in (B). Data are representative of 3 independent 
experiments with n of 3-5 mice per group.  
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that were inoculated with HBSS or poly(I:C). One day later, mice received a 
mixture of splenocytes that were pulsed without peptide, with K3L peptide, or 
with GP33 peptide. All splenocytes were labeled with CellTrace Far Red DDAO 
to distinguish donor from hosts, and each peptide-pulsed target was labeled with 
a different concentration of CellTrace Violet. After a ~20 hour in vivo incubation, 
spleens were harvested and stained, and specific lysis was determined.  
I wanted to identify if the poly(I:C)-treated donor P14 cells still maintained 
a naïve phenotype after the 20 hour in vivo cytotoxicity assay. The phenotype of 
the donor P14 cells is shown in Figure 4.21A, where representative flow plots 
are gated on donor P14 cells. The majority of the P14 cells remained CD44lo, 
showing they are naïve in phenotype. Poly(I:C)-pretreated CD44lo P14 cells 
showed significant upregulation of CD69 as compared to their HBSS-treated 
counterparts. In addition, CD44lo P14 cells downregulated CD62L if pre-exposed 
to poly(I:C) to a greater extent over controls.  
Representative histograms gated on donor CellTrace Far Red DDAO cells 
are shown in Figure 4.21B. Control-treated mice did not receive donor P14 cells, 
nor did they receive poly(I:C). The HBSS and poly(I:C) groups refer to the 
inoculation received after donor P14 cells were transferred. Three separate 
populations are depicted, where the lowest concentrations of CellTrace Violet are 
splenocytes which were not pulsed with any peptide (red), the middle 
concentration represents splenocytes pulsed with the irrelevant K3L peptide 
(green), and the highest concentration of CellTrace Violet represents splenocytes   
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Figure 4.21: Primed P14 cells specifically lyse GP33 peptide pulsed target 
cells in vivo 
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Figure 4.21: Primed P14 cells specifically lyse GP33 peptide pulsed target 
cells in vivo 
Congenic P14 cells were transferred into WT B6 mice, which were inoculated 
with HBSS or poly(I:C). One day later, mice received splenocytes which were 
pulsed with either no peptide, K3L, or GP33, each labeled with DDAO far red and 
a different concentration of CellTrace Violet. Approximately 1 day later, spleens 
were harvested, and phenotype of donor P14 cells and frequency of peptide-
pulsed target cells were determined. (A) Representative flow plots gated on 
donor P14 cells expressing CD69 or CD62L from HBSS- and poly(I:C)-treated 
mice are shown. (B) Representative histograms gated on donor DDAO Far red+ 
splenocytes with the lowest concentration of CellTrace Violet representing no 
peptide-pulsed (Red), middle concentration, K3L peptide (Green), or highest 
concentration, GP33 peptide (Blue). C) Percent specific lysis was calculated for 
K3L- and GP33- specific cells. Correlation between % specific lysis and 
frequency of P14 cells expressing CD69 (D) or CD62L (E) is graphed. Data are 
representative of 2 individual experiments with n of 4-5 mice per group.  
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pulsed with GP33 peptide (blue). Both the unlabeled control and the nonspecific 
peptide targets were used to ensure there were no off target effects of poly(I:C) 
treatment, and that the donor P14 populations are indeed mediating the effect. 
The control and HBSS histogram profiles look very similar to one another, 
showing comparable frequencies of each of the donor populations between the 
two groups. However, the poly(I:C)-treated group shows reduced frequencies of 
GP33 peptide-pulsed targets, and an increase in both the unlabeled and K3L-
labeled group when compared to both of the controls. The percent specific lysis 
was calculated for both the K3L-pulsed and the GP33-pulsed targets using the 
un-pulsed peptide as the control by using the following equation:  
% specific lysis = 100 - ((Experimental/Control)/Control x 100)   
K3L-pulsed target cells were not preferentially lysed in either the HBSS- or 
poly(I:C)-treated hosts (Figure 4.21C). However, GP33-pulsed splenocytes were 
found to be specifically lysed in poly(I:C)-treated (black bars) mice to a significant 
extent over HBSS-treated mice (open bars). When we plot the % specific lysis of 
GP33- (blue) or K3L- (green) pulsed targets vs. CD69 or CD62L expression on 
P14 cells, we find that only GP33-pulsed targets correlate with P14 cell 
phenotype. Figure 4.21D shows a positive correlation between P14 CD69 
upregulation and % GP33 specific lysis, such that as the frequency of CD69+ 
P14 cells increases, so does the % GP33-specific lysis. On the other hand, there 
is a negative correlation with CD62L expression, where the higher the CD62L 
expression, the lower the GP33-specific lysis is (Figure 4.21E). There is no 
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correlation between P14 phenotype and % K3L-specific lysis, indicating 
specificity of the P14 cells for GP33-pulsed targets. 
 Immediate effector function exhibited by poly(I:C)-primed naïve CD8 T 
cells was not associated with any cell division during this time period (previously 
shown Figure 4.10). Because P14 cells persisted in the donor hosts during the in 
vivo cytotoxicity assay for such a long period of time (Figure 4.21), I questioned 
whether they were dividing during this time. Congenic P14 cells were adoptively 
transferred into WT host mice that were inoculated with HBSS or poly(I:C) for 1 
day. A similar experimental design as the in vivo cytotoxicity assay was 
performed, but instead of mice receiving a combination of peptide-pulsed target 
cells, they only received one target population. Representative flow plots gated 
on donor P14 cells are shown in Figure 4.22A, and the frequencies of CD44lo 
Ki67+ P14 cells are graphed in Figure 4.22B. P14 cells from HBSS-treated mice 
that received un-pulsed splenocytes or the nonspecific K3L-pulsed splenocytes 
did not induce Ki67 expression. Upon receiving GP33-pulsed splenocytes, P14 
cells from HBSS-treated mice showed upregulation of the proliferation marker 
Ki67, indicating they were no longer in a G0 resting state. Interestingly, P14 cells 
from poly(I:C)-treated mice that received un-pulsed or the nonspecific K3L-
pulsed splenocytes showed significantly higher frequencies of Ki67+ cells 
compared to their control-treated counterparts. Moreover, poly(I:C)-pretreated 
P14 cells showed increased Ki67 staining over controls if they received the 
GP33-specific peptide-pulsed targets.  
244 
 
Figure 4.22: Poly(I:C)-primed P14 T cells increase effector transcription 
factors over controls in response to cognate antigen stimulation 
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Figure 4.22: Poly(I:C)-primed P14 T cells increase effector transcription 
factors over controls in response to cognate antigen stimulation 
Congenic P14 cells were transferred into WT B6 hosts, which were inoculated 
with HBSS or poly(I:C). One day after inoculation, mice received splenocytes that 
were pulsed with K3L peptide, GP33 peptide, or no peptide. One day after 
transfer, spleens were harvested and stained. Representative flow plots gated on 
donor P14 cells expressing the proliferation marker Ki67 (A), and frequencies of 
P14 cells expressing Ki67 (B) are shown. P14 cells expressing transcription 
factors IRF4 (C), BATF (D), and Eomes (E) are graphed. Frequency of P14 cells 
expressing granzyme B is shown in (F). Experiment with 2-5 mice per group.  
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Results from this experiment were somewhat surprising due to the fact 
that induction of cell cycle in CD8 T cells prior to any antigen stimulation is 
indicated. Results from Figure 4.10C show no upregulation of Ki67 expression 
after 1 day of poly(I:C) treatment, but Figure 4.22B shows Ki67+ cells at ~48 
hours post-poly(I:C) inoculation. Therefore, Ki67 is being induced between 24-48 
hours post-treatment in the absence of cognate antigen.  
To determine if the longer exposure to cognate antigen stimulation had an 
effect on poly(I:C)-pretreated P14 cells, effector-associated TFs were quantified 
during this experiment. As shown in multiple figures previously in this chapter, 
CD44lo P14 cells upregulate IRF4 after poly(I:C) treatment. In the present 
experiment, IRF4 was similarly upregulated in naive P14 cells from poly(I:C)-
pretreated mice that received any of the pulsed target populations (Figure 
4.22C). Moreover, higher frequencies of CD44lo P14 cells upregulated IRF4 after 
poly(I:C) treatment than after HBSS treatment, regardless of the specificity of the 
peptide-pulsed splenocytes they received. However, it should be noted that 
CD44lo P14 cells from HBSS-treated mice induced IRF4 if they received GP33-
pulsed splenocytes but not the un-pulsed or K3L-pulsed targets. These data 
indicate that IRF4 upregulation in HBSS-treated P14 cells was specific.  
The levels of two additional TFs, BATF and Eomes, were then 
determined. BATF is a transcription factor known to associate with IRF4 and is 
important in effector CD8 T cells (158). The frequency of CD44lo BATF+ P14 
cells are graphed in Figure 4.22D, and CD44lo Eomes+ P14 cells are graphed in 
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Figure 4.22E. Both BATF and Eomes showed similar patterns and changes as 
IRF4. Poly(I:C)-pretreated mice had increased proportions of CD44lo BATF+ P14 
cells and CD44lo Eomes+ P14 cells compared to HBSS-treated mice, regardless 
of the splenocytes that were transferred. Furthermore, the frequency of HBSS-
treated CD44lo P14 cells upregulating BATF and Eomes increased after 
receiving GP33-pulsed targets, but the poly(I:C)-treated CD44lo P14 cells 
showed more BATF and Eomes than controls. Together, these data reveal that 
poly(I:C) pretreatment induces upregulation of TFs associated with CD8 T cell 
effector function prior to cognate antigen exposure, and upon antigen exposure, 
they will further increase levels of these TFs to a significant extent over controls.  
Because acquiring effector-associated TFs does not necessarily 
correspond to effector function, expression of granzyme B was also determined 
in the present study. There were increased proportions of CD44lo granzyme B+ 
P14 cells in poly(I:C)-pretreated mice compared to HBSS-treated mice (Figure 
4.22F), and these were further increased if recipients received GP33-pulsed 
splenocytes. It should be noted that P14 cells did not upregulate granzyme B 
from any of the HBSS-treated groups, even those receiving GP33-pulsed target 
cells. This is consistent with the literature that shows that costimulation and 
signal 3 cytokines are important for granzyme B expression (170).  
4. Summary 
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These results demonstrate that pretreatment with poly(I:C) reduces the 
requirements or threshold required for primed naïve CD8 T cells to produce 
effector functions compared to control T cells. Not only were poly(I:C)-pretreated 
naïve T cells able to produce immediate effector function to high-affinity high-
density antigen, but they also produced these effector functions in response to 
reduced concentrations of cognate ligand (Figure 4.17) Moreover, poly(I:C)-
primed naïve T cells were able to respond to a number APLs and were able to 
produce immediate effector functions, when conventional naïve T cells were not 
(Figure 4.18-4.19). 
Poly(I:C)-primed naïve CD8 T cells had increased levels of effector-
associated TFs including IRF4, BATF, and Eomes and could induce further 
expression upon stimulation with high-affinity ligand in vivo. Poly(I:C)-primed 
CD44lo P14 cells upregulated granzyme B levels after in vivo stimulation with 
GP33-pulsed splenocytes (Figure 4.22). This may have enabled them to exhibit 
immediate cytolytic effector function, because in addition to being able to 
produce multiple cytokines in response to antigen stimulation, poly(I:C)-primed 
naïve P14 cells were also found to specifically lyse target cells (Figure 4.21). 
This is compared to conventional naïve P14 CD8 T cells, which did not 
upregulate granzyme B and showed no cytolytic ability. 
Primed naïve CD8 T cells acquired immediate effector function without cell 
division. However, during a prolonged exposure to cognate antigen in vivo, both 
HBSS and poly(I:C)-treated P14 cells upregulated the proliferation marker Ki67 
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(Figure 4.22). Pretreatment with poly(I:C) showed increased frequencies of 
Ki67+ P14 cells compared to controls, but the upregulation of Ki67 does not 
necessarily indicate that the cells have divided, as it is a marker that is expressed 
on all non-resting cells. Therefore, we do not know in which stage of the cell 
cycle primed and non-primed cells are when stained positive for Ki67, nor can we 
discern the potential fate of Ki67-expressing cells.  
E. Conclusions 
This chapter describes how out-of-sequence priming differs from 
conventional naïve T cell priming. Upon activation, acquisition of naïve T cell 
effector function usually requires cell division (141). In some instances, however, 
naïve T cells will acquire effector functions. For example, naïve T cells were 
found to produce TNF in response to anti-CD3 stimulation and/or cognate 
antigen stimulation in vivo and in vitro (161, 162). However, production of other 
cytokines and cytolytic effector function requires additional signals. Using 
adoptive transfers, I discovered that naive T cells acquired an early 
intermediately activated phenotype after being exposed to a poly(I:C)-induced 
inflammatory environment for as little as 12 hours (Figures 4.1-4.3). This 
phenotype was associated with upregulation of the activation markers CD69 and 
CD86, as well as downregulation of the IL-7 and type 1 IFN receptors. Poly(I:C)-
primed naïve T cells also upregulated effector-associated transcription factors 
including IRF4 and Eomes (Figures 4.4-4.6).  
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Primed naïve CD8 T cells have a reduced threshold required for 
production of multiple effector functions compared to conventional naïve T cells. 
Compared to control naïve cells, poly(I:C)-primed CD8 T cells responded to 
lower density cognate antigen, and produced IFNγ and TNF and released 
granzyme B (Figure 4.17). In addition, primed CD44lo CD8 T cells responded to 
a number of different APLs, of which the TCR has a lower affinity for compared to 
the higher affinity cognate ligand (Figure 4.18-4.19). Naïve P14 cells primed with 
poly(I:C) also gained cytolytic capability, as they specifically lysed GP33-pulsed 
target cells in an in vivo cytotoxicity assay (Figure 4.20-4.21). These immediate 
effector functions produced by poly(I:C)-primed naïve T cells are distinct from 
conventional naïve T cells, which do not exert these functions in response to the 
same stimuli. Therefore, primed T cells behaved more similarly to memory CD8 T 
cells rather than naïve T cells upon antigen encounter.  
It is postulated that type 1 IFN acts on the APC to upregulate self-MHC 
and costimulatory molecules and, through TCR stimulation, will induce an early 
activated phenotype of naïve CD8 T cells. BM chimeras made using WT or H2-
Db KO BM suggested that self-MHC on hematopoietic cells were required to 
mediate priming of naïve T cells (Figure 4.11). To support the hypothesis that 
professional APCs mediated these effects, B7 costimulation was found to be 
important for T cell acquisition of immediate effector function (Figure 4.13). The 
specificity of the peptides and/or amount of Class I being expressed may be 
important as well (Figure 4.14-4.15). T cells are not primed in TAP KO hosts, 
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which exhibit very low Class I but, upregulated costimulatory molecules, and T 
cells are not primed as efficiently in IFNAR KO hosts (compared to WT hosts), 
which show relatively high levels of Class I, but reduced costimulatory molecule 
expression.  
 A model is depicted in Figure 4.23. Taken together, our working 
hypothesis is that poly(I:C)-induced IFN causes APCs to upregulate both self-
MHC and costimulatory molecules, including B7. The specific of the amount of 
Class I or specific peptide(s) on the surface may play an important role. 
Nevertheless, Class I MHC and costimulatory molecules will trigger TCR 
stimulation and induce an early partially activated phenotype coupled with an 
increase in effector-associated TFs. These T cells are now primed and ready to 
go, such that upon stimulation even with low-density or low-affinity ligands, due 
to their reduced threshold for induction of effector function, the T cells will 
produce multiple cytokines, degranulate and exert cytotoxic effector function. 
This suggests that during an acute infection, T cells that are primed in an out-of-
sequence manner may be able to elicit immediate effector functions and 
contribute to controlling initial pathogen load prior to clonal expansion.  
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Figure 4.23: Model: Interferon primes naïve T cells to exhibit immediate 
effector function upon antigen stimulation  
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Figure 4.23: Model: Interferon primes naïve T cells to exhibit immediate 
effector function upon antigen stimulation  
  
Type 1 IFN acts on APCs to upregulate Class I MHC and costimulatory 
molecules. Naïve T cells exposed to self-MHC, costimulation, and IFN adopt an 
early activated phenotype associated with the upregulation of CD69, granzyme 
B, Eomes and IRF4. These T cells are armed with the ability to elicit immediate 
effector functions in response to lower affinities and densities of cognate antigen 
prior to cell division. 
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CHAPTER V: Discussion 
A. Dichotomy of out-of-sequence signaling effects 
Studies described in this thesis highlight the growing complexity of CD8 T 
cell activation. Not only does the presence or absence of signals 1, 2 and 3 
contribute to T cell activation, but the timing of these signals also proves to be of 
great importance. The findings presented here may seem somewhat 
contradictory, because in one situation we find that naïve T cells that are pre-
exposed to inflammatory environments gain the ability to immediately respond to 
antigen and produce multiple effector functions. However, in another situation the 
pre-exposure of naïve T cells to IFN caused reduced CD8 T cell expansion, 
differentiation and development of effector function. How can the same out-of-
sequence exposure of signal 3 cytokines cause such different outcomes 
concerning CD8 T cell activation? The timing at which CD8 T cell activation was 
assessed can explain the contradictory results. The ability of naïve T cells to 
produce immediate effector function, if pre-exposed to IFN-induced 
environments, was assessed within a few hours of cognate antigen stimulation, 
whereas suppression of CD8 T cell responses was investigated several days 
after initial exposure to antigen. 
During an acute infection, not all T cells will see antigen, costimulation and 
inflammatory cytokines in the same order. CD8 T cells that come into play later in 
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infection, so called latecomer T cells, will have been exposed to inflammatory 
environments prior to antigen. Therefore, identifying how latecomer T cells 
respond to antigen is of great importance. A model depicting conventional T cell 
activation, expansion and differentiation (blue), vs. out-of-sequence activation, 
expansion and differentiation (green) is depicted in Figure 5.1. 
Under circumstances where naïve T cells encounter antigen, costimulation 
and signal 3 cytokines in the conventional order, T cell acquisition of effector 
function requires cell division (141, 161, 162). Conventionally-primed naïve CD8 
T cells will efficiently clonally expand and differentiate into a heterogeneous 
population of effectors that have the capacity to elicit multiple effector functions, 
including production of cytokines and cytotoxic capability (96). After antigen is 
cleared, the majority of effector cells die, but a subset of the effector population 
survives to form memory cells, which have the ability to respond rapidly upon 
encountering the same pathogen. We show here that out-of-sequence-primed T 
cells, such as latecomer T cells, adopt an early-activated phenotype associated 
with the ability to elicit effector functions immediately upon stimulation with 
cognate ligand, prior to cell division (Chapter 4). As described in Chapter 3, out-
of-sequence CD8 T cells show impairment in clonal expansion and defects in 
effector cell differentiation and function. Moreover, CD8 T cells pre-exposed to 
IFN-induced environments had reduced memory formation. Therefore, out-of-
sequence exposure to IFN may initially stimulate effector function, but this may 
come at the expense of clonal expansion and subsequent memory formation.  
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Figure 5.1: Conventional CD8 T cell activation vs. out-of-sequence CD8 T 
cell activation 
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Figure 5.1: Conventional CD8 T cell activation vs. out-of-sequence CD8 T 
cell activation 
During conventional priming (blue), naïve CD8 T cells exhibit limited effector 
function prior to cell division. Once antigen-specific CD8 T cells have divided, 
they acquire the ability to produce effector functions, such that upon 
encountering antigen, effector cells can produce multiple cytokines and can 
specifically lyse target cells. After antigen is cleared, the majority of effector T 
cells die but the ones that survive form a memory population which has the ability 
to respond immediately to cognate antigen, without the need to divide. During 
out-of-sequence CD8 T cell activation (green), cells that are exposed to 
inflammatory environments prior to antigen and costimulation have the capability 
of producing effector functions immediately in response to antigen, without the 
need to divide. However, out-of-sequence CD8 T cells showed reduced clonal 
expansion and effector function at the peak of the T cell response. Defects in 
memory cell formation were also seen in out-of-sequence-primed CD8 T cells 
compared to conventionally-primed memory formation.  
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The dichotomy between the major findings here may help to explain how 
individuals can be either more or less susceptible to secondary or super 
infections during acute virus infections. During acute infections, third-party 
antigen-specific T cells will be primed in an out-of-sequence manner. Therefore, 
T cells may adopt one of the two phenotypes described here: acquisition of 
immediate effector function or suppression of CD8 T cell responses. If naïve T 
cells are armed to immediately respond to antigen encounter, individuals may be 
more resistant to secondary infections. On the other hand, third-party antigen-
specific CD8 T cells may not respond as robustly, showing limited expansion and 
effector function, thus enhancing susceptibility to secondary infections. The 
timing of exposure to a secondary infection in the midst of an ongoing immune 
response may play an important role in determining whether or not individuals 
are more or less susceptible to secondary infections.   
B. Stimulatory effects of out-of-sequence signaling 
Efficient clonal expansion and differentiation of CD8 T cells are required to 
develop protective memory CD8 T cells. Conventional naïve T cell activation is 
associated with changes in expression of a number of different activation 
markers including CD62L, CD69, and CD127 (137, 138, 141, 200, 206). The 
upregulation or downregulation of these specific activation markers is thought to 
be antigen driven. However, we show here that poly(I:C) priming of naïve T cells 
in the absence of cognate antigen induced an early-activated phenotype 
characterized by the upregulation of CD69 and CD86 and downregulation of 
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CD62L and CD127. This phenotype is normally associated with recently-
activated antigen-experienced T cells.   
In conventionally activated naïve T cells, CD69 is one of the earliest 
activation markers induced, but its role in T cell function has not been fully 
elucidated (138). CD69 signaling may contribute to T cell proliferation and 
effector acquisition by increasing intracellular Ca2+ levels and upregulating CD25, 
(138, 207). That being said, one study determined that lack of CD69 expression 
on DCs or CD8 T cells did not dramatically affect CD8 T cell expansion (206). 
We have identified cognate-antigen-independent upregulation of CD69 on naïve 
T cells after poly(I:C) inoculation (Figure 4.1-4.3) and a strong positive 
correlation between CD69 upregulation and cytotoxic capability (Figure 4.21). 
Intracellular Ca2+ is an important signaling component in T cell activation; 
therefore, CD69 signaling may be contributing to immediate effector functions 
seen in poly(I:C)-primed naïve T cells upon stimulation with antigen (208). 
Another interesting aspect of primed naïve CD8 T cells is the upregulation 
of CD86. Although CD86 is normally found on activated macrophages, DCs, and 
B cells, it has recently been shown to be expressed on T cells from some chronic 
infections, including HIV and HCV (209, 210). Studies have shown that IL-2 
signaling can induce the upregulation of CD86 on T cells, yet the function of 
CD86 on T cells has not been well characterized (209, 210). Both naïve CD8 T 
cells (Figure 4.1-4.3) and CD4 T cells (data not shown) primed with poly(I:C) 
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rapidly upregulate CD86. Although a role for CD86 on T cells hasn’t been 
identified, it is tempting to speculate that it could provide costimulatory (or 
inhibitory) signals to other T cells. This might suggest that poly(I:C)-primed naïve 
T cells could interact with one another via CD4:CD8 or CD8:CD8 and contribute 
to their immediate effector function. We know that costimulatory molecules CD80 
and CD86 in the priming host are required for poly(I:C)-induced arming of T cells, 
so it is not outrageous to postulate that costimulatory signals could be coming 
from other T cells.  
 Priming of naïve T cells with poly(I:C) induces expression of the effector-
associated TFs IRF4 and Eomes. TCR stimulation regulates IRF4 expression in 
a positive manner, where stronger TCR signaling results in more IRF4 
expression (148). Therefore, it was quite surprising to see IRF4 upregulation in 
poly(I:C)-inoculated naïve T cells that have not seen cognate antigen (Figure 
4.4-4.6). If IRF4 expression is regulated by strength of TCR signals, then why is 
there such a strong upregulation in primed naïve T cells? Although poly(I:C)-
primed naïve T cells do not see cognate antigen, they do encounter self-MHC. A 
combination of self-MHC:TCR signaling and other inflammation-induced signals, 
like costimulation and/or cytokines may drive IRF4 expression in primed naïve T 
cells. IRF4 is important for CD8 T cell effector differentiation. Therefore, the 
upregulation of IRF4 in primed T cells may give them an advantage over un-
primed cells, such as reducing the amount of additional TFs needed to induce 
effector functions.  
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Type 1 IFN signaling is required for the early-activated phenotype and 
upregulation of effector-associated TFs in poly(I:C)-primed naïve T cells. Naïve T 
cells that lacked the IFNAR did not upregulate CD69 or CD86 (Figure 4.2), nor 
did IFNAR KO naïve T cells induce expression of TFs IRF4 and Eomes (Figure 
4.5) after poly(I:C) inoculation. Consistent with this, a recent study identified a 
role for type 1 IFN in inducing Eomes expression in CD8 T cells (211).  
Expression of Class I MHC and B7 costimulatory molecules from the priming 
environment also played an important role in naïve T cell priming. Naïve T cells 
upregulated Eomes and CD69 when primed in B7 KO hosts but did not produce 
IFNγ when stimulated and assessed for immediate effector functions (Figure 
4.13).  
The upregulation of Eomes in primed naïve T cells was perplexing, 
because Eomes is associated with memory T cells, not naïve T cells. Eomes 
expression is known to be high in memory CD8 cells and in a distinct population 
of cells termed innate-like-lymphocytes, both of which exhibit immediate effector 
function in response to cognate antigen stimulation (152, 203, 211, 212). Given 
the role Eomes plays in memory CD8 T cells and innate-like lymphocytes, the 
presence of Eomes in primed naïve T cells may be one component regulating 
immediate effector functions. We hypothesized that Eomes upregulation in 
poly(I:C)-primed naïve T cells could also serve this type of role. Therefore, it was 
interesting to see that in B7 KO hosts, poly(I:C) induced upregulation of Eomes in 
naïve T cells, but these primed CD8 T cells did not exhibit immediate effector 
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function. Virtual memory (VM) cells, are antigen-inexperienced memory-
phenotype (CD44hi CD122hi) CD8 T cells generated by homeostatic 
proliferation. Although VM cells express high levels of both Tbox TFs, Tbet and 
Eomes, analysis of these cells showed they did not produce significant amounts 
of IFNγ in response to cognate antigen like conventional memory cells (211, 213-
216). This indicated that the presence of Eomes alone is not always sufficient for 
IFNγ production. In our poly(I:C)-priming model, events required for Eomes 
upregulation may contribute to, but are not sufficient for, immediate IFNγ 
production.  
IFNγ is regulated by a number of TFs but can also be regulated by 
epigenetic modifications (217, 218). The differences in epigenetic modifications 
between naïve CD8 T cells, which do not produce IFNγ, and effector and 
memory CD8 T cells, which do produce IFNγ, are still being investigated. One 
thing that has been fairly consistent within the literature is that naïve CD8 T cells 
show increased CpG methylation of the IFNγ promoter compared to effector and 
memory CD8 T cells, and this may result in repression or silencing of the gene 
(218). Therefore, B7 costimulation in poly(I:C)-primed naïve T cells may alter 
epigenetic modifications of the IFNγ promoter (i.e. demethylation), thus 
contributing to increased transcription in the presence of appropriate TFs (i.e. 
Eomes). Naïve T cells primed with cognate antigen in the absence of B7:CD28 
costimulation show reduced cytokine production compared to cells that receive 
costimulation (219). Interestingly, some cytokines, including IL-6 and TNF, have 
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been shown to compensate for B7 costimulation, in terms of T cell acquisition of 
cytotoxic effector function. However, these CD28-independent cytokine-
stimulated CD8 T cells showed limited cytokine production in response to peptide 
re-stimulation (118). These observations support the idea that costimulation may 
be important for epigenetically regulation the IFNγ locus.  
We and others have shown that type 1 IFN induces upregulation of Class I 
MHC and costimulatory molecules (Figure 4.16) (32, 74, 205). The combination 
of signals from self-MHC, costimulation molecules, and IFN during priming may 
enable naïve T cells to produce immediate effector functions upon stimulation 
with antigen, but only when a certain threshold of activation signals is reached. 
Without one of these signals, the ability of primed T cells to elicit immediate 
effector function may be reduced. It is plausible that there is a specific threshold 
of signals needed for the T cell to acquire activation markers or proliferate, and it 
may not matter so much as to where those signals originate as long as the T cell 
reaches some critical threshold. The combination of signals from self-antigen, 
costimulation and cytokines may provide sufficient activation of naïve T cells for 
acquisition of immediate effector function, but the proliferative capability and 
subsequent effector differentiation may have a higher threshold or require 
additional signals. 
Type 1 IFN induces activation of immature DCs, resulting in upregulation 
of Class I MHC, and costimulatory molecules (Figure 4.16) (32). The activation 
of immature DCs results in trafficking to LNs and other secondary lymphoid 
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organs (76, 220, 221). Therefore, upon poly(I:C) treatment in vivo, although there 
is no exogenous antigen present, immature DCs are activated and migrate to 
LNs, where they encounter naïve T cells. Naïve T cells are constantly trafficking 
throughout the body in search of cognate antigen (114, 221). Upon exposure to 
cognate antigen, T cells arrest, but if cognate antigen is not encountered, T cells 
continue moving (221). In the priming to immediate effector function model 
described here, it is unknown whether or not T cells are arresting. Are the IFN 
signals and contact with self-MHC and costimulation enough for a naïve T cell to 
stop and begin programmed division? I suspect not; I do think, however, that 
primed naïve T cells might stay in contact with APCs for a longer period of time 
than conventional naïve T cells do. This longer interaction may not be sufficient 
for full activation and induction of programmed division, but it may be enough to 
arm T cells with the ability to immediately produce effector functions in response 
to cognate antigen.  
Chapter 4 identifies how out-of-sequence signaling can affect CD8 T cell 
function immediately after antigen stimulation. We determined that T cells that 
are pre-exposed to type 1 IFN-induced environments in the presence of 
costimulation and self-MHC can manifest immediate effector functions upon 
stimulation with cognate antigen (Figures 4.7-4.10). These armed T cells have 
the ability to produce effector functions in response to lower concentrations of 
high-affinity ligands and lower affinity ligands, all without the need to divide 
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(Figures 4.17-4.19). Moreover, T cells gain the ability to specifically lyse target 
cells, while still maintaining a naïve phenotype (Figures 4.20-4.21).  
In vitro studies have shown that VACV epitopes can be presented as early 
as 30 minutes post infection (222). The amount of viral proteins expressed within 
the cell often correlates with the peptides presented. That being said, not all viral 
proteins are induced at the same time and expressed to the same levels. 
Immediately after infection, when viral antigen presentation is low, primed naïve 
T cells may be able to recognize these recently infected cells because of their 
ability to respond to lower density antigens. In addition, epitopes from viral 
proteins that are not expressed as abundantly may be more efficiently 
recognized by primed naïve T cells. Many viruses have evolved mechanisms to 
reduce levels of Class I MHC in order to avoid recognition by the adaptive 
immune system. Therefore, the ability of primed naïve T cells to respond to lower 
density antigens may also be advantageous to the host, when infected with 
viruses that employ these evasion strategies (6). Primed naïve T cells may help 
to initially control infections prior to antigen-specific clonal expansion and may 
also have the ability to prevent, or control secondary infections.  
So far, I have described primed naïve T cells as being an important 
component in the anti-viral T cell response that may contribute to reduced 
susceptibility to secondary infections. On the other hand, priming of naïve T cells 
may have a potentially negative implication and help to explain an association 
between onset of autoimmune disorders and virus infections. Infections are 
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thought to promote autoimmune disorders by a number of different mechanisms. 
Superantigen-induced and so-called bystander-induced activation of self-reactive 
T cells may contribute to autoimmune disorders. Molecular mimicry may also 
serve as a potential mechanism of antigen-induced autoimmune disorders (179, 
223-225). Virus infections and resulting inflammatory environments may prime 
self-reactive T cells to become more sensitive to antigen stimulation. I have 
shown that primed naïve T cells can respond to lower concentrations of antigen 
and lower affinities of antigen, so self-reactive T cells may be more prone to 
activation by self-antigen. Poly(I:C) priming may break tolerance to self-antigens, 
thus allowing naïve auto-specific CD8 T cells to exert effector activity and 
contribute to induction of autoimmune disorders.  
It is possible that the poly(I:C)-induced priming of naïve CD8 T cells by 
self-antigen, costimulation and IFN may have regulatory effects, rather than anti-
viral effects. IFNγ has been shown to induce many of the same effects as type 1 
IFN and can even act as a signal 3 cytokine, promoting clonal expansion of CD8 
T cells (11). Primed T cell production of multiple cytokines, including IFNγ and 
TNF, may activate surrounding cells and could even act in an autocrine manner. 
However, the function of primed naïve T cells production of IFNγ and TNF during 
viral infections has yet to be determined.  
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C. Inhibitory effects of out-of-sequence signaling 
Transient states of immune suppression occur during many acute viral 
infections, and it has long been known that individuals should not get vaccinated 
when they are sick. Virus-induced immune suppression was first noted over 100 
years ago. More recent studies have shown immune suppression to be a 
common element of many viral infections and often to be associated with 
suppressed T cell proliferation in response to antigens and mitogens (183-189, 
191, 192). While studying viral infection models, we recently found that a general 
mechanism of virus-induced immune suppression could be linked to type 1 IFN, 
normally induced at high quantities in most viral infections (182). This was 
somewhat surprising, given that type 1 IFN has been described as a signal 3 
cytokine, which drives the expansion and differentiation of T cells after they have 
encountered cognate ligand (signal 1) and costimulation (signal 2). The primary 
observation of Chapter 3 is that if T cells are exposed to type 1 IFN inducers 
before exposure to cognate ligand, they lose their sensitivity to further IFN 
stimulation and do not receive the benefits of a signal 3 cytokine. Instead, they 
behave like T cells receiving only two signals, with defects in effector cell 
differentiation, effector function, expression of a pro-survival protein, and clonal 
expansion.      
Type 1 IFN, like many other cytokines, can render treated cells resistant to 
further IFN stimulation by down regulating the IFN receptor and by inducing 
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factors like SOCS1 that impair IFN-induced signal transduction (28, 30). We 
show here that T cells pre-exposed to IFN fail to derive the benefit of the positive 
signal 3 effects of IFN signaling. The implications of this phenomenon are 
widespread. Because IFN is induced so rapidly during viral infections, one can 
deduce that the T cells that encounter antigen in the first day or two of infection 
would respond more impressively than latecomer virus-specific T cells stimulated 
later in infection. Thus, the dynamics of how much antigen is synthesized and 
presented vs. how much and how quickly IFN is induced may dictate the efficacy 
of the host response. Secondly, the T cell response to many acute infections, at 
least in mouse models, is relatively ordered and undergoes a rather 
synchronized contraction from 6-9 days post-infection. How can this occur when 
the amount of T cell proliferation is a programmed event and when different T 
cells should encounter antigen at different time periods (115-117, 226)? The 
latecomer T cells, because of their previous exposure to IFN, would not undergo 
as many divisions and possibly have lower survival properties, thereby enabling 
them to contract when the rest of the T cells do. Third, we would argue that naïve 
or memory T cells specific to third party antigens would not respond well to a 
cognate antigen stimulus if they were first exposed to the IFN milieu of a viral 
infection and then stimulated with antigen. This failure to respond to recall 
antigens, such as tetanus toxoid or tuberculin, is a common feature of virus-
induced immune suppression in humans, and the weak efficacy of vaccines in 
already infected individuals may well be a function of the same problem (227, 
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228). Finally, under conditions when a host develops a persistent viral infection 
there would be a chronic stimulation of the type 1 IFN response, and such hosts 
would probably not immunologically respond well to either the antigens of the 
infecting virus or to third party antigens on challenge. This weak response to third 
party antigens is not only seen during persistent viral infections but also during 
chronic autoimmune diseases, such as lupus erythematosus, where signal 3 
cytokines may be chronically produced (229, 230). We therefore suggest that the 
elimination of signal 3 stimulation by out-of-sequence exposure to the signal 3 
stimulant, in this case IFN, would be a common factor disrupting T cell responses 
in the context of acute or persistent viral infections.       
Type 1 IFN can have both stimulatory and inhibitory effects on CD8 T cell 
proliferation, but here it was initially unclear if poly(I:C)-pretreated CD8 T cells 
were receiving direct inhibitory signals or fewer stimulatory signals from IFN. 
Since type 1 IFN signaling can act through multiple STATs, each capable of 
altering cell fate, it might have been expected that poly(I:C)-pretreated CD8 T 
cells would have had different STAT phosphorylation in response to IFNβ 
stimulation. Recent work has shown that virus-specific CD8 T cells downregulate 
total STAT1 and upregulate STAT4, so that, when IFN signals through the IFN 
receptor, the anti-proliferative effects of STAT1 will be overcome by the positive 
effects mediated through STAT4 (90, 91, 95). Therefore, poly(I:C)-pretreated 
CD8 T cells could have had more pSTAT1 and less pSTAT4 than control-treated 
cells after IFNβ stimulation. However, this was not the case at the time points 
270 
 
studied, as phosphorylation of all tested STATs was reduced (Figures 3.11-
3.13). The fact that all pSTATs were reduced in poly(I:C)-pretreated CD8 T cells 
suggested that IFN was not having a direct negative effect other than by 
desensitizing cells to the positive effects that a later exposure to IFN could 
mediate.  
It should be noted that not only were naïve CD8 T cells unresponsive to 
IFNβ stimulation after poly(I:C) treatment, but CD4 T cells and NK cells were also 
refractory to further IFNβ stimulation in terms of STAT phosphorylation (Tables 
3.1-3.4). Type 1 IFN has been shown to act directly on CD4 T cells, NK cells and 
B cells to promote effector function, and these results may indicate that in 
addition to poly(I:C) inducing inhibitory effects on CD8 T cell proliferation, it may 
also have suppressive effects on other lymphocyte populations that utilize IFN at 
another time for their activation (15, 48, 49, 60, 67). Indeed, reduced antibody 
production by B cells and lower NK cell cytotoxicity have been seen under 
conditions of virus-induced immune suppression (60).  
Antigen and costimulatory molecules provide proper signals for T cell 
activation and differentiation, but more recent studies have focused on the role 
for inflammatory cytokines in these processes. We find here an additional layer of 
complexity in that the timing of T cell exposure to signal 3 cytokines is extremely 
important. If CD8 T cells are unable to receive the positive effects of type 1 IFN, 
as shown in this study, they should behave more like T cells that only received 2 
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signals, rather than 3 signals. This was the case, as the out-of-sequence signal 3 
CD8 T cells had defects in SLEC differentiation and effector function. Poly(I:C)-
pretreated CD8 T cells degranulated, as shown by CD107a/b staining, but they 
had reduced granzyme B expression (Figures 3.23-3.25), suggesting that 
poly(I:C)-pretreated CD8 T cells have lower cytolytic capabilities at day 5 post-
infection. Indeed, reduced T cell responses correlated with increased viral titers 
at day 6 post infection (Figure 3.28). 
Another hallmark of 2-signal only CD8 T cells is limited clonal expansion, 
which in many cases is attributed to decreased survival. Although the exact 
mechanism is unknown, Bcl-3 prolongs the survival of activated CD8 T cells after 
signal 3 cytokine addition or CpG adjuvant administration (86-88, 198). The IFN-
induced suppression of proliferation seen here may also have been due to a 
decrease in survival. This idea was supported by poly(I:C)-pretreated CD8 T cells 
having lower expression of the pro-survival protein Bcl-3 (Figure 3.21). We show 
here that poly(I:C)-pretreated P14 cells also had a delay in cell division compared 
to HBSS-treated cells in response to LCMV infection (Figure 3.19-20). 
Interestingly, the delay in cell division of poly(I:C)-pretreated P14 cells is seen at 
day 3 post infection, but not at day 4 post infection, matching the kinetics of the 
timing of the ability of CD8 T cells to respond to IFNβ signals by phosphorylating 
downstream STATs (Figure 3.3). The positive effects that an inflammatory 
environment can have on CD8 T cell expansion are also shown here, whereby 
P14 T cells expanded ~ 20 fold in response to GP33 peptide, but they expanded 
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more than 30,000 fold in response to LCMV infection. The facts that poly(I:C)-
pretreated P14 cells are suppressed in proliferation in response to LCMV 
infection but not to GP33 peptide stimulation support the idea that the 
refractoriness to IFN stimulation contributes to reduced expansion (Figure 3.22). 
This mechanism of IFN-induced immune suppression may explain how many 
virus infections can inhibit T cell responses, by limiting the ability of T cells to 
receive stimulatory effects from the environment.  
As described in chapter 3, if CD8 T cells see signal 3 first, they become 
refractory to further IFN stimulation and are unable to receive the positive signals 
that type 1 IFN can provide when delivered at the proper time after antigen and 
costimulation. This limits their ability to clonally expand, to sustain cytolytic 
capabilities, and possibly to form effective memory. Our studies show lower 
proportions and numbers of out-of-sequence CD8 T cells at early memory stages 
(Figure 3.20) and as late as 11 weeks post infection. The effectiveness of the 
memory cells that do form has yet to be investigated, but this is important to 
determine because of implications it can have in vaccine design and 
administration.  
D. Conclusions 
Studies described in this thesis clarify some complex elements of CD8 T 
cell activation. Not only does the presence or absence of signals 1-3 contribute to 
T cell activation, but the timing of these signals also proved to be of great 
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importance. Thus, under circumstances when CD8 T cells can receive positive 
signals, such as during an infection or vaccination with adjuvants, out-of-
sequence signals can have a profound effect on CD8 T cell expansion and 
activation. This generalized IFN-induced impairment of proliferation is one 
example of how out-of-sequence signaling can alter responses to cognate 
antigen exposure. Another example described here is the ability of out-of-
sequence signaling to arm naïve T cells with the ability to produce immediate 
effector functions in response to reduced antigen densities and specificities. We 
do not know if the CD8 T cells sensitized to rapid effector function are in fact the 
same cells that ultimately are suppressed in proliferation. However, we do know 
that these two changes in T cell response to cognate antigen stimulation occur 
by very distinct mechanisms (Figure 5.2) and occur in virus-induced 
inflammatory environments; consequently, the impairment of proliferation may 
contribute to generalized IFN-induced immune suppression, even though there 
may be an initial transient activation of the T cells.   
The discoveries presented here may be extrapolated to many different 
aspects of the immune system, including a profound and universal mechanism of 
virus-induced immune suppression seen during both acute and chronic 
infections. In addition, these studies may describe how both latecomer and third-
party antigen-specific T cells behave when and if they encounter cognate antigen 
in the midst of an ongoing infection. Although they may exhibit the ability to  
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Figure 5.2 Model: Direct vs indirect effects of IFN in out-of-sequence 
signaling of naïve T cells 
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Figure 5.2 Model: Direct vs indirect effects of IFN in out-of-sequence 
signaling of naïve T cells 
IFN plays a role in both mechanisms of out-of-sequence signaling. However, IFN 
acts indirectly through APCs to mediate priming of T cells to early activation, but 
directly on T cells to mediate impaired proliferation and differentiation. 
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respond immediately to antigen encounter, it may be at the expense of clonal 
expansion, differentiation and memory formation.  
These studies may help explain why vaccines are not as effective when 
administered to individuals with ongoing infections and other immune-mediated 
disorders. However, the immediate effector function naïve T cells gain during 
similar out-of-sequence priming may explain how individuals are more resistant 
to superinfections. Importantly, results identified here can be applied to 
developing better and more effective vaccines.  
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